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Foot-and-Mouth Disease Virus (FMDV) is a globally important pathogen 
responsible for causing Foot-and-Mouth Disease (FMD) in wildlife and domestic 
livestock species and has significant economic impacts. FMD is difficult to 
control due to its highly infectious nature, wide diversity of host species and the 
existence of multiple serotypes; therefore, understanding the processes of 
FMDV infection and viral RNA replication are key to the development of 
improved diagnostics and vaccines.  
 
This thesis investigates the potential roles of the FMDV 3A non-structural 
protein using a combination of sub-genomic replicons, recombinant viruses and 
proteomics techniques. The picornavirus 3A protein has previously been linked 
with roles in replication complex formation, virulence and determining viral host 
range. This thesis presents findings showing that a naturally occurring deletion 
in 3A had differing effects on replication in cells lines derived from different 
natural hosts thereby supporting the conclusion that 3A has an important  role in 
viral host range.  
 
Proteomic (immunoprecipitation and mass spectroscopy) investigations were 
carried out to identify potential cellular interaction partners of FMDV 3A, and the 
impact on infection and replication of reducing expression of two selected 
cellular proteins Rab7L1 and TBC1D20 was investigated. The 3A protein of 
FMDV was shown to include a conserved FFAT motif (which bind the ER 
resident protein VAP) in its N terminal domain. A role for this motif was also 
investigated with the results suggesting that the 3A FFAT motif is important for 
efficient viral replication.  
 
Finally, the potential role of 3A to act as the donor of 3B during replication was 
investigated. Key findings from experiments using FMDV replicons and 
recombinant viruses showed that full-length P3 and the processing intermediate 
 3ABBB are not required for viral RNA replication suggesting that the preferred 
donor of 3B for uridylation is likely a 3BC containing precursor protein. 
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Chapter 1: Introduction 
1.1 Foot-and-Mouth Disease 
Foot-and-mouth Disease (FMD) is an important notifiable disease that affects 
both domestic livestock (cattle, pig, sheep and goats) and a large number of 
wildlife species (including deer and buffalo). FMD is a global problem and 
outbreaks have occurred in almost every part of the world where livestock are 
kept and the disease is currently endemic in areas of Africa and Asia (Jamal 
and Belsham, 2013). 
Infected animals often show symptoms of fever and lameness as well as 
developing lesions on the tongue, snout, and feet, although symptoms in sheep 
can be very mild and hard to detect. Symptoms are often similar to that of other 
vesicular diseases including vesicular stomatitis virus and swine vesicular 
disease (Grubman and Baxt, 2004). Although FMD normally has a low mortality 
rate, in young animals the infection can spread to the heart and cause 
myocarditis. FMD also causes reduced milk production and weight loss leading 
to reduced productivity, particularly as disease can spread rapidly leading to a 
100% morbidity rate. In addition some animals may become carriers of FMD, 
where they are asymptomatic but are persistently infected and continue to shed 
virus after 28 days (Kitching and Hughes, 2003) although it is still debatable 
whether or not these animals contribute to the spread of disease. 
The aetiological agent of FMD is Foot-and-mouth disease virus (FMDV) which 
is considered one of the most important pathogens in global agriculture, due to 
the huge economic burden and impacts on food security that outbreaks of FMD 
lead to. Outbreaks of FMD cause reduced productivity and loss of stocks as 
well as trade restrictions on animals and animal products from affected 
countries leading to economic losses of billions of pounds (Knight-Jones and 
Rushton, 2013). 
Due to the diversity of strains and broad host range of FMDV, outbreaks of FMD 
tend to spread quickly and are difficult to contain. Transmission routes include 
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direct contact between infected and naïve animals, mechanical transmission via 
contaminated vehicles, bedding, and clothing of handlers and by 
aerosols(Sutmoller et al., 2003, Alexandersen and Donaldson, 2002). Current 
methods of control vary depending on if a cuntry is classed as disease free or 
not. Areas of South America use vaccination to prevent disease and are 
beginning to successfully achieve a “free with vaccination” status (Sutmoller et 
al., 2003). In Europe vaccination was used until 1992 where following disease 
free status it was decided vaccination would no longer be used in order to allow 
trade to be maintained throughout the continent providing a free without 
vaccination status. The main impact of FMD in Europe is now caused by 
sporadic outbreaks that occur, the largest most recent one being in 2001 which 
spread throughout the UK, France and the Netherlands and was caused by a 
Pan Asia type O virus (Knowles et al., 2005). Control methods implemented 
during this outbreak included culling of infected animals, restriction of animal 
movement and trade, and emergency vaccination in the Netherlands (Sutmoller 
et al., 2003). However despite the implementation of control methods the 
estimated losses due to loss of stock, tourism and trade was estimated at 
billions of pounds (Knight-Jones and Rushton, 2013). 
Current FMDV vaccines use an inactivated form of the virus grown in BHK-21 
cells. However these vaccines do have limitations, firstly as they are made from 
whole virus antigen and they can contain contaminating amounts of non-
structural proteins, inoculated animals develop antibodies to these non-
structural proteins making it hard to differentiate between animals that have 
been infected and those that have been vaccinated (Lee et al., 2006). Secondly 
production of these vaccines requires large amounts of virus to be grown up 
which requires high containment bio-secure facilities, and once inoculated 
animals don’t develop a rapid response meaning they are still susceptible to 
infection for a short period of time following inoculation which is not ideal in an 
outbreak situation (Doel, 2003). Also due to the large number of circulating 
strains and a lack of immunological cross protection between the different 
serotypes control of FMD outbreaks is incredibly difficult (Rodriguez and Gay, 
2011). Improved control measures including better vaccines would have large 
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benefits worldwide; however developing of new methods requires improved 
understanding of the mechanisms involved during viral infection and replication. 
 
1.2 The Picornaviridae 
 
The Picornaviridae are a group of small non-enveloped viruses with positive 
sense single stranded RNA genomes classifying them as type IV viruses 
according to the Baltimore classification system of viruses. The majority of 
known picornaviruses have been identified in mammals and birds although 
recently others have been identified in reptiles and fish (Fichtner et al., 2013, 
Reuter et al., 2015). There are currently 35 genera of Picornaviridae each 
including at least one or more species (Zell et al., 2017). The most studied 
genus of Picornaviridae is the Enterovirus genus which includes poliovirus (PV) 
and Coxsackie virus (CV). Since PV is so well studied it is frequently used as a 
model for how other picornaviruses replicate, meaning it is often compared with 
FMDV despite the fact there are a number of significant differences between 
them.  
 
1.2.1 Important members of and major diseases caused by the 
Picornaviridae  
PV is the causative agent of poliomyelitis which affects humans and in some 
cases affects the central nervous system leading to flaccid paralysis. Prior to 
vaccinations being developed poliomyelitis epidemics used to occur frequently 
(Racaniello, 2006). Since the introduction of both inactivated and live attenuated 
PV vaccines and the World Health Organisation initiative to eradicate wild PV, 
the number of cases has dropped dramatically and cases of wildtype 




Another well studied picornavirus is human rhinovirus (HRV), like PV it belongs 
to the Enterovirus genus. HRV is reported to cause over half of upper 
respiratory tract infections worldwide, and although normally only causes 
common colds in healthy individuals, in the elderly and immunocompromised it 
is  linked with more severe disease including pneumonia and increasing 
severity of asthma (Royston and Tapparel, 2016). 
Other examples of important members of the Picornaviridae include 
enterovirus-71 (EV-71), which causes hand-foot-and-mouth disease and 
enterovirus-68 (EV-68) both of which have recently become more common and 
widespread. In addition to respiratory illness they can cause neurological 
problems particularly in children and are a leading cause of viral meningitis 
(Chang et al., 2016, Messacar et al., 2016). There are currently no vaccines 
available against these diseases. 
 
1.3 Foot-and-Mouth Disease Virus 
FMDV is a member of the Picornavirdae family within the order Picornavirales 
and is the type species of the Aphthovirus genus The Aphthovirus genus 
currently consists of 4 classified species: Foot-and-mouth Disease virus 
(FMDV), Equine rhinitis A virus (ERAV), Bovine rhinitis A virus (BRVA) and 
Bovine rhinitis B virus (BRVB).  
FMDV exists as 7 different serotypes: O, A, C, Asia-1 and Southern African 
Territories (SAT 1, 2, and 3) and each contains multiple and constantly evolving 
strains (Domingo et al., 2003). The type O FMDV serotype is the most common 
and widespread followed by type A, whereas the Asia-1 serotype tends to only 
found in south East Asia and the SAT viruses are normally restricted to sub-
Saharan Africa (Knowles and Samuel, 2003). 
The virion consists of a single-stranded (ss) positive-sense RNA genome 
approximately 8.5 Kb in length packaged inside an icosahedral capsid 
consisting of 60 identical copies of each of the structural proteins. Unlike the 
enteroviruses, such as PV, the capsid of FMDV does not have canyon like 
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depressions upon its surface, a feature believed to be involved in receptor 
binding of some picornaviruses including the enteroviruses (Hogle et al., 1985, 
Belnap et al., 2000). Instead FMDV has a pronounced loop on the surface on its 
capsid, which makes up part of the VP1 protein. This feature  known as the G-H 
loop is more pronounced in FMDV than other picornaviruses and is involved in 
virus attachment to cells through a conserved RGD motif (see section 1.5.1) 
(Logan et al., 1993, Burman et al., 2006). 
 
1.4 The FMDV genome and the viral proteins 
The FMDV genome is approximately 8.5 KB in length and encodes a single 
open reading frame. Unlike PV and some other picornavirus genera it encodes 
for a leader protease and uniquely among the Picornaviridae encodes in 
tandem 3 non-identical copies of the 3B protein. The roles of each component 
of the genome from 5’ to 3’ are discussed in the sections below. Figure 1.4 
shows the layout of the FMDV genome. 
 
Figure 1.4: Organisation of the FMDV Genome. FMDV has a single stranded 
positive sense RNA genome encoded as a single open reading frame that is 
translated to produce a single polyprotein that undergoes further processing to 
give a variety of intermediate and 14 mature viral proteins. The genome has 
small protein (VPg) linked to the 5’ end and is followed by the 5’ Untranslated 
region (UTR) which contains several different structures and features, the S 
fragment (S), Pseudoknots (PKs), the cis acting replication element (cre), the 
IRES, and a long stretch of cytosine residues (polyC). The FMDV genome then 
encodes the Leader protein, a protein which is not present in all picornavirus 
Adapted from Mason et al (2003) 
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species, followed by the 4 capsid proteins (VP4, VP2, VP3 and VP1 shown in 
red). The genome then encodes the short 2A peptide (purple) which separates 
the structural proteins and the remaining non-structural proteins encoded 
downstream  of 2A shown in blue. Finally there is a short 3’UTR followed by the 
poly A tail (poly A). 
 
1.4.1 VPg 
Unlike cellular mRNAs picornavirus genomes are not capped at the 5’ end by a 
7-methyl guanine cap, instead they have a covalently bound small genome 
linked protein known as VPg which is encoded by the 3B gene (Grubman, 
1980). During replication VPg acts as the primer of the viral polymerase (3D) 
allowing synthesis of both positive and negative sense RNA strands (Paul and 
Wimmer, 2015).  
 
1.4.2 The 5’ UTR 
Following the VPg is the 5 untranslated region (5’ UTR) of the genome. This 
contains a number of different RNA structures and features including the S 
fragment, poly C tract, pseudoknots, a cis acting replication element (cre) in the 
case of FMDV and the internal ribosome entry site (IRES). 
The S fragment is a large stem loop at the 5’ end of the genome, which in 
FMDV is larger than in that of other picornaviruses. PV also has a highly 
structured region at the end of the 5’UTR known as a cloverleaf, and this has 
been shown be required for negative strand RNA synthesis and genome 
stability (Barton et al., 2001) which suggests that the S fragment may play a 
similar role in FMDV replication. The precise role of the poly C tract is unknown, 
but it has been shown that virus engineered with varying poly C tract lengths 
(down to those with just 2 cytosine residues) can be recovered, but those with 
longer length poly C tracts appear to have an advantage in cell culture (Rieder 
et al., 1993). Downstream of the poly C tract in FMDV are three or four smaller 
pseudoknot structures, these structures are also found in EMCV but upstream 
of the poly C tract but the function of these is also unknown (Duke et al., 1992). 
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In FMDV the next structure found in the 5 UTR is the cis acting replication 
element (cre), a small stem loop with a conserved loop sequence of AAACA. 
Alteration of this sequence has been shown to attenuate replication but doesn’t 
appear to affect translation (Mason et al., 2002). FMDV is unusual as all other 
picornavirus cre so far identified are located within the coding regions of the 
genome. For example, the cre of PV is located in the coding region for the 2C 
protein (Goodfellow et al., 2000, Paul et al., 2000) and in HRV 14 the cre is in 
the VP1 coding region (McKnight and Lemon, 1998). The cre acts as a template 
for uridylation of VPg to produce VPgpUpU by the viral polymerase 3D.  
VPgpUpU then in turn acts as a primer for the polymerase in viral replication 
(Nayak et al., 2006, Paul et al., 2000). 
The final element of the 5’ UTR is the IRES which directs translation of the 
genome by a cap independent mechanism. Different picornaviruses use 
different types of IRES, with the IRES of PV belonging to group 1 and that of 
FMDV belonging to group 2. The FMDV IRES is approximately 450 nucleotides 
in length (Belsham and Brangwyn, 1990). These highly conserved structures 
are responsible for recruitment of the 40S ribosomal subunit as opposed to 
relying on scanning of the genome from the 5’ end. 
 
1.4.3 Leader protein 
The first protein encoded within the FMDV genome coding region is the leader 
protein which in FMDV is a papain like cysteine protease and is involved in 
shutting off host cell translation. The L protein is only found in some 
picornavirus species (including members of the aphthoviruses, kobuviruses and 
cardioviruses) and plays varying roles in the different genera including  aiding 
RNA replication and encapsidation in kobuviruses, and acting as a viral 
protease in members of the aphthovirus and erbovirus genera (Belsham, 2013, 
Romanova et al., 2009, Sasaki et al., 2003). The FMDV L protein has two 
initiation codons separated by 84 nucleotides; consequently, the protein can be 
produced in two forms Lab and Lb. Deletion of the Lab region appears to be 
lethal but viruses which have Lb removed can still replicate (Belsham, 2013). 
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The FMDV L protein has been shown to cleave the cellular translation initiation 
factor eIF4G to inhibit host cell translation and is responsible for cleaving itself 
from the end of the P1 region of the genome (Belsham, 2013, Devaney et al., 
1988).  
1.4.4 The Capsid proteins 
Following L is the P1 region of the genome that encodes the structural (or 
capsid) proteins VP4, VP2, VP3 and VP1. Initially, the capsid proteins are 
formed as P1-2A, and VP4 and VP2 are made as a single protein known as 
VP0. Single copies of VP0, VP3 and VP1 assemble to form promoters, and 5 
protomers then combine to form a pentamer. Subsequently, 12 pentamers 
associate, to form a provirion into which RNA is packaged. Finally the 
maturation cleavage of VP0 to VP2 and VP4 occurs producing a complete 
virion. 
In addition to protecting the viral RNA (vRNA), the structural proteins play a 
variety of roles, for example, VP1 has a large extended G-H loop that includes 
an RGD motif which has been shown to mediate integrin binding (Burman et al., 
2006, Logan et al., 1993). Clusters of histidine residues at the interface between 
VP2 and VP3 in the assembled capsid have been suggested to be the possible 
reason for FMDV dissociation at acidic pH (Curry et al., 1995). Finally the VP4 
protein is a small myristolated protein located on the inner face of the capsid 
and for HRV has been linked with formation of a multimeric pore predicted to 
allow release of the RNA genome into the cytoplasm (Panjwani et al., 2014) it is 
possible a similar role may be played by that of FMDV VP4.  
 
1.4.5 The 2A protein 
Separating the structural and non-structural regions of the genome is the 2A 
protein. In FMDV, 2A is shorter than in other picornaviruses and is only 18 a.a 
in length. For FMDV, it is thought that 2A, rather than cleaving itself at the C 
terminus or being cleaved by another viral protease, promotes hydrolysis of the 
linkage between P1-2A and 2B effectively simultaneously separating P1-2A 
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from the rest of the polyprotein and allowing the ribosome to continue to 
process the downstream proteins during translation (Donnelly et al., 2001b). 
The FMDV 2A peptide and first a.a residue of 2B have been shown to be able 
to mediate cleavage in multiple artificial systems (Ryan and Drew, 1994, 
Minskaia et al., 2013). 
1.4.6 The 2B protein 
The next part of the genome encodes the 2B protein. The 2B proteins of 
picornaviruses are predicted viroporins. The structure and characteristics of 
FMDV 2B agrees with this hypothesis as it exhibits intracellular localisation at 
the ER and has two predicted trans-membrane domains both of which are 
characteristics of class IIB viroporins (Ao et al., 2015). Viroporins alter 
membrane permeability and monomers of these can also assemble within cell 
membranes, leading to the formation of pores which promotes virus budding 
from the cell. In PV, 2B has also been shown to disrupt calcium balance within 
the cell inducing apoptosis (Aldabe et al., 1997).  
1.4.7 The 2C protein 
 
The next part of the genome encodes the 2C protein. The 2C proteins of 
picornaviridae appear to have ATPase and GTPase activity (Sweeney et al., 
2010, Klein et al., 1999). PV 2C has been shown to be involved in the initiation 
of negative strands synthesis (Barton and Flanegan, 1997). All the 2C proteins 
of the picornaviruses also contain helicase domains (Klein et al., 1999, Pfister et 
al., 2000) with the EV-71 2C protein having been shown to have helicase 
activity (Xia et al., 2015). Additionally an interaction between the structural 
protein VP3 and the nonstructural 2C protein of PV has been linked with a 
possible role in aiding genome encapsidation (Wang 2014). The exact role of 
FMDV 2C is as yet undetermined although the intermediate 2BC protein has 
been linked with inhibition of protein secretion (Moffat et al., 2005, Moffat et al., 





1.4.8 The 3A protein 
Following 2C, the genome encodes the proteins that make up the P3 region of 
the genome, which are responsible for playing key roles in viral replication. The 
first of these is 3A. The 3A protein of picornaviruses has been linked with 
virulence, replication and host range and is discussed in more detail in sections 
1.6 and 1.7. 
 
1.4.9 The 3B proteins 
3B encodes the VPg protein which acts as the primer for the viral polymerase 
(3D) and is found linked to the 5’ end of the genome. FMDV is unusual in  that it 
encodes 3 non-identical copies, all of which are found linked to viral RNA (King 
et al., 1980) and can be uridylated by the 3D polymerase in vitro (Nayak et al., 
2005).The majority of Picornaviruses encode a single 3B protein although  
some members of the Picornavirdae have been shown to encode multiple 
copies of the 3B protein within their genomes  (including aquamavirus A and 
mosavirus A) (Boros et al., 2013, Reuter et al., 2014). FMDV 3B3 has been 
found to be the most efficient substrate for this reaction followed by 3B2 and 
3B1 respectively (Nayak et al., 2005). Despite encoding multiple copies FMDV 
is still able to replicate without 3B1 and 3B2 although a reduction in replication 
is observed (Falk et al., 1992, Pacheco et al., 2010, Pacheco et al., 2003). Until 
recently no naturally isolated strains of FMDV encoding less than 3 copies of 3B 
have been identified, however a type O virus has recently been identified from 
an outbreak in South Korea that contains a 23 a.a nucleotide deletion that 
removes the last 5 a.a of 3A and first 18 residues of 3B1, which effectively 
removes the first copy of 3B (3B1). This virus appeared to have a low 
pathogenicity in pigs under experimental conditions which could imply that 3B 
copy number may be an important determinant of virulence in pigs (Park et al., 
2016). However this study used limited animals and only investigated effects in 
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pigs and did not test effects of infection in other FMDV natural hosts such as 
cattle. 
1.4.10 The 3C viral protease 
The genome then encodes 3C. The picornavirus 3C protein has been shown to 
be a viral protease and is responsible for most of the cleavages of the viral 
polyprotein. Aside from processing of the L protease from P1-2A, and the final 
maturation cleavage of VP0 to VP2 and VP4, FMDV 3Cpro is thought to carry 
out all other processing events. However, for some picornaviruses 3CD 
containing precursors have also been shown to be responsible for processing 
the capsid proteins (Spear et al., 2015). 
Like Lpro the 3C protease (3Cpro) is also involved in shutting off host cell 
translation. It is able to cleave eIF4G late in the replication cycle, but is also 
able to cleave eIF4A which is part of the cap binding complex (Belsham et al., 
2000). FMDV 3C has also been shown to cause fragmentation of the Golgi 
apparatus (Zhou et al., 2013) during replication. 
 
1.4.11 The 3D polymerase 
The 3D protein is the last protein encoded by the genome. The 3D protein of 
picornaviruses (3Dpol) is the viral encoded polymerase (an RNA-dependent 
RNA polymerase) responsible for replication of the viral genome. Like other viral 
RNA-dependent RNA polymerases, that of FMDV has a right hand shaped 
structure consisting of thumb, fingers and palm domains The active site of the 
polymerase contains a conserved YGDD motif (Hansen et al., 1997, Ferrer-Orta 
et al., 2004). FMDV 3Dpol is likely to interact with a number of viral and cellular 
proteins during the synthesis of new genome copies, and studies using PV have 
suggested interactions with PABP (Barton et al., 2001) as well as with 3AB 
(Hope et al., 1997) and, it is therefore possible similar interactions may occur 




1.4.12 The 3’ UTR 
Following the 3D polymerase is the 3’ UTR, which is shorter than the 5’ UTR 
and contains fewer structures with just two predicted stem loops (SL1 and SL2) 
that are followed by a poly A tail. These structures are predicted to interact with 
stem loops and RNA structures in the 5’ UTR, namely the IRES and S-fragment 
(Serrano et al., 2006) and are required for replication as deletion of the entire 3’ 
UTR inhibits replication (Sáiz et al., 2001). There is also some evidence to 
suggest the 3’UTR of PV may interact with the 3AB protein of PV (Harris et al., 
1994). 
 
1.5 The Viral life cycle 
 The infection cycle of FMDV is shown in the top panel of Figure 1.5 (adapted 
from Whitton et al, 2013). Key steps are summarised in the table in the lower 















Virus binds receptor: This is either  integrins or/ and heparan sulfate glycan 
 
2. Entry 
Virus enters cell using clathrin dependent endocytosis 
 
3. Uncoating 
(i) Virion particle dissociates in early endosome due to acidic pH of early 
endosome  
(ii) Viral genome released into cytoplasm 
 
4. Translation 
Viral genome is translated by cap independent mechanism to produce a single 
polyprotein 
5.Polyprotein Processing 
Polyprotein is processed by viral proteases (Lpro and 3Cpro) to produce 
intermediates and mature viral proteins 
6. Replication 
(i) Positive sense genome used to make negative sense RNA template 
(ii) Synthesis of new positive sense RNA genome copies for translation or new 
virion synthesis 
7. Genome Packaging and Assembly 
Viral genome is packaged into assembled (exact mechanism is unknown) 
8. Maturation Cleavage  
Following viral genome packaging and  assembly of the capsid VP0 is cleaved 





















Adapted from Whitton et al ,2013 
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Figure 1.5. The FMDV viral infection cycle: The main stages of the infection 
cycle of FMDV are shown and numbered in the diagram (top, adaped from 
Whitton et al, 2013), with explanations of key events including translation 
genome replication and assembly are described in the table (bottom).  
 
1.5.1 Attachment and Entry 
Picornaviruses have been shown to utilise various cellular receptors for 
attachment to the cell surface. For PV the main receptor has been identified as 
CD155 (Mendelsohn et al., 1989) whereas major type rhinoviruses use ICAM-1 
(Greve et al., 1989). Both these viruses have canyons on their surface which 
act as the interaction point between virus and receptor (He et al., 2000). FMDV 
has been found to use two main groups of receptors, integrins and heparan 
sulfate. Integrins are a group of cell surface receptors made up of different 
alpha and beta subunits forming heterodimeric glycoproteins. Heparan sulfate is 
a glycosaminoglycan and highly sulphated and hence negatively charged 
(Meneghetti et al., 2015). 
Field isolates of FMDV use RGD binding integrins including αvβ3, αvβ6, αvβ8 
and αvβ1 integrins as receptors (Baranowski et al., 2000, Jackson et al., 2000, 
Jackson et al., 2002, Berryman et al., 2005, Neff et al., 1998). The presence of 
an RGD motif located on the GH loop of VP1 allows the virus to interact with the 
integrin receptor (Burman et al., 2006). Tissue culture adapted strains of FMDV 
have been shown to have an increased affinity for heparan sulfate, which is 
thought to be due to accumulations of mutations that lead to an increase in 
positive charge on the outer capsid surface (Chamberlain et al., 2015, Jackson 
et al., 1996). 
Entry of FMDV into the cell has been shown to occur through clathrin mediated 
endocytosis for isolates that bind to the αvβ6 integrin, this pathway has also 
been shown to be utilised by a second Aphthovirus, equine rhinitis A virus 
(ERAV) (Berryman et al., 2005, Groppelli et al., 2010). In comparison heparan 
sulfate binding virus isolates were found to use caveolae mediated endocytosis 
suggesting the receptor used can influence the entry pathway (O'Donnell et al., 
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2008). Following uptake by either mechanism the virus is trafficked to early 
endosome where a change to acidic pH is believed to trigger particle 
dissociation and genome uncoating and membrane penetration (see below). 
1.5.2 Uncoating of the viral particle  
 
Two mechanisms of uncoating appear to be utilised by picornaviruses. 
Following binding to its receptor PV has been shown to undergo a 
conformational change to produce an A type or infectious particle, which leads 
to exposure of VP4 and the N terminal of VP1 (Belnap et al., 2000). FMDV 
which differs from the enteroviruses in both its receptors and lack of canyon on 
the cell surface is predicted to have a simpler mechanism of uncoating in that it 
doesn’t appear to produce intermediate particles. Instead the uncoating 
mechanism of FMDV seems to be pH triggered with particle dissociation 
occurring in intracellular acidic endosomes following a pH change (Caridi et al., 
2015, O'Donnell et al., 2005).  
Following uncoating the capsid protein VP4 is released and interacts with the 
cell membrane forming a multimeric pore, which likely allows the vRNA to be 
released into the cytoplasm (Panjwani et al., 2014). Once the vRNA has been 
released translation and replication is able to take place within the cytoplasm. 
 
1.5.3 Translation of the Genome 
Picornaviruses rely on a cap-independent mechanism to translate their 
genomes where the ribosomal subunit binds directly to the IRES located in the 
5’ UTR of the genome.  As is the case for cap-dependent translation, a number 
of cellular proteins are required to form a complex at the IRES, including a 
group known as IRES transacting factors (ITAFs). The binding of cellular protein 
PCBP2 to a stem loop within the IRES has been shown to be essential in 
translation of PV (Sean et al., 2008). The cellular factor p57 (also known as 
PTB) has been shown to interact with the IRES of several picornaviruses 
including FMDV, Encephalomyocarditis virus (EMCV) and PV, having varying 
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effects (Kafasla et al., 2011, Wang et al., 2013). PTB is believed to be a splicing 
factor (Belsham and Sonenberg, 1996). The protein G3BP1 has recently been 
found to bind RNA sequences within the IRES of FMDV, this event has been 
suggetsed to have a regulatory effect on translation of the genome (Galan et al., 
2017). 
In addition to utilising the cellular machinery to translate its genome viral 
proteins have also been shown to be involved in shutting down cap dependent 
translation. The initiation factor eIF4G, which usually forms part of the cap 
binding complex and helps initiate translation, is cleaved by the L protein of 
FMDV and the 2A protease of PV leading to inhibition of host cell cap-
dependent translation. This is thought to aid the translation of the viral genome 
by reducing competition with host cell translation (Etchison et al., 1982, Gradi et 
al., 1998, Devaney et al., 1988). The genome is translated as a single 
polyprotein which then undergoes a cascade of proteolytic processing to 
produce a number of intermediate processing products prior to further cleavage 
producing the mature viral proteins.  
The FMDV polyprotein is cleaved by the viral proteases the  L protein and 
3Cpro and the 2A peptide to produce initial precursor proteins of L, P1-2A, 2BC 
and 3ABCD. These precursors undergo subsequent series of cleavages by the 
3C protease to produce a number of processing intermediates (e.g. VP0 and 
3CD) in addition to the 14 mature viral proteins (Mason et al., 2003). 
Following translation and production of viral proteins the viral RNA is then 
replicated. The exact mechanism that cause the switch between translation and 
replication remains poorly understood. One theory suggested for PV is that 3CD 
cleaves PCBP2 thereby disrupting its ability to interact with SRp20 and recruit 
ribosomes to the IRES and allowing the synthesis of a negative strand template 






1.5.4 Genome Replication 
To allow RNA synthesis the vRNA is thought to circularise. For PV this is 
thought to occur due to an interaction of the cloverleaf and the PCBP2 complex 
at the 5’UTR with PABP that is bound to the poly A tail (Herold and Andino, 
2000). The following step in viral RNA replication is the uridylation of 3B, 
thought to occur at the cre (located in the 5’UTR of FMDV and 2C in PV (Mason 
et al., 2002, Goodfellow et al., 2000). Uridylated 3B is then transferred to the 3’ 
end of the genome (likely as part of a complex by 3D or 3CD) to act as primer 
for the 3D polymerase allowing synthesis of negative-sense strands. This leads 
to production of an intermediate double stranded RNA product known as the 
replicative form, which is then unwound and acts as a template for further 
positive strand synthesis (Paul and Wimmer, 2015, Daijogo and Semler, 2011). 
Replication of many positive strand RNA viruses, including hepatitis C virus 
(HCV), Zika and Dengue as well as the picornaviruses is associated with 
cellular membranes. This association with membranes is thought to provide a 
structural scaffold for the formation of the replication complex (RC) thereby 
allowing RNA replication. These enclosed membrane structures have been 
defined as replication organelles (Hsu et al., 2010) and are often enriched with 
PI4P and cholesterol. Formation of these organelles requires the virus to trigger 
rearrangement of cellular membranes through diverting different cellular 
pathways and viral proteins including 3A are thought to play a key role in this 
process (this process is described in further detail in sections 1.6.2 and 1.6.3). 
 
1.5.5 Genome Packaging and virion assembly 
The exact mechanism of packaging for FMDV is not fully understood. It is 
believed that specific sequences may exist within the genome that act as signal 
to aid genome packaging. Studies with Aichi virus (AiV) have found possible 
roles for the leader protein in RNA encapsidation (Sasaki et al., 2003) and the 
current theory is that viral genomes contain specific packaging signals that 
trigger packaging of the genome prior to the maturation cleavage of VP0. It is 
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however known that processing of the polyprotein produces capsid proteins 
VP1, VP3 and VP0, single copies of which form a protomer. Five of these 
protomer units then combine to form pentameric subunits, 12 of which form the 
fully assembled icosahedral capsid structure. Following genome packaging a 
final maturation cleavage of VP0 occurs resulting in VP2 and VP4 mature 
proteins.  
 
1.6 The Picornavirus 3A protein 
The 3A protein is the first protein encoded by the P3 region of the picornavirus 
genome and has been shown to play a number of roles during viral replication, 
with the majority of studies using PV 3A as a model protein. The 3A protein is a 
membrane-associated protein and therefore thought to play a key role in virus 
replication and formation of the viral replication complex and organelles (see 
section 1.6.2) as well as being linked with virulence and host range. For 
example, studies have found that changes to the 3A proteins of Hepatitis A 
virus (HAV) may be involved in adaptation to cell culture (Graff et al., 1994) and 
for PV a single amino acid (a.a) change of isoleucine to threonine at a.a 46 of 
3A impaired the viruses ability to cause CPE in Vero cells (the virus retained its 
ability to cause CPE in HeLa cells) (Lama et al., 1998).  Additionally Harris et al. 
identified residues in 3A which when combined with mutations in 2B led to 
improved replication of HRV in murine cells (Harris and Racaniello, 2005). 
Furthermore mutations in the 3A protein of Coxsackie virus B3 (CVB3) have 
been linked with reduced myocardiogenicity when tested in vivo in mice 
(Massilamany et al., 2015). FMDV 3A also appears to play similar roles in viral 
host range and virulence as discussed in section 1.7.2. 
 
1.6.1 Picornavirus 3A and the early secretory pathway 
 
PV 3A has been shown to inhibit protein secretion from cells (Doedens et al., 
1997), however for FMDV this process is carried out by the processing 
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intermediate protein 2BC or co-expression of 2B and 2C (Moffat et al., 2005, 
Moffat et al., 2007). This suggests there are likely potential differences between 
FMDV and the enteroviruses in their interactions with the early secretory 
pathway. Furthermore, expression of PV 3A has also been found to lead to a 
reduction in the expression of the major histocompatibility complex 1 and inhibit 
the secretion of some pro-inflammatory cytokines including IL-6 and IL-8(Dodd 
et al., 2001). This ability is considered beneficial for the virus, providing a 
mechanism by which to avoid the innate immune response. 
 
1.6.2 Host cell membranes remodeling; the role of 3A in forming the 
replication complex and replication organelles  
 
During infection the Picornaviridae (like many RNA viruses) cause 
reorganisation of intracellular membranes generating structures termed 
replication organelles (RO). These membrane structures are specialized sites 
dedicated to vRNA replication and are thought to provide membranes with 
unique protein and lipid compositions and provide a structural scaffold for the 
formation of replication complexes (Miller and Krijnse-Locker, 2008) through 
providing an environment where the viral proteins e.g. 3Dpol (Hsu et al., 2010) 
and cellular factors e.g. OSBP required for replication concentrate (Arita et al., 
2013, Roulin et al., 2014, Strating et al., 2015).  
The exact role of viral non-structural proteins in RO formation is unclear but 
studies have found that expression of some viral non-structural proteins is 
enough to lead to rearrangement of the intracellular membranes and trigger 
formation of ROs (Teterina et al., 1997). The PV 3A, 2C, and 2BC can each 
induce ER modifications but co-expression of 3A and 2BC together is required 
to induce membrane structures that are similar to those observed in naturally 
infected cells (Suhy et al., 2000). 
Recent evidence has established that enteroviruses, cardioviruses and 
kobuviruses (e.g. PV, CV, EMCV and AiV) utilise components of both vesicular 
(e.g. GBF1) and non-vesicular (e.g. PI4K, OSBP, PI4P and cholesterol) lipid 
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trafficking to generate RO. Interestingly, formation of RO by viruses form 
different genera appear to require different cellular proteins and PI4KIIIβ 
(phosphatidylinositol 4-kinase IIIβ), PI4KIIIα, Arf1 (ADP-ribosylation factor 1), 
GBF1 (Golgi brefeldin A resistant guanine nucleotide exchange factor 1), Sar1 
(secretion-associated and Ras-related 1), ACBD3 (acyl-coenzyme A [CoA]-
binding protein domain 3) and OSBP (oxysterol-binding protein) have all been 
implicated in facilitating virus replication (Arita et al., 2013, Belov et al., 2008, 
Greninger et al., 2012, Hsu et al., 2010, Lanke et al., 2009, Midgley et al., 2013, 
Roulin et al., 2014, Wessels et al., 2006).  
The 3A protein has a central role in formation of ROs and studies of RO 
formation support a model where the picornavirus 3A protein subverts lipid 
homeostasis, including phospholipid biosynthesis and cholesterol trafficking to 
generate membranes required for developing an RO. During RO formation it is 
thought that enterovirus 3A binding to GBF1 leads to the recruitment of 
phosphatidylinositol 4-kinase III β (PI4KIIIβ) which in turn generates PI4P 
(phosphatidylinositol 4-phosphate) which then accumulates at the RO. The 
accumulation of PI4P leads to the recruitment of OSBP which in turn leads to an 
accumulation of cholesterol at RO that is driven by the OSBP-mediated 
PI4P/cholesterol counter flow system. A direct interaction between the 3A 
protein of PV, CVB3 and HRV14 and GBF1 has been found providing 
supporting evidence for this theory (Wessels et al., 2006, Greninger et al., 2012, 
Viktorova et al., 2015). GBF1 has also been found to be present in the ROs 
generated during CVB3 and PV infection and depletion of GBF1 causes 
inhibition of vRNA synthesis, implying it is required for enterovirus replication 
(Belov et al., 2007, Belov et al., 2008, Mossessova et al., 2003). 
Interestingly, expression of CVB3 non-structural protein 3A on its own leads to 
membrane enrichment of both PI4KIIIβ and PI4P suggesting that 3A is 
responsible for the active recruitment of the kinase to RO (Dorobantu et al., 
2014). Other picornaviruses such as EMCV and AiV also generate PI4P-
enriched RO. Similarly to the enteroviruses, PI4KIIIβ is also essential for AiV 
(genus Kobuvirus) replication but is recruited to RO by a different strategy from 
that used by enteroviruses. Multiple non-structural proteins, (2B, 2BC, 2C, 3A, 
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and 3AB) of AiV have been shown to interact with the Golgi protein acyl-
coenzyme A binding domain containing 3 (ACBD3).  In uninfected cells, ACBD3 
and PI4KIIIβ interact which is thought to contribute to localisation of PI4KIIIβ at 
the Golgi. Therefore, binding of the AiV non-structural proteins to ACBD3 
appears to mediate the recruitment of PI4KIIIβ to RO (Greninger et al., 2012, 
Greninger et al., 2013, Klima et al., 2017, Sasaki et al., 2012). 
In comparison, the cardiovirus EMCV replicates independently of PI4KIIIβ and, 
instead, subverts PI4KIIIα (phosphatidylinositol 4-kinase III alpha) to generate 
PI4P at ROs and siRNA-mediated knockdown and pharmacological inhibition of 
PI4KIIIα inhibits EMCV genome replication. Furthermore, EMCV as the 3A 
protein interacts directly with and PI4KIIIα, which appears to be responsible for 
PI4KIIIα recruitment to RO.  However, similar to the enteroviruses, PI4P 
produced at RO recruits OSBP to RO and inhibition of OSBP shuttling inhibits 
EMCV RNA replication. Additionally  Dorubantu et al found that mutations in the 
3A of EMCV overcame the requirement of PI4KIIIα for replication, providing 
further evidence of a direct interaction between EMCV 3A and PI4KIIIα 
(Dorobantu et al., 2016). 
1.6.3 Formation of FMDV ROs 
 
FMDV replication differs from that of the enteroviruses in a number of ways. For 
example enterovirus replication has been shown to be inhibited by the fungal 
metabolite Brefeldin A (BFA) whereas FMDV (and also the cardioviruses) are 
insensitive to its effects. This is potentially due the fact that enteroviruses 
require an intact Golgi for infection and replication (Gazina et al., 2002, Lanke et 
al., 2009, Cuconati et al., 1998), while FMDV in comparison appears to be able 
to replicate even when the Golgi is disrupted due to the action of BFA (Gazina 
et al., 2002, Martin-Acebes et al., 2008, Midgley et al., 2013, Monaghan et al., 
2004, O'Donnell et al., 2001). 
 
Formation of RO has also been studied for FMDV. Initial investigations showed 
that consistent with other picornaviruses, FMDV infection generates large 
numbers of single- and double-membrane structures that are likely to be RO 
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(Martin-Acebes et al., 2008, Monaghan et al., 2004). Early after infection, the 
ER-Golgi intermediate compartment (ERGIC) and Golgi are disrupted by FMDV 
before major changes are detected in the ER (Zhou et al., 2013, Midgley et al., 
2013), suggesting FMDV may inhibit vesicular traffic through the early secretory 
pathway and that FMDV replication membranes are likely derived from the ER 
or pre-Golgi membranes. Enteroviruses on the other hand are predicted to 
utilise Golgi derived membranes (Gazina et al., 2002, Lanke et al., 2009). 
 
The viral components of FMDV RO have been investigated in detail (Berryman 
et al., 2016) using IBRS2 cells at the mid-phase of the replication cycle and 
labelling for double stranded RNA, which is produced during infection and 
considered to be a marker for RO (Sasaki et al., 2012, Richards et al., 2014). 
Double stranded RNA did not co-localise with FMDV 2C or 3D, both of which 
are markers of ROs, it also showed little co-localisation with positive strand 
RNA. However, there was extensive co-localisation of the positive strand RNA 
with both 2C and 3D. FMDV 3A also co-localised with positive strand RNA but 
was also found distributed throughout the cytoplasm (Berryman et al., 2016) 
suggesting 3A may be present in more than one location and have multiple 
roles in replication.  
 
Despite the apparent differences in how RO form, common themes to emerge 
are that picornavirus replication requires PI4P and cholesterol (Harak and 
Lohmann, 2015, Dorobantu et al., 2015a). Cells infected with various 
picornaviruses show elevated PI4P levels, with PI4P being thought to localise to 
ROs (Dorobantu et al., 2015a, Greninger et al., 2012, Sasaki et al., 2012). In 
FMDV infected cells however this is not the case, PI4P levels are not elevated 
nor does PI4P localise to ROs (Berryman), therefore FMDV appears to utilise a 
novel mechanism to generate ROs. As described above, the enteroviruses and 
kobuviruses both use PI4KIIIβ, and EMCV utilises PI4KIIIα to increase levels of 
PI4P at ROs. In comparison FMDV doesn’t require activity of either of these 
enzymes, and replication is unaffected when they are inhibited by the selective 




The observation that FMDV replication is independent of PI4KIIIα is consistent 
with a study by Dorobantu et al (Dorobantu et al., 2015a) who reported that 
infection by ERAV (also an Aphthovirus) is was not inhibited by AL-9. In addition 
a  study using CVB3 found that a 3A point mutation resulted in virus able to 
replicate independently of PI4KIIIβ (van der Schaar et al., 2012) therefore drug-
resistant variants of CVB3 appear to behave similarly to FMDV as they can 
replicate independently of PI4KIIIβ. This implies that picornaviruses from 
multiple genera may have evolved to replicate independently of type III PI4Ks. 
Taken together these results suggest the RO membranes generated by FMDV 
lack PI4P and therefore have a different lipid composition to those found in 
other picornavirus-infected cells. FMDV has also been found to be able to 
replicate independently of OSBP, this is consistent with findings described 
above as PI4P is required to recruit OSBP to the RO. Studies utilizing the 
OSBP inhibitor 25-HC have found not all picornaviruses require OSBP for 
replication including ERAV (another member of the Aphthovirus genus) and 
Human Parechovirus in addition to FMDV (Strating et al., 2015, Berryman et al., 
2016). Due to the potential differences in how FMDV generates RO in 
comparison to other picornaviruses, it is possible that FMDV 3A may recruit 
alternative host factors that enable virus replication.  
 
1.7 FMDV 3A 
1.7.1 General characteristics of the FMDV 3A protein 
FMDV 3A differs from that of other members of the picornaviridae in that it is 
much longer due to an extension of its C terminal domain. The 3A protein of 
FMDV is 153 a.a in length whereas PV 3A is just 87 a.a. All other 
picornaviruses have a 3A protein of less than 100 a.a with the exception of 
equine rhinitis virus B (ERBV) (Wutz et al., 1996) and BRBV (Hollister et al., 
2008). Figure 1.7.1 shows the alignment of 3A protein sequences from the 4 
currently classified members of the Aphthovirus genus (panel A), each of which 
are longer than the majority of picornaviruses that belong to other genera of the 
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picornaviridae. This includes the kobuviruses and enteroviruses as shown in 
Figure 1.7.1 panel B which shows the alignment of FMDV 3A with other 
members of the picornaviruses belonging to different genera. Sequences are 
aligned based on the predicted transmembrane regions of the proteins. Table 
1.7.1 shows the genus and length of each of the viruses included in the 
alignments (both panels A and B) in Figure 1.7.1. These alignments show that 






FMDV                                    ISIPSQKSVLYFLIEKGQHEAAIEFFEGMVHDSIKEELRPLIQQTSFVKRAFKRLKENFEIVALCLTLL 
BRBV MGKYMTLDDIKKRKPVVIPFTGRSYQAGRDINASPEMQEKLLKYLVKNEHLDAALNFYNEECDEDVRDKWGPSIGKYLEVKTLWMKVKKYSHLFLTGLMLIGNM 
BRAV        VKTLHDKLKASLPKGRGYRCDREVNLKTDEAERMFRYLLNRDPALAGEFLEKECDPELADKYLPLLREHTGKSKLWAMLTKHCDLFLHGLLLVANLV 








FMDV         ISIPSQKSVLYFLIEKGQHEAAIEFFEGMVHDSIKEELRPLIQQTSFVKRAFKRLKENFEIVALCLTLLANIVIMIRETRKRQKMVDDAVNEYIEK 
Aichi  GNRVIDAEPREIPLEYADDLLEAMAHHRPVPCSL GLSQAIANNTPIQQISETFWKYRKPIFTCTTFLAVLGFLCSSVIPLARSLWKSKQDTPQEPQ 
CVB3   GPPVYREIKISVAPETPPPPAIADLLKSVDSEAVREYCKEKGWLVPEINSTLQIEKHVSRAFICLQALTTFVSVAGIIYIIYKLFAGFQ 
EMCV                      APVDEVSFHSVVQQLKARQEATDEQLEELQEAFAKVQERNSVFSDWLKISAMLCAATLALSQVVKMAKDLVRVQLDEQEQ 
PV      GPLQYKDLKIDIKTSPPPECINDLLQAVDSQEVRDYCEKKGWIVNITSQVQ TERNINRAMTILQAVTTFAAVAGVVYVMYKLFAGHQ 
EV-71     GPPKFRPIKICLEEKPAPDAISDLLASVDSEEVRQYCRDQGWIIPETPTNVERHLNRAVLVMQSIATVVAVVSLVYVIYKLFAGFQ 
HRV        GPVYKDLEIDVCNTPPSECINDLLKSVDSEEIREYCKKKKWIIPEIPTNIERAMNQASMIINTILMFVSTLGIVYVIYKLFAQT 
Continued 
FMDV  ANITTDDKTLDEAEKSPLETSGASTVGFRERTLPGQKACDDVNSEPAQPVEEQPQAE 
 
Figure 1.7.1.1 Sequence alignments of Picornavirus 3A proteins: The 3A a.a sequences of selected 3A proteins, aligned 
based upon the sequence of  their predicted  trans-membrane domains, are shown. The top alignment (A) shows FMDV 3A in 
comparison to the other members of the aphthoviruses and the lower panel (B) shows the FMDV 3A sequence in relation to 
picornavirus 3A from other genera, all of which are shorter in length, predicted transmembrane domains of each virus are 




Table 1.7.1.1: Comparison of Picornavirus 3A proteins: The length (in a.a) 
of selected picornavirus 3A proteins from various genera is shown. FMDV is the 
longest followed by BRBV, another member of the Aphthovirus genus, whereas 









The N terminal domain of FMDV 3A is highly conserved across serotypes 
despite being one of the most variable proteins of FMDV (Knowles et al., 2001). 
The protein itself contains the N terminal domain which has two predicted alpha 
helices that are thought to be involved in dimerization of 3A (Gonzalez-Magaldi 
et al., 2012). FMDV 3A also has a predicted hydrophobic transmembrane 
domain spanning residues 59-76, the flanking N and C termini are predicted to 
point towards the cytosol (González-Magaldi et al., 2014). Downstream of the 
transmembrane domain is the much more variable C terminal domain, this 
domain is considerably longer in FMDV in comparison with other members of 
the picornaviridae. This region has also been found to be a hotspot for deletions 
and substitutions (Carrillo et al., 2005). Figure 1.7.1.2 shows the predicted 
features found within 3A including the alpha helices within the N terminal 
domain, predicted to be involved in dimerization of FMDV 3A (Gonzalez-
Magaldi et al., 2012) and the predicted  hydrophobic transmembrane domain of 
the protein. Like other picornavirus 3A proteins that of FMDV is membrane 
associated and is thought to interact with membranes via its predicted 
Virus Genera 3A  length (a.a) 
FMDV Aphthovirus 153 
BRBV Aphthovirus 133 
BRAV Aphthovirus 109 
ERAV Aphthovirus 100 














HRV14 Rhinovirus A 85 
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hydrophobic transmembrane domain, as shown in Figure 1.7.1.2, lower panel. 










Figure 1.7.1.2 Predicted features of  FMDV 3A: The top panel shows the 
location of both predicted alpha helicies within the N terminal domain (residues 
25  to 33 and 37 to 44 ) shown in green and the position of the hydrophobic 
transmembrane domain (residues 59 to 76) shown in blue. The lower panel 
shows the predicted interaction of FMDV 3A with intracelluar membranes via its 
transmembrane domain (as described by González-Magaldi et al., 2014), where 
both the N and C protein termini point towards the cytosol.  
 
1.7.2 FMDV 3A and links with viral host range 
FMDV 3A has been linked with determining viral host range. Virus isolates with 
deletions in the C terminal domain (ranging in size from 10-20 a.a) have 
previously been identified in vaccine strains passaged in eggs and in outbreak 
strains (Beard and Mason, 2000, Giraudo et al., 1990, Knowles et al., 2001).  
The strain responsible for the 1997 FMD outbreak in Taiwan contained the 
same deletion of a.a 93-102 as identified in the vaccines strains passaged 
through eggs (Beard and Mason, 2000, Giraudo et al., 1990). During this 
outbreak, pigs were severely affected with approximately 4 million pigs from 
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affected farms being slaughtered, there was however no reported cases in 
cattle during the outbreak (Dunn and Donaldson, 1997, Beard and Mason, 
2000). A second deletion of a.a residues 133-143 has also been identified in 
viruses that affected pigs; however, this virus was also found in  cattle and 
studies that used these viruses to infect keratinocytes from both cattle and pigs 
showed the that viruses with this deletion grew equally well in either cell type 
(Knowles et al., 2001). Interestingly, such deletions have been identified in a 
number of viruses that have been circulating in Asia since at least the 1970s 
(Knowles et al., 2001). 
Deletions in 3A have been associated with an attenuated phenotype in cattle 
and bovine cells but viruses with theses deletions appear to be highly infectious 
in pigs (often referred to as porcinophillic) (Beard and Mason, 2000, Dunn and 
Donaldson, 1997). Further work showed a recombinant virus containing a much 
larger deletion had a similar phenotype and was attenuated for cattle but 
remained virulent for pigs (Pacheco et al., 2013, Pacheco et al., 2003). In 
addition, it has also been shown that removing the entirety of 3A downstream 
from a.a residue 81 does not affect replication in BHK-21 cells (Behura et al., 
2016). Furthermore a single a.a change within 3A led to adaptation of the virus 
to a guinea pig host supporting the idea that 3A plays a role in viral host range 
(Nunez et al., 2001). Although recently Ma et al have suggested other regions 
of the FMDV genome could also be responsible for determining viral host range 
in addition to that of 3A (Ma et al., 2014, Ma et al., 2016).   
Recent evidence has shown that the attenuation of replication caused by 
deletions within 3A appears to be able to overcome following accumulation of 
mutations upstream in the genome. In particular a threonine to isoleucine 
change at residue 135 in 2C was identified as causing enhanced growth in 
BHK-21and IBRS2 cells of a virus that had a deletion of a.a 84 to 143 in 3A. 
This change occurred following passaging of the virus, which initially exhibited a 
reduced growth rate and smaller plaques than that of a virus with full-length 3A 
(Yuan et al., 2017). 
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FMDV 3A has also been linked with virulence, Rosas et al have shown that viral 
replication levels increased in cells that stably expressed FMDV 3A or 3AB 
whereas viral susceptibility was  lower in cells transiently expressing 3A (Rosas 
et al., 2008).  
 
1.7.3 Cellular Interacting partners of 3A 
A number of cellular proteins have been reported to interact with the 3A protein 
of picornaviruses. As discussed above in sections 1.6.2 and 1.6.3, the 3A 
protein of EMCV has been shown to bind the lipid kinase, PI4KIIIα (Dorobantu 
et al., 2016), the 3A proteins of enteroviruses (e.g., PV and CV) bind GBF1 
(Wessels et al., 2006) and several viruses of both the enterovirus and kobuvirus 
genera (e.g. AiV) directly bind ACBD3 (Greninger et al., 2012, Klima et al., 
2017, Sasaki et al., 2012). As these proteins are required for formation of viral 
RCs and ROs, the above observations support a key for 3A in picornavirus 
replication. For FMDV, a Y-2-H screen identified DCTN3 (Dynactin 3) as a 
cellular interacting partner of 3A (Gladue et al., 2014) . DCTN3 is a subunit of a 
dynactin complex, which serves as a cofactor for the dynein motor. However, a 
direct interaction between 3A and DCNT3 was not demonstrated and the 
functional significance of this interaction for FMDV replication is unknown. 
However, it was shown that over expression of DCTN3 or proteins predicted to 
disrupt the dynactin complex decreased FMDV infection (Gladue et al., 2014). 
 
1.7.4 Other potential roles of 3A in genome replication  
The 3A protein is believed to play an important role in replication, as described 
above. There is also the likely probability that 3A containing intermediates (e.g. 
3AB), produced during post translational processing of the polyprotein, may 
play key roles in replication. The VPg (3B) protein has been shown to be a 
substrate for uridylation when a free peptide, however this may not be the only 
form to undergo this reaction in infected cells and it has been suggested that 3B 
containing precursors (both 3AB and 3BC) or the entirety of P3 may be the 
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functional source of 3B for uridylation (Nayak et al., 2005, Paul and Wimmer, 
2015). 
For PV, 3BC, 3BCD and P3 have been shown to serve as substrates for 
uridylylation in vitro although the reaction is less efficient for the larger 3B 
containing precursors (3BCD and P3) (Pathak et al., 2008), suggesting that 
3BC may be the VPg donor for replication. This conclusion has been supported 
by the observation that (in contrast to 3C-containing precursors) attempts to 
uridylate PV 3AB in vitro were unsuccessful (Paul and Wimmer, 2015). This 
could also be the case for FMDV, however, since FMDV encodes multiple 
copies of 3B within its genome a wider range of 3A or 3C-containing processing 
intermediates e.g. 3A3B1, 3AB12, 3AB123 or 3B1233C could potentially be the 
source of VPg for uridylation.  
 
1.7.5 Possible Chaperone activity of 3A 
 
The 3A of picornaviruses have been reported to have chaperone activity. 3AB 
of EV71 is reported to be a nucleic acid chaperone protein and to have nucleic 
acid helix-destabilizing and strand annealing activity. This activity is dependent 
on 3B and the last 7 a.a at the C-terminal of 3A, of which 5 a.a were identified 
as critical for RNA chaperone activity (Tang et al., 2014). Furthermore 3AB of 
PV has been suggested as having a chaperone effect promoting hybridization 
of complementary nucleic acids and destabilizing secondary structure 
(DeStefano and Titilope, 2006). It is therefore possible that FMDV 3A may also 









This project utilised a combination of sub-genomic replicons, reverse genetics 
and proteomics techniques with the aim of gaining further understanding of the 
roles played by the non-structural viral protein 3A during FMDV replication. 
Project Aims: 
1. FMDV 3A has been implicated as a factor of host specificity. Aim 1 is to 
investigate the effects of a novel naturally occurring large deletion in 3A 
and deletion of 3B1 on replication in different host derived cell lines 
2. Picornavirus 3A binds cellular proteins and plays a central role in 
formation of replication organelles. Aim 2 is to utilise proteomics 
techniques to identify potential cellular protein interaction partners of 3A 
and investigate effects of reducing expression levels of these partners on 
infection and viral replication 
3. 3A is membrane associated. VAP proteins bind proteins with a FFAT 
motif. Aim 3 is to investigate the role of a potential FFAT-like domain in 
3A in FMDV replication 
4. 3A and 3C have the potential to deliver VPg (3B) to a replication 
complex. Aim 4 is to investigate the role of 3A as the chaperone for 
delivery of VPg to the viral replication complex. 
32 
 
Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Cell lines: 
Baby Hamster Kidney-21 clone 13 cells (BHK-21), and Madin Darby Bovine 
Kidney (MDBK) and Human Embryonic Kidney293 (HEK 293) cells were 
obtained from the central service unit at Pirbright and maintained in Glasgow’s 
minimum essential media (GMEM) with 10% Foetal Bovine Serum (FBS) 
(Sigma) 1% L-glutamine (Sigma) and 1% penicillin/streptomycin (P/S) (Sigma). 
Porcine kidney IBRS2 cells were obtained from the central service unit at 
Pirbright and maintained in GMEM with 10% Adult Bovine Serum and P/S. A 
second porcine kidney cell line, SK-RST cells were obtained from the American 
Type Culture Collection and maintained in Dulbecco’s Modified Essential 
Medium (DMEM), supplemented with 10% FBS and P/S. 
Primary bovine thyroid (BTY) cells were provided by the central service unit at 
the Pirbright Institute growing in GMEM supplemented with 10% FBS and 
1%Field Antibiotics (Pirbright Institute). 
Parental and TBC1D20 knockout HeLa cell lines were kindly provided by Dr 
M.Handley (The Roslin Institute) and maintained in DMEM supplemented with 
10% FBS and P/S. 
 
2.1.2 Viruses and sub-genomic FMDV replicons: 
FMD viruses in this study were based on the full length infectious clone of O1 
Kaufbeuren (O1K) strain (Zibert et al., 1990, Ellard et al., 1999).  
A schematic representation of the FMDV genome and wildtype FMDV replicons 
based on FMDV O1K is shown in Figure 2.1.2.  Replicons contained Ptilosarcus 
guernyi Green Fluorescent Protein (Pt.GFP or mCherry reporter genes in place 
of majority of the capsid proteins are referred to as O1K Pt.GFP or O1K 
mCherry respectively. Negative control replicons that had 2 a.a mutations within 
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the polymerase active site (GDD motif mutated to GNN), of the viral polymerase 
(3D) were used to measure background signal from non-replicative input RNA 
(referred to as O1K Pt.GFP GNN and O1K mCherry GNN). Replicons were all 
kindly provided by Dr F. Tulloch (University of St Andrews) and modified from 
the GFP-PAC replicon system developed by Tulloch et al (Tulloch et al., 2014). 
In the course of this project O1K Pt.GFP was modified to produce various 
mutations or deletions to the P3 proteins in order to test effects on replication.  
The full length FMDV O1K cDNA clone plasmid (pT7S3) was used as template 
DNA to PCR amplify the capsid coding region required to restore sub-genomic 







Figure 2.1.2 Genome organisation of FMDV and Design of sub-genomic 
FMDV replicons: The full length genome of FMDV (top panel) and with the 
majority of the capsid coding region replaced with either a Pt.GFP reporter gene 
(middle panel) or an mCherry reporter (bottom panel) were used to study effects 
of changes to the P3 region by using fluorescent reporter gene expression as 
an indirect measure of replication. 
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2.1.4 Fusion protein expression plasmids 
3A and 3ABBB-GFP fusion protein expression plasmids were developed by 
cloning in PCR products encoding 3A or 3ABBB into the multiple cloning site 
region of the pEGFP-N1 expression plasmid (Clonetech). 
2.1.5 DNA Gene Blocks 
DNA sequences synthesised in plasmid backbones used to make the ∆3A81-
137 deletion and the 3A, 3C and No Donor replicons were obtained from Gene 
Art (Life technologies). Gene blocks used to create the ∆3A93-143, SKR∆3B1, 
SKR+3B1, O1K∆3B1, OSBP and Protrudin replicons were obtained from 
Eurofins. 
2.1.6 Oligonucleotides 
All primers used in this study were ordered from Integrated DNA Technologies 
and Sigma, and suspended to 100 µM stock solutions in dH2O before further 
dilution for working stock concentrations as required. 
2.1.7 Antibodies 
2.1.7.1 Primary Antibodies 
The monoclonal antibody to FMDV protein 3A (2C2) was kindly gifted to the 
Picornavirus group by Emiliana Brocchi (IZS, Brescia, Italy) and the polyclonal 
Rabbit antibody TC27, raised against FMDV 3D, was generated in house  at the 
Pirbright Institute. The primary antibodies to PDI (ER marker) and GM130 
(Golgi marker) were kindly provided by the Bioimaging group at Pirbright. 
Primary antibodies to β-actin and GFP were obtained from Roche and Sigma 
respectively 
2.1.7.2 Secondary Antibodies 
Alexa fluor conjugated secondary antibodies: goat anti-mouse (IgG H+L) 488, 
goat anti-mouse (IgG2a) 568, goat anti mouse (IgG1) 488 and goat anti-mouse 
(IgG H+L) 568 were all obtained from Invitrogen Molecular probes. 
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Goat Anti-Rabbit and Rabbit-anti mouse horse radish peroxidase conjugated 
secondary antibodies were acquired from Biorad and Dako respectively. 
2.2 Methods 
2.2.1 Tissue culture 
2.2.1.1 Maintaining of cell lines 
All cell lines were maintained through regular passage when cells reached 
confluence. Media was removed and monolayers washed with PBSa (without 
Ca2+ and Mg2+ ions). Cells were removed from flasks by incubation with 
Trypsin-EDTA (life technologies), detached cells in trypsin were transferred into 
universals and growth medium added to inactivate the trypsin. The cell 
suspension was centrifuged for 3 minutes at 1000 rpm to pellet cells. The 
supernatant was removed and the cell pellet re-suspended in 5ml complete 
growth media and seeded into T175 flasks (Greiner). 
2.2.1.2 Freezing and resuscitation of cells 
Frozen cell stocks were made by detaching confluent cell monolayers and 
pelleting as described in section 2.2.1.1, re-suspending in FBS with 10% DMSO 
(Sigma), dividing into 1 ml aliquots and storing at -80°C or in liquid nitrogen for 
long term storage. 
2.2.1.3 Transfection of cells  
Plasmid DNA and in vitro transcribed RNA was transfected using Lipofectamine 
2000 (Invitrogen). Plasmid DNA or in vitro transcribed RNA were diluted in 
Optimem serum free media (Gibco) and incubated for 5 minutes at room 
temperature. Lipofectamine 2000 was diluted in optimum in a separate tube and 
incubated for 5 minutes. The contents of the two tubes were mixed and 
incubated for 15 minutes at room temperature.  Growth medium was removed 
from cells and transfection mix pipetted on, fresh complete growth media was 
then added to cells. For plates going onto the IncuCyte zoom for live cell 
analysis clear FluoroBrite media (Gibco) with 10% FBS was added in place of 





























T25 flask 3 µg 8 µl 500 µl 
 
Table 2.2.1.3 Conditions used for transfection of DNA and RNA using 
Lipofectamine 2000: Cells seeded into various size tissue culture vessels were 
transfected using the ratios of lipofectamine to DNA and RNA shown in the 
table above. DNA, RNA and lipofectamine were diluted into Optimem serum 
free media and mixed to total volume shown and transfection mix added to 
cells. 
 
siRNA was transfected into cells using Dharmafect 4 transfection reagent 
(Dharmacon). siRNA in a 5 µM solution was diluted in a 10 µl volume of 
Optimem, in a separate tube Dharmafect 4 was diluted in 10 µl volume of 
Optimem. The contents of each tube were gently pipetted to mix and incubated 
for 5 minutes. The contents of the two tubes were then mixed together and 
incubated for a further 20 minutes. 80 µl of antibiotic free GMEM with 10% FBS 
was then added to transfection mix, complete media was removed from cells in 
a 96 well plate and replaced with the 100 µl mix of transfection mix and media 
per well. 
 
2.2.1.4 Treatment of cells with BFA 
Cells (BHK-21 or SK-RST) cells were seeded into 24 well plates and incubated 
overnight until 80% confluent. Prior to transfections cells were pre-treated for 15 
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minutes with either DMSO (the solvent carrier) or BFA (5mg/µl) diluted in 
fluorobrite media with 10% FBS at 37°C. BFA containing media was left on cells 
for the duration of the experiment. 
2.2.2 Infection of cells with FMDV 
Cells seeded in T25 flasks or multi well plates at approximately 80% confluency 
were infected with supernatant from previous viral passages using MOIs 
calculated based on viral titre. Infectious supernatant was diluted to correct 
multiplicity of infection (MOI) in Viral Growth Medium (VGM), complete growth 
medium was removed from cells and replaced with infectious supernatant. 
Flasks and plates were incubated and frozen at different time points post 
infection. 
 
2.2.3 DNA work and Generation of constructs 
2.2.3.1 Bacterial transformation 
JM109 (Promega), DH5α (Invitrogen) or XL 10 Ultra competent cells (Agilent) 
were transformed (according to manufactures protocols). DNA was added to 
competent cells, incubated on ice before heat shocking for 30 seconds at 42°C 
and incubating on ice for a further 2 minutes. Cells were left to recover in SOC 
media for an hour at 37°C before plating on plates containing ampicillin or 
kanamycin dependent on antibiotic resistance gene in plasmid. Plates were 
incubated at 30°C for 20-24 hours. 
2.2.3.2 Small and large scale preparation of plasmid DNA 
Colonies from transformed bacteria were picked and used to inoculate 5 or 10 
ml of LB broth containing antibiotics (ampicillin (100µg/ml) or kanamycin 
(50µg/ml) depending on sensitivity of plasmid). Cultures were incubated 
overnight at 30 or 37°C, shaking at 200 rpm. Between 1 and 3 ml of culture for 
small scale preps were spun at 13300 rpm for 3 minutes, to pellet bacteria. 
Pellets were subjected to alkaline lysis and neutralisation, and plasmid DNA 
purified through columns containing affinity matrixes. In order to prepare larger 
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amounts of plasmid DNA the 5 or 10 ml cultures described above were diluted 
into 250 ml LB broth with antibiotics and grown overnight as described above, 
before pelleting bacteria from the entire volume by centrifugation at 5000 rpm 
for 10 minutes. Plasmid DNA was prepared using Qiagen plasmid maxi prep 
spin kit (Qiagen) as per manufacturer’s instructions. 
2.2.3.3 Restriction digestion of DNA 
Restriction digest of DNA was carried out according to manufactures protocol 
(Promega and New England Biolabs). Typically reactions were set up in a total 
volume of 20 µl, consisting of: DNA (100ng-1µg), 2µl 10X reaction buffer, 5u/µg 
of DNA of enzyme and dH20 to 20µl. Reactions were incubated at 37°C (unless 
a different temperature was stated by manufacturer) for 2 hours to ensure 
complete digestion of the DNA. Reactions were run on a Tris/Borate/EDTA 
(TBE) agarose gel to check for complete digestion before being used in further 
downstream processes. 
2.2.3.4 Agarose gel electrophoresis 
DNA and RNA samples were run on 1% TBE gels for analysis unless otherwise 
stated. For a 1% gel 1g of Agarose was dissolved in 100ml of 1X Ultrapure TBE 
buffer (diluted 10X stock in dH2O) through heating. Once cooled 2.5 µl of 
ethidium bromide was added to agarose prior to pouring. DNA samples were 
mixed with 6X purple loading dye (New England Biolabs) and loaded onto gel, 
Quick load 1Kb DNA marker (New England Biolabs) was used unless otherwise 
stated. Gels were run in 1X TBE buffer at 120V until the dye front reached the 
end of gel. Gels were imaged using a Biorad gel documentation system and 
image lab software. 
2.2.3.5 Extraction of DNA from agarose gels 
Gels were placed on a UV light box to visualise DNA bands and cut out. 
Capture buffer was added to gel slices and melted at 65°C. DNA was then 
extracted through column purification using GE healthcare illustra GFX PCR 
DNA and Gel extraction kit and eluted into 20 µl dH2O.  
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2.2.3.6 Ligation of DNA 
DNA that had been prepared by restriction digest and gel extraction was used 
as vector and insert fragments for ligations to create new constructs. Vector 
DNA was phosphatase treated prior to ligation with recombinant shrimp alkaline 
phosphatase (New England Biolabs) for 30 minutes at 37°C and enzyme heat 
inactivated for 5 minutes at 65°C. Ligations, including vector only control 
reactions, were set up at varying ratios in 10µl volumes with T4 DNA ligase and 
ligase buffer containing ATP (New England Biolabs). Reactions were incubated 
overnight at 16°C and 2-5 µl transformed into competent cells (See section 
2.2.3.1). 
2.2.3.7 Quikchange mutagenesis 
Quikchange mutagenesis reactions were carried using a Quikchange lightening 
mutagenesis kit (Agilent) as per manufacturer’s instructions. Mutagenic primers 
were designed to fit specifications using Agilent’s online design tool and 
purchased from Sigma. Following Quikchange reaction DNA was transformed 
into XL 10 Gold Ultracompetent cells (See section 2.2.3.1).  
Colonies from transformed bacteria were used to inoculate Lb broth mini prep 
cultures, mini prep DNA was prepared (Section 2.2.3.2) from these and clones 
screened by either restriction digest (Section 2.2.3.3) or by Sanger sequencing 
(2.2.8.1). 
2.2.3.8 Polymerase Chain Reaction 
Fragments of DNA were amplified using Polymerase Chain Reaction. Standard 
PCR reactions were carried out using Taq DNA polymerase (NEB) and 
consisted of template DNA, 1µl Forward primer (10µM), 1µl Reverse primer 
(10µM), 1µl dNTPs, 5µl 10X standard Taq polymerase buffer, 1µl Taq 
polymerase and dH2O to 50µl. 
Typical cycling conditions are shown in Table 2.2.3.8  Annealing temperatures 
were normally set to approximately 4°C below the lowest primer Tm and tended 
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to range between 55°C and 60°C. Reactions were run on an Eppendorf 
Mastercycler Thermocycler. 
Stage Temperature Duration  
Initial denaturation 95°C 30 seconds  
Denaturing 95°C 15 seconds 
X 30 cycles Annealing 55-60°C 30 seconds 
Extension 68°C 1 minute/kb DNA 
Final Extension 68°C 5 minutes  
 
Table 2.2.3.8 Standard PCR cycling conditions: PCR amplification of DNA 
was carried out using conditions shown in the table above with Taq DNA 
polymerase. Primer annealing temperatures and extension times were adjusted 
accordingly with regard to primer melting temperatures and product length. 
 
2.2.4 RNA work 
2.2.4.1 In vitro transcription of RNA 
All RNA work was carried out in areas and with equipment that had been 
treated with RNAse zap (Sigma). DNA from replicon or infectious clone 
plasmids was linearized by restriction digest using AscI (New England Biolabs) 
as described in section 2.2.3.3. Linearized DNA was used as a template for in 
vitro transcription reactions set up as follows: Template DNA (up to 5µl), 5x 
transcription reaction buffer (4µl), DTT (2µl), rNTPs (8µl), RNAsin (0.5µl 
(40U/µl)), DNA dependent RNA T7 polymerase (1µl (10U/µl)), dH20 to 20µl 
(Promega) Reactions were incubated for 2-4 hours at 37°C, and treated with 
RNAse free DNAse (2µl) (Promega) for 15 minutes at 37°C. RNA integrity was 






2.2.4.2 Quantification of RNA with Qubit fluorimeter 
RNA was quantified using a fluorimeter (Qubit (Invitrogen) or Quantus 
(Promega)) using the broad range RNA assay kit as per manufacturers 
protocol. Briefly 1µl of sample was mixed with 199 µl of fluorescent RNA binding 
dye (molecular probes) and read against prepared standards. 
2.2.4.3 siRNA assays 
Three different SiRNAs were designed against different points in the porcine 
Rab7L1 sequences using the Dharmacon design tool. The SiRNAs were re-
suspended in nuclease free dH2O and diluted to 5µM then pooled together and 
transfected into IBRS2 cells (porcine kidney cells) in 96 well plates to a final 
amount of 5pg per well (See section 2.2.4.3). At 48 hours post transfection cells 
were infected with O1K FMDV for 4 hours , fixed with 4% PFM (see section 
2.2.7.1) and labelled for FMDV 3A using the 2C2 primary monoclonal antibody 
and a secondary antibody conjugated to a fluorophore (goat anti-mouse alexa 
fluor 488 (molecular probes)). Cell nuclei were labelled with ToPro 3 dye 
according to manufacturer’s protocol (Molecular probes). The total number of 
cells and number of infected cells were then counted using the Spectramax I3 
minimax plate reader (Molecular Devices) to determine if knockdown of Rab7L1 
expression impacted on FMDV infection in porcine cells. Cellular GFP intensity 
was also measured to see if the siRNA was impacting in any way on replication. 
 
2.2.5 Virus assays 
2.2.5.1 Virus passage and recovery 
BHK-21 cells were seeded into T25 flasks to be 80% confluent the following 
day. Cells were then transfected with in vitro transcribed RNA from infectious 
FMDV clones using method described in section 2.2.1.3. Following the addition 
of transfection mix, 5ml viral growth media (VGM) consisting of GMEM with P/S 
and 1%FBS was added to cells. Cell monolayers were monitored for up to 48 
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hours and flask frozen at observation of total CPE compared to non-transfected 
flasks or at 48 hours post transfection.  
Frozen flasks were thawed and supernatant collected and spun down to pellet 
cellular debris and split into 1 ml aliquots. One of these 1 ml aliquots was 
passaged onto fresh BHK-21 cells in T25 flasks containing 5ml of VGM and 
appearance of CPE monitored before passaging again as described above. 
2.2.5.2 Virus titrations  
Viral titre was calculated by plaque assay.  Briefly cells were seeded into 6 well 
plates and allowed to adhere overnight. Virus samples were serially diluted ten-
fold into PBS, cells were washed with PBS and viral dilution series added to 
wells. Plates were incubated at 37°C for 15 minutes and wells overlaid with 
Eagles Overlay (containing tryptose phosphate broth, FBS and P/S ) mixed with 
melted indubiose agarose. Plates were left at room temperature to allow overlay 
to set then incubated at 37°C for 48 hours. Cells were then fixed and stained 
using formaldehyde containing Methyl blue cell stain and left overnight at room 
temperature. Overlays were removed and plaques counted to determine viral 
titre. Titrations were carried out in duplicate for each sample therefore plaque 
counts from each sample at the same dilution were averaged and multiplied by 
ten to give final viral titre in plaque forming units  per ml (pfu/ml). 
2.2.5.3 Viral RNA extraction 
Extraction of RNA from clarified supernatant was performed using the Qiamp 
Viral RNA Mini Kit from Qiagen. Briefly 140µl of viral supernatant was added to 
560µl of lysis buffer mixed and incubated for ten minutes. 560µl of 100% 
ethanol was added to samples and tubes vortexed briefly before being affinity 
matrix column purified according to kit protocol and RNA eluted into 60µl elution 
buffer and stored at -80˚C. 
2.2.5.4 Reverse transcription (RT) PCR reactions 
RT reactions were carried out on extracted viral RNA or in vitro transcribed RNA 
to produce cDNA. Reactions were carried out as follows: 15µl of RNA, 3µl 
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10mM DNTPs (Promega), 3µl of primer (UK FMDV Rev6), were mixed and 
heated for 3 minutes at 70°C. Tubes were cooled on ice before adding: 5 x first 
strand synthesis buffer 8µl (Invitrogen), nuclease free H2O 5µl (Ambion), 2µl 
0.1µM DTT (Invitrogen) and 1µl Superscript III RT enzyme (Invitrogen). 
Reactions were incubated at 45°C for 60 minutes and 85°C for 5 minutes 
followed by 4˚C indefinitely. cDNA was purified using illustra GFX GE 
healthcare kit before being used in PCR reactions.  
 
2.2.6 Protein Analysis 
2.2.6.1 Preparation of samples for SDS PAGE 
Cells (BHK-21, MDBK) were seeded into multi-well plates and left to adhere 
overnight at 37°C before being transfected with plasmid DNA, or RNA from 
replicons or infectious clones or infected with FMDV virus and incubated for 
37°C for time required. Media from transfected or infected cells was then 
removed and replaced with 3X lysis buffer (3X SDS loading dye, with DTT in 
PBS). Lysed samples were scraped from wells into 1ml screw cap tubes and 
heated at 96°C for 5 minutes to denature proteins. 
2.2.6.2 Analysis of proteins by SDS PAGE 
Samples were prepared as described in section 2..2.6.1 and loaded onto 12% 
SDS (unless otherwise stated) prepared polyacrylamide gels alongside a 10-
250 KDa pre-stained protein ladder (Biorad). Gels were run in 1X Tris-Glycine 
Buffer with SDS at 100V until dye front just ran off the end.  
2.2.6.3 Western Blotting  
Proteins were transferred from SDS polyacrylamide gels onto nitrocellulose 
membranes as follows: Gels were removed from plates and placed in a blotting 
cassette with dH2O pre-soaked sponges, membrane and filter paper. Cassettes 
(Biorad) were place in tank with an ice block and 1X transfer buffer (1X Tris-




Membranes were blocked for 1 hour at room temperature or overnight at 4°C in 
5% Marvel milk block buffer (5% Marvel milk in PBS-Tween) in falcon tubes 
rotating on a spiramix. Primary antibodies were diluted as required in block 
buffer (primary antibodies were use at 1 in 100 dilution and secondary 
antibodies at a 1 in 250 dilution unless otherwise stated, and membranes 
incubated with them for 1 hour on rotating then washed in PBS-Tween for 15 
minutes, changing buffer at 5 minute intervals. Secondary antibodies were 
diluted in block buffer 1 in 2000 and incubated with membranes in falcon tubes 
for 1 hour on rotating. Washing step was repeated as above. Membranes were 
placed in a clean white tray and West Pico Supersignal Chemiluminescent 
substrate added (Thermo scientific) and imaged using the Syngene G: box. 
2.2.6.4 Immunoprecipitations 
BHK-21 cells were seeded into 20cm diameter tissue culture dishes and 
allowed to adhere overnight. Cells were transfected with 20µg of fusion protein 
DNA (3AGFP or 3AB GFP) or a pEGFP-N1 control and incubated for 12 and 24 
hours (see section 2.2.1.3 for transfection method). Cells were checked for GFP 
expression prior to removal using an Evos cell imaging system microscope. 
Immunoprecipitation (IP) buffer was added to monolayers and cells harvested 
and aliquoted into 1 ml tubes. Following harvesting samples were sonicated and 
50µl of sample retained as total cell lysate (TCL). Remaining lysate was 
centrifuged at 18,0000g for 10 minutes at 4°C, a further 50µl was removed as 
starting material. Magnetic anti GFP beads (Dundee cell products) were re-
suspended in 100µl of RIPA buffer and split into 1.5ml tubes. Remaining lysates 
were added to the tubes with beads, mixed and incubated for 2 hours on a 
rotating wheel at 4°C. Beads were pelleted by centrifugation and the entire 
supernatant kept as flow through (TCL). Anti GFP beads were re-suspended in 
IP Buffer, and washed three times before finally being re-suspended in elution 
buffer and heated to detach complexes. Tubes were placed against a magnetic 
rack and eluted liquid separated from beads (IP sample). TCL, FT and IP 
samples were run on a 4 to 20 % gradient gel (Biorad) SDS gel and western 
blotted (as described in sections 2.2.6.2 and 2.2.6.3) using a GFP antibody to 
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ensure IPs had worked before further preparation of samples for mass 
spectrometry was conducted (section 2.2.6.5).  
2.2.6.5 Preparation of samples for Mass spectrometry 
IP samples from section 2.2.6.4 were run on a 4-12% gradient gel (Biorad), and 
stained with Sypro Ruby red to visualise bands. Bands were cut out, dehydrated 
using Carbon Nitrile, washed and in gel digested with Trypsin. Following 
digestion peptide samples were cleaned up using a tC18 Sep-Pak Plate and 
eluted into low protein binding eppendorfs. Finally they were dried by 
centrifugation overnight and re-suspended in 5% Formic acid and run on the 
mass spectrometer. All steps in this preparation and final running of samples 
was carried out according to protocols adapted by and with help of Dr Armel 
Nicolas (University of Dundee). 
2.2.6.6 Transcription and translation coupled reactions 
TnT reactions were carried out using a TnT T7 Quick for PCR DNA kit 
(Promega) using PCR products that were produced by amplifying the 3A to mid 
3C region of each of the donor constructs. The forward primer was designed to 
include a T7 promoter and Kozak sequence followed by a start codon directly 
upstream of the N terminus of 3A. The reverse primer was situated in the 
middle region of 3C meaning that 3C was truncated to approximately 10KDa 
and inactive as it was truncated to upstream of the predicted active site.  
Reactions were set up as per manufacturer’s instructions, and following 
incubation half of the samples were treated with exogenously expressed 3C 
protease (kindly provided by Dr J.Newman). Samples run on 4-20% gradient 
gels (Biorad) which were then soaked in salicylic acid dried and exposed to film 






2.2.7 Microscopy and fluorescence assays 
2.2.7.1 Fixation of cells 
Media covering infected cells was aspirated off and replaced with 4% 
paraformaldehyde in PBS for 1 hour. The PFM was removed and cells washed 
3 times with PBS. Fixed cells were placed in fresh PBS and stored at 4°C. 
2.2.7.2 Preparation of slides for confocal microscopy 
Cells on coverslips were fixed as described in section 2.2.7.1 and treated with 
0.1% Triton X100 in PBS. Coverslips were washed 3 times with PBS (Sigma), 
followed by blocking with fish skin gelatin block buffer for 1 hour. Primary 
antibody diluted in block buffer was added for 1 hour and cells washed 3 times 
with PBS. Secondary antibody conjugated to an Alexafluor (either 488 or 561, 
for red or green fluorescence respectively), was diluted 1 in 200 in block buffer 
and added to cells that were incubated for 45 minutes in the dark, then washed 
3 times with PBS. Finally cell nuclei were stained with DAPI, 1 in 10000 in 
dH2O for 10 minutes followed by washing with PBS. Coverslips were mounted 
onto cells using vector and sealed with clear nail varnish. 
2.2.7.3 Confocal Microscopy 
Fluorescently labelled cells on coverslips were visualised using the Leica 
TCS/SP2 or Leica TCS/SP8 confocal laser scanning microscope. Further image 
analysis and preparation was done using the Leica LAS software. 
2.2.7.4 Replicon assays using the IncuCyte Zoom 
During this work a number of replicon based assays were carried out using 
expression of a fluorescent reporter gene (Pt.GFP or mCherry) as an indirect 
measurement of viral RNA replication and a method adapted from Tulloch et al 
(Tulloch et al., 2014).: In vitro transcribed RNA from FMDV replicons was 
transfected into cells in 24 well plates using the method described in section 
2.2.1.3. GFP or mCherry expression was measured at hourly intervals using an 
IncuCyte zoom cell imaging system (Essen Bioscience) housed inside an 
incubator at 37°C with 5% CO2 allowing measurement of replication in real time. 
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Expression was measured at 4 sites within each well and combined to give 
single measurements for each well of levels of intensity and numbers of cells 
expressing GFP or mCherry and an image per site at each time point. Analysis 
of data was carried out using the IncuCyte software with processing definitions 
developed to correct for object size and intensity levels. All data shown is 
expressed as Green Object Average mean calculated using size and pixel 
intensity of objects, or as the Green object count per image calculated by 
averaging the total number of objects counted across all 4 images within the 
well. Values from triplicate wells were combined and averaged and the standard 
deviations calculated. 
2.2.7.5 Minimax assays 
Assays to measure infection in SiRNA treated cells and replicon assays in 
TBC1D20 knockout cell lines, were carried out using a Minimax i3 Spectramax 
imaging plate reader (Molecular devices). For both types of assay, cells were in 
black sided clear bottomed plates. In the replicon assays a single site in each 
was chosen to image at an hourly interval. In the SiRNA assays 4 sites per well 
were imaged at a single time point and intensity and count data combined and 
divided by 4 by the softmax pro 6 software (Molecular devices). Data was 
exported and upper and lower thresholds of intensity set and any outlying 
results removed to allow accurate averages of triplicate (siRNA assays) or 
quadruplets (replicon assays) to be calculated.  
 
2.2.8 Sequence analysis  
2.2.8.1 Sanger Sequencing of plasmids and PCR products 
Sanger sequencing was carried out by University of Dundee sequencing or 
GATC Biotech as per manufacturer’s protocol, on samples from St Andrews or 
in house on samples from Pirbright. Plasmid DNA or PCR products from 
samples at Pirbright were prepared using ABI Big dye terminator v3.1 (Applied 
Biosystems) as per manufacturer’s instructions. Following PCR step samples 
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were ethanol precipitated, vacuum dried for 15 minutes and re-suspended in 
20µl Hi-Di Formamide (Applied Biosystems).  
 
2.2.8.2 Deep sequencing of plasmid DNA 
Infectious copy plasmid DNA was linearized using AscI, column purified and re-
suspended to the concentration of 0.2 ng/µl. Library preparation and running of 
samples on Miseq (Illumina) was kindly carried out at Pirbright by Dr Caroline 
Wright according to manufacturer’s protocol. 
2.2.8.3 Sequence data analysis  
Sequence analysis was carried out using DNASTAR Lasergene programs 
Seqman pro 14 and Seqman NGen 14 to produce consensus sequences. 
Alignments of consensus sequences were carried out using BioEdit and 
plasmid maps created and analysed using A plasmid Editor (ApE) and 
DNASTAR SeqBuilder 14. 
2.2.9 Statistical Analysis 
Statistical analysis was carried out using Minitab 17, General Linear Model, and 
One way-ANOVA with Tukey’s correction. Graphs were plotted using Graph 
Pad prism 7 software. 
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Chapter 3: Investigating effects of deletions within FMDV 3A on 
replication 
3.1 Introduction 
The FMDV 3A protein has an extended C terminal domain compared to other 
picornaviruses (See Chapter 1 figure 1.7.1.1). Naturally occurring deletions of 
10-20 a.a within this region of the protein have been found, both in viruses 
passaged through eggs for vaccines used in South America (Giraudo et al., 
1990), and in outbreaks strains including the type O virus responsible for the 
1997 FMDV outbreak in Taiwan (See Chapter 1 section 1.7.2). The 1997 
Taiwan virus had a 10 a.a deletion in the C terminal domain of 3A (residues 93-
102), which appeared to impact on viral host range as this virus was highly 
virulent in pigs but attenuated in cattle. A similar pattern of virus growth was 
seen when propagating these strains in bovine and porcine cells in vitro (Beard 
and Mason, 2000, Pacheco et al., 2003, Pacheco et al., 2013). 
Another deletion of 11 a.a in 3A (residues 133-143) has also been identified in a 
number of field viruses also isolated during FMD outbreaks in Asia, however 
viruses with this deletion were found in both cattle and pigs and appeared to 
replicate normally in both porcine and bovine keratinocytes (Knowles et al., 
2001). In addition, recombinant viruses with this deletion replicated normally in 
BHK-21 and both bovine and porcine kidney cells (Ma et al., 2014). 
Furthermore, a recombinant virus with a large internal deletion (so-called “super 
deleted” virus) in 3A that spanned a region containing both of the above 
deletions (residues 93-143) was shown to remain infectious in porcine cells but 
was also attenuated in bovine cells (Pacheco et al., 2003) and Behura et al. 
showed that the entire C terminal domain of 3A in an Asia-1 type isolate can be 
removed without impacting on replication in BHK-21 cells (Behura et al., 2016).  
Here I have investigated the effects of a large naturally occurring deletion in 3A 
of 57 a.a (residues 81-137) on replication in cells derived from different natural 
hosts of FMDV. The deletion was discovered during sequencing of an FMDV 
O1 Manisa vaccine isolate and appeared to exist as part of a mixed viral 
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population that included viruses that also contained the full length 3A protein. 
Initially, the ability of the 3A deleted virus (FMDV O1Man Δ3A81-137) to 
replicate independently as opposed to requiring “help” from other wildtype 
viruses in the mixed population was tested using sub-genomic replicons.  
FMDV is unusual among the picornaviridae as it is insensitive to Brefeldin A 
(BFA) (Martin-Acebes et al., 2008, O'Donnell et al., 2001, Midgley et al., 2013).  
To investigate whether the C terminal domain of the FMDV 3A is required for 
BFA resistance, the effect of BFA on replication of the replicon with the 81-137 
deletion was also investigated. BFA inhibits activation of the cellular factor 
ARF1 by inhibiting the GEF activity of GBF1 and thereby inhibits COP-I vesicle 
formation and disrupts the Golgi apparatus (Niu et al., 2005). The 3A of the 
enteroviruses binds directly to GBF1 (Wessels et al., 2006) and thus BFA also 
inhibits their replication (Lanke et al., 2009). Furthermore it has been found that 
mutations in PV 3A confer resistance to BFA. Since FMDV differs to the 
enteroviruses in its resistance to BFA and FMDV 3A has a longer C terminal 
domain compared to other picornaviruses, it was thought that this extended 
region may provide another way to interact with GBF1 thus allowing FMDV to 
evade the effects of BFA. Therefore the effects on replication of replicons with 
large deletion in this region were tested in BFA treated BHK-21 cells. 
The effects on FMDV replication of a second deletion, of 23 a.a that included 
the last 5 a.a of 3A and most of 3B1 except for the last 5 a.a was also 
investigated. This deletion was identified in a novel outbreak strain in South 
Korea that was discovered in pigs (Park et al, 2014). The FMDV genome is 
unusual as it encodes three non-identical copies of 3B (3B1, 3B2 and 3B3) 
(chapter 1 section 1.4.9) and the above deletion effectively removes the first 
copy (3B1). Studies with recombinant viruses have shown that FMDV remains 
replication competent when 3B1 or 3B2 are removed (Falk et al., 1992) or when 
only one copy of 3B is encoded as long as it is not 3B1 alone (Arias et al., 
2010). In contrast, Pacheco et al found that a virus with only one copy of 3B 
(3B3) was able to replicate in porcine cells but not in bovine cells in vitro, 
suggesting that multiple copies of 3B are required for efficient virus replication in 
bovine cells (Pacheco et al., 2003). Here the effect of the 23 a.a deletion on 
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replication in porcine and bovine cells using replicons was investigated.  The 
undeleted region of 3A was left as O1K (i.e. the sequence in our O1K Pt.GFP 
replicon) or changed to match that of the Korean virus (i.e. the virus identified 
with the 23 a.a deletion) and replicons with the deletion in each variation made 
(see section 3.6, figure 3.6.1). 
Finally each of the deletions described above (the 57a.a deletion in 3A and the 
23 a.a spanning 3A and 3B1) were introduced into infectious clones and 
recombinant viruses recovered using an established reverse genetics system. 
The recovered viruses were characterised to see if they exhibited the same 
replication characteristics as the replicons. 
 
3.2 Effects of deletions in 3A on replication of FMDV replicons in different 
host cell lines. 
To investigate whether an O1 Manisa virus with a large internal deletion in the C 
terminal region of 3A (FMDV O1Man Δ3A81-137) that was found within a mixed 
population of viruses with and without the deletion (see above), was able to 
replicate independently, the same deletion was made in the C-terminal coding 
region of 3A in an FMDV O1K replicon (FMDV O1K Pt.GFP). This replicon has 
Pt.GFP encoded in place of the majority of the FMDV capsid region and allows 
GFP expression to be used as an indirect measure of replication (Tulloch et al., 
2014), (See chapter 2  section 2.2.1.2). In addition, all of the a.a that were 
different in the remaining part of 3A were also changed so that the 3A sequence 
in the replicon matched exactly that of the Δ3A deleted O1 Manisa virus (FMDV 
O1Man ∆3A81-137). In addition, a second deletion in 3A of a.a 93-143 
(previously investigated by Pacheco et al) was also made in the FMDV O1K 
Pt.GFP replicon for use as an additional control (Pacheco et al., 2003). An 
alignment showing the differences in each of the 3A sequences compared to 
the sequence of O1K 3A (the 3A sequence found in the O1K Pt.GFP replicon) 











Figure 3.2.1: Alignment of 3A sequences from FMDV O1K and replicons and viruses with deletions in 3A. The 
alignment shows the 3A a.a sequences of (i) the WT O1K virus on which the O1K Pt.GFP replicon is based (blue), (ii) the virus 
with a large deletion in 3A that was isolated from a mixed population (O1Man ∆3A81-137) (purple), (iii) the sequence of 3A 
within the replicon after making the deletion found in O1Man ∆3A81-137 (red) and (iv) the 3A sequence of the replicon with the 
93-143 deletion (O1K ∆3A93-143)  (green). The predicted trans-membrane domain region of 3A is shown in black and 
residues differing between the O1K and O1Man ∆3A81-137 sequences are highlighted (yellow). These residues were changed 
in a version of the 81-137 deletion Pt.GFP replicon so the 3A sequence matched exactly that of the O1Man ∆3A81-137 
sequence (the virus in which the deletion was found). 
WT O1K          ISIPSQKSVLYFLIEKGQHEAAIEFFEGMVHDSIKEELRPLIQQTSFVKRAFKRLKENFEIVALCLTLLANIVI 
O1Man ∆3A81-137 ISIPSQKSVLYFLIEKGQHEAAIEFFEGMVHDSIKEELRPLIQQTSFVKRAFKRLKENFETVALCLTLLANIVI 
O1K ∆3A81-137   ISIPSQKSVLYFLIEKGQHEAAIEFFEGMVHDSIKEELRPLIQQTSFVKRAFKRLKENFETVALCLTLLANIVI 
O1K ∆3A93-143   ISIPSQKSVLYFLIEKGQHEAAIEFFEGMVHDSIKEELRPLIQQTSFVKRAFKRLKENFEIVALCLTLLANIVI 
 
           MIRETRKRQKMVDDAVNEYIEKANITTDDKTLDEAEKSPLETSGASTVGFRERTLPGQKACDDVNSEPAQPVEEQPQAE  
           MIRETR---------------------------------------------------------VSSEPAKPVEDRPQAE  
           MIRETR---------------------------------------------------------VSSEPAKPVEDRPQAE  
           MIRETRKRQKMVDDAVNE---------------------------------------------------QPVEEQPQAE 
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Equal amounts of in vitro transcribed RNA (500ng, quantified using a Qubit, 
(see chapter 2 section 2.2.4.2) from the WT replicon (O1K Pt.GFP) and the ∆3A 
replicons (O1K Pt.GFP ∆3A81-137 and O1K Pt.GFP ∆3A93-143) were 
transfected into BHK-21, SK-RST (porcine) and MDBK (bovine) cells. RNA from 
a fourth replicon, (O1K Pt.GFP GNN) with an inactive 3D polymerase was 
included and served as a control for GFP expression levels from non-replicating 
RNA. The natural fluorescence of GFP (GFP expression) was measured at 
hourly intervals and used as an indirect measure of RNA replication. Results 
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Figure 3.2.2: Effects of large deletions in 3A on replication in different 
host cell lines using GFP replicons. Triplicate wells of BHK-21, SK-RST and 
MDBK cells were transfected with 500ng of in vitro transcribed replicon RNA 
from 4 different replicons and average GFP intensity of the cells measured at 
hourly intervals to give an indirect measure of replication. Cells were transfected 
with either a wildtype (O1K Pt.GFP (blue)), 3D polymerase mutation control 
(O1K Pt.GFP GNN) (purple), or one of two replicons containing a deletion in 3A 
(O1K Pt.GFP ∆3A81-137 (red) and O1K Pt.GFP ∆3A93-143 (green). Graphs 
show results from 3 independent experiments each with triplicate samples 
(wells). Data points and error bars show mean +/- SD. 
 
In BHK-21 cells (Fig 3.2.2 Panel A), the GFP intensity levels for the replicons 
with deletions in 3A (O1K Pt.GFP ∆3A81-137 and O1K Pt.GFP ∆3A93-143) 
were slightly higher than for the WT replicon (O1K Pt.GFP) in all 3 experiments. 
Similar results were seen in porcine SK-RST cells (Fig 3.2.2 Panel B), where 
GFP expression for the ∆3A replicons was again higher than for the WT 
replicon. The overall average GFP intensity for each replicon was lower in SK-
RST cells compared to BHK-21 cells, suggesting that BHK-21 cells support 
higher levels of FMDV replication. In contrast, in the bovine MDBK cells (Figure 
3.2.2 Panels C) only the WT replicon appeared to replicate efficiently as the 
signal from both O1K Pt.GFP ∆3A81-137 (red) and O1K Pt.GFP ∆3A93-143 
(green) were reduced to the level of the O1K Pt.GFP GNN (purple) control in 2 
of the experiments (Panels CII and CIII) suggesting that the GFP signal was the 
result of translation of the input RNA. In the other experiment (panel CI) the 
GFP signal for the ∆3A replicons was higher than that from the O1K Pt.GFP 
GNN control but in this experiment the signal from the O1K Pt.GFP GNN control 
was noticeably lower than in the other experiments. Nevertheless, the replicons 
with deletions in 3A were strongly attenuated in MDBK cells. In MDBK cells, the 
levels of the GFP signal (intensity) for O1K Pt.GFP were similar to that of SK-
RST cells, but were reduced in comparison to that seen for BHK-21 cells. 
A statistical analysis (One way ANOVA multiple comparisons with Tukey’s 
correction) was carried out on the GFP intensity levels seen at the time 
(between 9 and 11 hours post-transfection) of peak GFP intensity of O1K Pt. 
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GFP (Figure 3.2.3). This analysis used combined data for each cell line from all 
3 experiments, (Note in Figure 3.2.3, only significant differences are shown).
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Figure 3.2.3: Effects on peak fluorescence and replication of deletions in 3A in different cell lines. Cellular GFP 
intensity data from the time point of peak fluorescence during the replicon time course assays (Figure 3.2.2) was used to 
compare replication in MDBK and SK-RST cells (One-way ANOVA with Tukey’s correction).  Data from 3 independent 
experiments each with triplicate samples was compared, solid symbols are replicates from experiment 1, half-filled symbols 
show replicates from experiment 2 and empty symbols show replicates from experiment 3. Lines and error bars show mean 
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In BHK-21 cells significant differences in the GFP intensity levels were seen for 
the wildtype replicon (O1K Pt.GFP) and for the Δ3A replicons (O1K 
Pt.GFP∆3A81-137 or O1K Pt.GFP∆3A93-143) compared to the replication 
deficient O1K Pt.GFP GNN control. In contrast, there were no significant 
differences between the GFP intensity levels for the wildtype (O1K Pt.GFP) and 
the Δ3A replicons (O1K Pt.GFP∆3A81-137 or O1K Pt.GFP∆3A93-143) or 
between the two ∆3A replicons themselves (Figure 3.2.3 BHK-21) suggesting 
that all 3 replicons (with and without 3A deletions) replicate similarly in BHK-21 
cells.  
As seen in BHK-21, in SK-RST cells (Figure 3.2.3 SK-RST) all 3 replicons (O1K 
Pt.GFP, O1K Pt.GFP ∆3A81-137 and O1K Pt.GFP ∆3A93-143) showed 
significantly higher GFP intensity levels compared to the O1K Pt.GFP GNN 
control. In addition, a significant difference (p=0.001) was seen between O1K 
Pt.GFP and O1K Pt.GFP ∆3A81-137 and there was a small significant 
difference between the two replicons with ∆3A deletions (p=0.026). However, 
no significant difference was observed between O1K Pt.GFP and O1K Pt.GFP 
∆3A93-143. This suggests that the 81-137 deletion in 3A may enhance 
replication in porcine cells. 
In MDBK cells, the GFP signal intensity for the WT replicon (O1K Pt.GFP) was 
significantly higher than for Pt.GFP ∆3A81-137 or O1K Pt.GFP ∆3A93-143, 
which is consistent with the apparent attenuation of the ∆3A deleted replicons in 
these cells (Fig 3.2.2 MDBK). However, statistical significant differences in GFP 
intensity were also seen for each of the ∆3A deletion replicons compared to the 
GNN control (O1K Pt.GFP GNN) (p=0.005 and p=0.001 respectively), 
suggesting that although they are severely attenuated in MDBK cells, both ∆3A 
deleted replicons were replication competent in these cells.   
The above observations show that both ∆3A deleted replicons can replicate 
efficiently in BHK-21 and porcine SK-RST cells but not in bovine MDBK cells. In 
addition, although the O1K Pt.GFP ∆3A93-143 replicon showed an apparent 
replication similar to the WT replicon (O1K Pt.GFP), the 3A deletion of a.a 81-
137 appeared to result in enhanced replication in SK-RST cells. These 
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observations suggest viruses with the 81-137 a.a deletion in 3A would be 
capable of independent replication and furthermore that this deletion may 
enhance replication in pig cells while leading to severe attenuation of replication 
on bovine cells and therefore that full-length 3A may be required for FMDV 
replication in bovine cells. 
3.3 Providing full length 3A in trans does not restore replication of 
replicons with deletions in 3A in MDBK cells 
Previously it has been shown that certain mutations and deletions in 
Picornavirus  genomes that cause attenuation can be overcome by providing 
the altered element in trans in the form of a helper virus or replicon. These 
include the cre of FMDV (Tiley et al., 2003) and also the 3AB protein of PV 
(Towner et al., 1998). Furthermore, other studies have shown that FMDV 
replicons containing insertions in 3A, that are lethal to replication, can be 
complemented and replication restored by supplying wildtype 3A in trans (Herod 
et al., 2015). In addition, Rosas et al. showed that infection of BHK-21 cell lines 
that stably expressed 3A led to an increase in virus yield and percentage of 
infected cells compared to infection of parental BHK-21 cells (Rosas et al., 
2008). 
Since the above deletions in 3A appear to negatively impact on FMDV 
replication in bovine (MDBK) cells it was decided to see if replication of the Δ3A 
deleted replicons could be restored by providing full length 3A in trans. RNA for 
each of the ∆3A-deleted replicons was co-transfected with either in vitro 
transcribed RNA from a “helper” replicon (O1K mCherry), containing full length 
3A and an mCherry reporter gene in place of Pt.GFP, or yeast tRNA to ensure 
the same amount of RNA was transfected into each cell. A co-transfection using 
wildtype O1K mCherry and wildtype O1K Pt.GFP replicons was also included.  
Transfections were carried out in parallel in both MDBK cells and BHK-21 cells 
(BHK-21 cells were used as a positive control for replication of the ∆3A deletion 
replicons). The average cellular intensity levels of both GFP and mCherry were 
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Figure 3.3.1: Effects of providing full length 3A in trans on replication of 
∆3A replicons in MDBK cells. RNA from O1K Pt.GFP panels AI, AII and AIII, 
and ∆3A deletion replicons (indicated on panels BI, BII, BIII and CI, CII and CIII) 
were co-transfected with either yeast tRNA (blue (panel A), red (panel B) and 
green (panel C) or RNA from the wildtype O1K mCherry replicon containing full 
length 3A and an mCherry reporter gene in place of Pt.GFP (orange) (panels A, 
B and C) into MDBK cells. O1K Pt.GFP GNN (purple) (panels A, B and C) was 
transfected with yeast tRNA as a negative control for signal produced from 
translation of input RNA. Average cellular GFP intensity (Panels A, B and C) 
was measured at hourly intervals for 16 hours, in 3 independent experiments 
each with triplicate samples. Data points and error bars show the mean +/- SD. 
The number of Pt. GFP expressing cells per image was also calculated (panels 
D, E and F) and the results shown for one representative experiment of the 
three experimental repeats. Data points and error bars show mean +/- SD. 
 
Figure 3.3.1 shows results from 3 independent experiments carried out with 
triplicate wells for each condition using MDBK cells. Panels AII and AIII showed 
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a clear decrease in GFP intensity levels when the O1K Pt.GFP replicon was co-
transfected with the O1K mCherry replicon when compared to when co-
transfection with yeast tRNA, possibly due a competition effect for limited 
cellular resources and factors required for FMDV replication. A similar but 
smaller decrease in GFP intensity was seen in experiment 1 (panel AI).  
Figure 3.3.1 panel B shows results for co-transfection using O1K Pt.GFP 
∆3A81-137. In all 3 experiments (BI, B II and BIII) the GFP intensity signal 
showed a slight improvement when co-transfected with the O1K mCherry 
replicon over co-transfection with yeast tRNA). The results from co-transfection 
using O1K Pt.GFP ∆3A93-143 were inconsistent and difficult to interpret, as the 
GFP intensity level showed an increase when co-transfected with O1K mCherry 
in experiment 1 (panel CI), was similar in experiment 2 (panel CII) and a 
decrease in experiment 3 (panel CIII) when compared to the level seen when 
co-transfected with yeast tRNA. The number of GFP expressing cells was also 
investigated to see if an increase in the number of green objects was observed 
when the ∆3A deletion replicons were co-transfected with O1K mCherry, as this 
could also indicate possible trans-complementation. Figure 3.3.1 panels D, E 
and F show the data for one experiment as the number of GFP expressing cells 
per image counted at hourly intervals for O1K Pt.GFP, O1K Pt.GFP∆3A81-137, 
and O1K Pt.GFP ∆3A93-143 respectively.  Similarly to what was seen with GFP 
intensity levels (in panels AII and AIII), panel D shows the number of GFP 
expressing cells decreased when O1K Pt.GFP was co-transfected with O1K 
mCherry replicon compared to when co-transfected with yeast tRNA, which fits 
with the theory that two replication competent replicons are competing for 
cellular resources. Panels E and F show that there was an increase in the 
number of GFP expressing cells when each of the ∆3A deletion replicons were 
co-transfected with O1K mCherry (orange lines) suggesting that there could be 
a possible “helper” effect from the O1K mCherry 3A that results in improved  
replication, as more GFP positive cells are seen, but the effects on replication is 




The above experiments were also carried out in parallel with BHK-21 cells, to 
test if any effects on replication were seen when co-transfecting replicons in a 
cell line where the ∆3A deletion replicons were replication competent. Figure 
3.3.2 shows that for all 3 replicons (O1K Pt.GFP, O1K Pt.GFP∆3A81-137, and 
O1K Pt.GFP ∆3A93-143) a drop in GFP intensity levels was seen when co-
transfected with the O1K mCherry replicon compared to yeast tRNA. This is 
similar to the results seen for the two wildtype replicons (O1K Pt.GFP with O1K 
mCherry) in MDBK cells (Figure 3.3.1, panels AII and AIII) and is potentially due 
to a competition effect, as all the replicons are replication competent in BHK 
cells and there is likely competition for cellular factors required for replication 
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Figure 3.3.2: Effects of providing full length 3A in trans on replication of 
∆3A replicons in BHK-21 cells. RNA transcribed from O1K Pt.GFP (panels AI, 
AII and AIII), and the indicated ∆3A deletion replicons (panels BI, BII, BIII and 
CI, CII and CIII) were co-transfected into BHK-21 cells with either yeast tRNA 
(blue (panel A), red (panel B) and green (panel C) lines) or RNA from an 
mCherry replicon containing full length 3A (orange lines panels A, B and C). 
The O1K Pt.GFP GNN (purple) (Panels A, B and C) was transfected with yeast 
tRNA as a negative control for signal produced from translation of input RNA. 
Average cellular GFP intensity was measured at hourly intervals for 16 hours, in 
3 independent experiments each with triplicate samples. Data points and error 
bars show mean +/- SD 
 
A statistical analysis (One way ANOVA multiple comparisons with Tukey’s 
correction) was carried out on the data for the time point (9 to 11 hours post 
transfection dependent on experiment) when the GFP intensity levels peaked 
for co-transfection of O1K Pt.GFP with yeast tRNA (Note on Figure 3.3.3, only 
significant differences between each replicon when co-transfected with yeast or 
O1K mCherry are shown). In MDBK cells, there was a significant difference 
(p=0.001) between the GFP intensity levels for the O1K Pt.GFP replicon when 
co-transfected with yeast tRNA(blue symbols) or O1K mCherry replicon RNA 
(orange symbols), indicating a significant reduction in replication when the two 
wildtype replicons are co-transfected.  However there was no significant 
difference for either of the ∆3A deletion replicons when co-transfected with 




Figure 3.3.3: Effects on peak GFP intensity levels of supplying full length 
3A in trans within a helper mCherry replicon. O1K Pt.GFP or the replicons 
with deletions in 3A were co-transfected into MDBK or BHK-21 cells with the 
wildtype O1K mCherry replicon (orange symbols) or with yeast tRNA (blue, red 
and green symbols). GFP intensity levels at time point of peak GFP intensity 
(between 9 and 11 hours depending on experiment) of O1K Pt.GFP co-
transfected with yeast tRNA from 3 independent experiments (each with 
triplicate samples) were compared (One-way ANOVA, Tukey’s correction). 
Filled symbols show replicates from experiment 1, half-filled symbols show 
replicates from experiment 2 and empty symbols show replicates from 
experiment 2 and empty symbols show replicates from experiment 3  
 
In BHK-21 cells there was a significant difference between intensity levels of 
each of the GFP replicons when they were co-transfected with yeast (blue, red 
and green symbols) in comparison to when co-transfected with the wildtype 
O1K mCherry replicon (orange symbols).  
Overall these results show that large deletions (a.a 81-137 and a.a 93-143) in 
the C terminal domain of 3A cannot be complemented efficiently by full-length 
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3.4 Effects of Brefeldin A (BFA) on replication of FMDV replicons with 
deletions in 3A 
FMDV has previously been reported to be resistant to BFA (Midgley et al., 
2013, Martin-Acebes et al., 2008, O'Donnell et al., 2001). To test if the 81-137 
and 93-143 a.a deletions in 3A, (shown in Figure 3.2.1), led to sensitivity to 
BFA, BHK-21 cells were pre-treated with BFA (5 µg/ml) or, DMSO (the solvent 
carrier) for 15 minutes at 37°C or were left untreated before being transfected 
with RNA from O1K Pt.GFP, O1K Pt.GFP GNN, O1K Pt.GFP ∆3A81-137 or 
O1K Pt.GFP ∆3A93-143 replicons.  The average GFP intensity of cells was 
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Figure 3.4.1: Effects of BFA on replication of FMDV replicons with 
deletions in 3A. BHK-21 cells were pre-treated with BFA (5µg/ml), DMSO or 
left untreated for 15 minutes prior to transfection with in vitro transcribed RNA 
from the O1K Pt.GFP (panel A), ∆3A deleted replicons (panels B and C) or the 
O1K Pt.GFP GNN replicons (panels A, B and C). Shown are the results from 3 
independent experiments each with triplicate samples. Intensity levels for cells 
treated with DMSO are shown in pale blue and for cells treated with BFA in 
pink. Intensity levels for cells left untreated are shown in dark blue, red, green 
and purple for O1K Pt.GFP, O1K Pt.GFP∆3A81-137, O1K Pt.GFP∆3A93-143 
and O1K Pt.GFP GNN respectively. The number of GFP expressing cells per 
image was also quantified (panels D-F) to determine the effects of treatment 
with DMSO and BFA on transfection efficiency. Results from one representative 
experiment are shown in panels D (O1K Pt.GFP), E (O1K Pt.GFP∆3A81-137) 
and F (O1K Pt.GFP∆3A93-143). Data points and error bars show the mean +/- 
SD.   
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Results from 3 independent experiments are shown in Figure 3.4.1. For all 3 
replicons, (Panel A, O1K Pt.GFP, panel B, O1K Pt.GFP ∆3A81-137 and panel 
C O1K Pt.GFP ∆3A93-143) and for each experiment, there was a noticeable 
decrease in GFP intensity levels, (indicating an inhibitory effect on replication) 
when the cells were pre-treated with BFA. There was little differences seen in 
GFP intensity between cells pre-treated with DMSO or cells left untreated in any 
of the experiments suggesting the apparent inhibitory effects on replication seen 
with BFA were not due to the solvent carrier. No effect of BFA treatment was 
observed on the GFP intensity levels of cells transfected with RNA from O1K 
Pt.GFP GNN replicon suggesting that BFA did not affect replicon RNA 
translation. As FMDV has been reported to be insensitive to BFA the results for 
the wildtype O1K Pt.GFP replicon was unexpected (see section 3.8, 
Discussion).  
It is possible that the apparent inhibitory effect of BFA on replication could result 
from BFA having an effect on the transfection efficiency. Therefore the number 
of GFP expressing cells per image was also quantified to check if the pre-
treatment conditions (DMSO or BFA) had an effect on transfection efficiency. 
Figure 3.4.1 panels D, E and F show representative results from one 
experiment. The number of GFP expressing cells transfected with O1K Pt.GFP 
GNN was similar regardless of the pre-treatment showing translation was not 
affected. The number of GFP expressing cells for O1K Pt.GFP, and the ∆3A 
deleted replicons were all higher in cells pre-treated with BFA than cells which 
were untreated. In DMSO treated cells, the number of GFP expressing cells 
was higher than both the BFA treated and untreated cells for the O1K Pt.GFP 
and O1K Pt.GFP ∆3A81-137  replicons (panels D and E) and was similar to the 
untreated cells for O1K  Pt.GFP ∆3A93-143 (panel F). Together, these 
observations suggest that pre-treatment with BFA was not having a negative 
effect on transfection efficiency of replicon RNA. 
A statistical analysis (One way ANOVA multiple comparisons with Tukey’s 
correction) was carried out using the data from the time point (9 to 10 hours 
post transfection dependent on experiment) where the GFP intensity levels from 
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untreated cells transfected with O1K Pt.GFP replicon RNA were at their peak 
















Figure 3.4.2: Effects of BFA on replication of FMDV replicons with 
deletions in 3A: Cells were pre-treated with DMSO or BFA or left untreated 
and transfected with RNA from the O1K Pt.GFP, the ∆3A deleted replicons or 
O1K Pt.GFP GNN replicons and GFP intensity measured over time. Data from 
the time point at which the GFP intensity levels of the untreated cells 








































































































Tukey’s correction). Significant differences were seen for each replicon between 
replication (apart from O1K Pt.GFP GNN) in the cells pre-treated with BFA 
compare to the untreated cells or cells pre-treated with DMSO. No significant 
difference in replication was seen between cells pre-treated with DMSO or 
those left untreated. Shown are results from 3 independent experiments each 
with triplicate samples. Data for cells treated with DMSO are shown in pale blue 
and for cells treated with BFA in pink.  Filled symbols show replicates from 
experiment 1, half-filled symbols show replicate from experiment 2 and empty 
symbols show replicates from experiment 3. 
 
Figure 3.4.2 shows there was a significant decrease (p=<0.0001) between GFP 
intensity levels for each of the replicons between untreated cells (blue, red and 
green symbols) or DMSO treated cells (pale blue symbols) with cells pre-treated 
with BFA (pink symbols) for O1K Pt.GFP and the ∆3A deletion replicons. As 
expected significant differences were not seen between untreated and DMSO 
pre-treated cells confirming that the inhibitory effects on replication is due to 
BFA and not the solvent carrier (DMSO). No significant effect was seen 
between the GFP intensity levels for the O1K Pt.GFP GNN replicon regardless 
of cell treatment suggesting that pre-treatment with BFA does not affect 
translation. 
 
3.5 Virus recovery and characterisation of viruses with deletions in 3A on 
different cell lines 
The above results report the effect on FMDV replication of deletions involving 
3A in cells derived for the porcine and bovine hosts of FMDV by using sub-
genomic replicons. To further test if the virus containing the 3A deletion (a.a 81-
137) could replicate independently, and if it has the same replication 
characteristics as the replicon in different host cell lines, replicons O1K Pt.GFP, 
Pt.GFP ∆3A81-137 and O1K Pt.GFP ∆3A93-143 were converted into full length 
infectious genomes. This was done by replacing the region encoding the 
Pt.GFP reporter gene in the replicon plasmids with the capsid coding region 
from the FMDV O1K infectious clone. The resulting infectious copy plasmids 
were used as a template to transcribe vRNA in vitro, which was then transfected 
into T25 flasks of BHK-21 cells and the flasks monitored for up to 48 hours for 
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the appearance of CPE. At CPE (or at 48 hours post transfection), the cells 
were freeze-thawed and clarified cell supernatants passaged onto fresh BHK-21 
cells.  Following 2 passages (BHKp2), RNA was extracted from the infected cell 
lysate, reverse transcribed to make ss cDNA  and used as the template in a 
PCR reaction using primers that annealed in the 2C and 3C coding regions. The 
PCR products were gel extracted and sequenced using primers internal to the 
PCR product. All 3 viruses (O1K WT, O1K∆3A81-137 and O1K∆3A93-143) 
were successfully recovered, and the sequence data showed that the 3A region 
(including the deletions) was stably maintained.  
The recovered viruses (O1K WT, O1K∆3A81-137 and O1K∆3A93-143) at 
(BHKp2) were titrated by plaque assay on BHK-21, MDBK and IBRS2 (a 
porcine kidney cell line, known to be infected efficiently by FMDV) cells and the 
virus titres are shown in Table 3.5.1. Consistent with previous reports showing 
that the 93-143 deletion in 3A attenuates replication in bovine cells (Pacheco et 
al., 2003), the O1K∆3A93-143 virus gave no visible plaques in MDBK cells, 
whereas plaques caused by the O1K∆3A81-137 virus were small, indistinct, and 
difficult to quantify. Nevertheless, the MDBK titre for the O1K∆3A81-137 virus 
was much lower than for the wildtype virus. In contrast, all 3 viruses showed 
similar titres in BHK-21 and IBRS2 cells. These results are consistent with those 
seen using GFP replicons (section 3.2) and confirm that the deletions in 3A 
attenuate replication in MDBK cells but not in porcine or BHK-21 cells.  
 
Table 3.5.1: Viral titres of passage 2 (BHKp2) viruses on different cell lines. 
Viral supernatants from infected BHK-21 (BHKp2) cells were titrated by plaque 
 Virus Titre (log10 pfu/ml) 
Virus BHK-21 IBRS2 MDBK 
O1K WT 
 
1.3x107 6.5x107 1.3x106 
O1K ∆3A81-137 1.5x107 3.2x106 8x102 
O1K ∆3A93-143 1x107 2.2x107 No plaques 
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assay on BHK-21, IBRS2 and MDBK cells in duplicate and an average titre 
calculated. 
 
The reason for the apparent attenuation of the 3A-deleted viruses in bovine 
cells is unclear and it is possible that the reduced replication could be due to a 
difference in the innate immune response between cell lines used allowing 
viruses to grow to a higher titre in BHK-21 and IBRS2 cells. Therefore, to 
confirm the attenuation in bovine cells it was decided to further investigate 
replication using primary bovine thyroid cells (BTY), which are highly sensitive 
to FMDV infection and routinely used in FMD diagnosis (Ferris et al., 2002). 
Triplicate wells of IBRS2 and BTY cells were infected at an MOI of 1 (based on 
original end point titres from BHK-21 cells, see Table 3.5), with each of the 
viruses, O1K WT, O1K∆3A81-137 or O1K∆3A93-143 (BHKp2) for 8 hours. The 
cells were freeze thawed and cell supernatants collected. Figure 3.5.1 shows 














Figure 3.5.1: Effects of deletions in FMDV 3A on viral growth in different 
host cells. Infectious viruses with deletions in 3A (residues 81-137 or 93-143) 
were recovered in BHK-21 cells to passage 2 (BHKp2) and used to infect 
triplicate wells of IBRS2 and BTY cells at an MOI of 1 for 8 hours. Infected 
supernatant was collected and viral titre calculated by plaque assay for each 
sample on BHK-21 cells. Comparison of means (One way ANOVA with Tukey’s 
correction) showed no significance between viral titres for FMDV O1K WT or 
either of the ∆3A deleted viruses between cell types. 
 
This experiment showed the end point titres (i.e. at 8h post infection) for O1K 
WT and O1K∆3A81-137 were similar when the viruses were passed through 
IBRS2 or BTY cells while the titres of the O1K∆3A93-143 were slightly reduced 
in both cell types when compared to the other viruses. Furthermore, although 
for each virus the titre on BTY cells was lower that on IBRS2 cells there was no 
significant difference seen (when analysed by one way ANOVA, Tukey’s 
correction) (Figure 3.5.1).  
Together, the above experiments show that the viruses with 3A deletions could 


























































potentially attenuated in another (MDBK). Presently it is not clear why this 
should be so; however, it could suggest that the innate immune status of the 
cells themselves rather than what host species they are derived form could be 
contributing to the attenuation of the replicons and viruses with deletions in 3A 
seen in MDBK cells. However, the results shown in Figure 3.5.1 are based on 
end point titres (the virus titre is calculated on BTY and IBRS2 cells at 8 h post-
transfection) and therefore can only be interpreted to show that the viruses with 
3A deletions are competent for replication in porcine and bovine cells and do 
not inform on the relative fitness of the viruses in porcine and bovine cells (see 
Discussion).  
 
3.6 Effects of a deletion spanning the end of 3A and majority of 3B1 on 
replication of FMDV replicons in different host cell lines 
FMDV is unusual among picornaviruses in that it encodes three copies of VPg 
(or 3B) yet recombinant viruses with one copy removed remain replication 
competent (Falk et al., 1992, Pacheco et al., 2003, Pacheco et al., 2010). Here 
the effects on FMDV replication of a 23 a.a deletion spanning the C terminal 
end of 3A and most of 3B1 was investigated (Figure 3.6.1). This deletion 
removes the last 5 a.a. of 3A and all of 3B1 except for the last 5a.a at the 
carboxyl terminal end and therefore, effectively removes the first copy of VPg 
(3B1) and was identified in a virus (O/SKR/6/2014) isolated from pigs in South 
Korea. Interestingly, the outbreak affected both cattle and pigs but when tested 
the virus appeared to have a low pathogenicity in pigs (Park et al., 2016).  
This deletion was made in the O1K Pt.GFP replicon (Figure 3.6.1) creating O1K 
Pt.GFP∆3B1. A second replicon (Pt.GFP SKR∆3B1) with this deletion was also 
made that had further a.a changes in the remaining part of 3A so that it 
matched exactly the sequence of the South Korean virus in 3A. A third replicon 
was made that had full-length 3A using the 3A sequence (O1K Pt.GFP 
SKR+3B1) from a closely related strain to the South Korean virus 
(O/HKN15/2010). The sequence of 3A for each of the above replicons is shown 














Figure 3.6.1: Sequence alignment showing 3A and 3B1 region of replicons with a 23 a.a deletion in the C terminal end 
of 3A and majority of 3B1. The deletion identified in the O/SKR/6/2014 virus isolate was made in 2 different replicons. 
O1K∆3B1 (shown in orange) where the 23 a.a deletion was made in the existing FMDV O1K Pt.GFP replicon (which is based 
on O1K), and SKR∆3B1 (shown in green) which had both the deletion and the residues that differed between the O1K and 
O/SKR/6/2014 sequences in the remaining region of 3A altered to match those of the O/SKR/6/2014 virus. SKR+3B1 is shown 
in grey and, has the same sequence as SKR∆3B1 but with the deletion repaired using the sequence of a closely related virus 
O/HKN15/2010. The 3B1 region is shown outlined in red. 
O1K WT:  I S I P S Q K S V L Y F L I E K G Q H E A A I E F F E G M V H D S I K E E L R P L I Q Q T S F V K R A  
SKR∆3B1: I S I P S Q K S V L Y F L I E K G Q H E A A I E F F E G M V H D S V K E E L R P L I Q Q T S F V K R A  
SKR+3B1: I S I P S Q K S V L Y F L I E K G Q H E A A I E F F E G M V H D S V K E E L R P L I Q Q T S F V K R A  
O1K∆3B1: I S I P S Q K S V L Y F L I E K G Q H E A A I E F F E G M V H D S I K E E L R P L I Q Q T S F V K R A 
 
F K R L K E N F E I V A L C L T L L A N I V I M I R E T R K R Q K M V D D A V N E Y I E K A N I T T D D K T L  
F K R L K E N F E V V A L C L T L M A N I V I M I R E T R K R Q Q M V D D A V N E Y I E R A N I T T D D K T L  
F K R L K E N F E V V A L C L T L M A N I V I M I R E T R K R Q Q M V D D A V N E Y I E R A N I T T D D K T L  
F K R L K E N F E I V A L C L T L L A N I V I M I R E T R K R Q K M V D D A V N E Y I E K A N I T T D D K T L  
 
D E A E K S P L E T S G A S T V G F R E R T L P G Q K A C D D V N S E P A Q P V E E Q P Q A E G P Y A G P L 
D E A E K N P L E T S G A S T V G F R E R T L P G R K V G D D V S Y E P A H P G D E - - - - - - - - -- -- - 
D E A E K N P L E T S G A S T V G F R E R T L P G R K V G D D V S Y E P A H P G D E Q P Q A E G P Y A G P L 
D E A E K S P L E T S G A S T V G F R E R T L P G Q K A C D D V N S E P A Q P V E E - - -- - -- - - - - - - 
 
 E R Q K P L K V R A K L P Q Q E 
 - - - - - - - - - - - L P Q Q E 
 E R Q K P L K V R A K L P Q Q E 















RNA from each of the 3 replicons Pt.GFP O1K∆3B1, Pt.GFP SKR∆3B1 and 
Pt.GFP-SKR+3B1 was transfected into BHK-21, MDBK, and SK-RST cells. In 
addition the wildtype O1K Pt.GFP and polymerase knockout (O1K Pt.GFP 
GNN) replicons were included as controls. The GFP intensity was measured at 
hourly intervals over a 16 hour period and the results from 3 independent 
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O 1 K  P t.G F P  W T
O 1 K  P t.G F P  G N N  (3 D  p o l m u t)
P t.G F P  S K R + 3 B 1
P t.G F P  S K R  3 B 1
O 1 K  P t.G F P  3 B 1
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Figure 3.6.2: Effects of a 23 a.a deletion in the C terminal domain of 3A 
and 3B1 on replication in different cell lines. RNA from 5 replicons, 2 with 
full length 3A and 3B1 (O1K Pt.GFP and Pt.GFP SKR+3B1), and two variants 
with a 23 a.a deletion in 3A and 3B1 (O1K Pt.GFP ∆3B1 and Pt.GFP SKR∆3B1) 
and the translation only control O1K Pt.GFP GNN was transfected into either 
BHK-21, SK-RST or MDBK cells. The average GFP intensity levels were 
measured at hourly intervals as an indirect measure of replication. Shown are 
the results from 3 independent experiments with triplicate sample. Data points 
and error bars show the mean +/- SD.  
 
In BHK-21 and porcine SK-RST cells, each of the replicons with the deletion 
(O1K Pt.GFP ∆3B1, O1K Pt.GFP SKR∆3B1) showed little difference in 
replication (i.e. the GFP intensity) to their matched wildtype replicons 
(O1KPt.GFP and Pt.GFP SKR+3B1) suggesting that this deletion was not 
detrimental for replication in these cell lines.  In contrast, in two of the 
experiments (panels CII and CIII) with MDBK, the replicons with the deletion 
showed a lower level of GFP intensity compared to the respective matched 
wildtype replicons (O1K Pt.GFP and Pt.GFP SKR+3B1) whereas in experiment 
1 (panel CI) the GFP intensity levels were more similar to the replicons without 
the deletion. 
Data from the time of peak GFP intensity levels (9 to 10 hours post transfection) 
of O1K Pt.GFP for each cell line was compared (One way ANOVA, Tukey’s 
correction) and is shown in Figure 3.6.3. In BHK-21 cells the only significant 
differences seen were between each of the 4 replicons and the Pt.GFP GNN 
translation control. This was also seen in SK-RST and MDBK cells (not shown 
on the figure).  
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Figure 3.6.3:  Effects on replication of a 23 a.a deletion in 3A and 3B1 in different cell lines. Average GFP intensity data 
from the time point (9 or 10 hours post transfection dependent on experiment) of peak fluorescence of Pt.GFP (WT) during 
replicon time course assays (see Figure 3.6.2) was used to compare differences between GFP intensity levels of the different 
replicons with each other (One-way ANOVA, Tukey’s correction). All data from 3 independent experiments, each with triplicate 
samples was compared. Solid symbols are replicates from experiment 1, half-filled symbols show replicates from experiment 2 
and empty symbols show replicates from experiment 3. Lines and error bars show mean +/- SD. For clarity only significant 

































































































p = < 0 .0 0 0 1
p = < 0 .0 0 0 1
p = < 0 .0 0 0 1
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In SK-RST there was also a relatively small but significant difference in GFP 
intensity levels between the Pt.GFP SKR+3B1 replicon and its deleted 
counterpart, Pt.GFP SKR∆3B1 (p=<0.014), which suggested that the deleted 
replicon was replicating better than the wildtype replicon (Pt.GFP SKR+3B1) in 
porcine cells.  However, this difference was not seen for the O1K Pt.GFP 
replicon compared to O1K Pt.GFP∆3B1, as they appeared to replicate similarly.  
In contrast, in MDBK cells both of the replicons with the deletion showed a 
significant reduction in Pt.GFP levels compared to their wildtype counterparts 
suggesting that replication was reduced in bovine cells. 
3.7 Recovery of viruses with 3B1 deletion 
The Pt.GFP O1K∆3B1, Pt.GFP SKR∆3B1 and Pt.GFP SKR+3B1 replicons were 
made into infectious clones and viruses recovered in BHK-21 cells using the 
same method as described in section 3.5. The recovered viruses were further 
passaged twice through BHK-21 cells to produce working stocks (BHKp2). The 















Figure 3.7.1: Growth of viruses with a 23 a.a deletion spanning end of 3A 
and 3B1 in BHK-21 cells. Passage 2 (BHKp2) viruses with a deletion of 23 a.a 
spanning the last 5 a.a of the C terminal domain of 3A and covering the majority 
of 3B1 were titrated by plaque assay on BHK-21 cells. All viruses produced 
similar titres apart from SKR∆3B1 (green), which was slightly less 
(approximately 1.5 log) than its wildtype counterpart (SKR+3B1) (grey) and the 
O1K variant containing the deletion (orange). 
 
This analysis showed that both viruses with deletions were replication 
competent in BHK-21 cells. The titres for the O1K WT virus and its deleted 
counterpart (O1K∆3B1) were similar whereas the titre of the SKR∆3B1 virus 
was approximately 1.5 log less than its wildtype counterpart (SKR+3B1) 
suggesting that the SKR∆3B1 virus has a reduced ability to replicate.  However, 
as the data are end point titres (the infection time between BHKp1 and BHKp2 
was over 24h) from a single experiment they should be treated with caution. 
However, due to time constraints it was not possible to analyses these viruses 





























































Deletions in 3A have previously been identified in a number of FMDV isolates 
from both outbreak and vaccine strains. These deletions are relatively short (10-
20 a.a), in the C terminal domain of 3A (Beard and Mason, 2000, Pacheco et 
al., 2003, Giraudo et al., 1990) and have been linked to changes in host range 
and attenuated replication in cattle and bovine cells in vitro. The work in this 
Chapter has investigated a larger natural deletion of 57 a.a (residues 81-137) 
also in the C terminal domain that was identified within a vaccine isolate of a 
type O virus. Unusually, this deletion existed in a virus as part of a mixed 
population where some of the viruses also had a full-length 3A. Replicon assays 
showed that a replicon with this deletion was able to replicate as well as a 
wildtype replicon in BHK-21 and porcine (SK-RST) cells but was severely 
attenuated in bovine (MDBK) cells. These results confirm that the deletion does 
not compromise replication in all cell lines and are similar to previously studies 
in natural hosts of FMDV which showed that viruses with smaller deletions in 3A 
remain highly infectious for pigs and replicated well in porcine cells but had 
limited replication in bovine cells and were less virulent for cattle (Beard and 
Mason, 2000, Pacheco et al., 2003, Pacheco et al., 2013).  A study by Knowles 
et al. determined that the 93-102 deletion in 3A had been present in field 
viruses that were circulating in pigs in Asia since at least 1970. In addition, this 
analysis also showed that viruses with this deletion that were isolated before 
1983 appeared to grow equally well in bovine and porcine cells suggesting that 
this deletion on its own does not fully account for the inability of the deleted 
viruses to replicate in bovine cells (Knowles et al., 2001).The results from this 
study (Chapter 3) show that the larger deletion in 3A also attenuates replication 
in bovine cells, which suggest that the additional changes that lead to 
attenuation for bovine cells may also reside within the C terminal domain of 3A. 
A strategy for the production of safer FMDV vaccines currently under 
consideration is to grow replication-defective viruses in so-called “helper” cell 
lines that supply the defective viral protein in trans. Previous reports with 
defective replicons have concluded that 3A can be supplied in trans by a 
“helper” replicon (Herod et al., 2015) and that infection of cells stably expressing 
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3A led to an increase in viral yield (Rosas et al., 2008). In this study (Chapter 3), 
supplying full length 3A form a second wildtype helper replicon (O1K mCherry) 
in trans-complementation assays showed that supplying 3A in trans did not 
significantly restore replication of the replicon with the 81-137 deletion in 3A. 
However, there was a noticeable increase in the number of Pt.GFP positive 
cells when the replicon with the 81-137 deletion was co-transfected with the 
wildtype O1K mCherry replicon over when co-transfected with yeast RNA 
suggested that some rescue of replication may have occurred. This rescue was 
at best inefficient and suggests that “helper” cells to rescue 3A deleted viruses 
may not be a viable option.  Another option under consideration is to produce 
pig specific vaccines that could not replicate in bovines. The experiments 
present here suggest that vaccine viruses with large deletions in 3A have the 
potential to be developed as such pig specific vaccines, as if these isolates 
were attenuated to a level safe to act as a live attenuated vaccine in pigs they 
would pose less risk to bovine species if they were to infect. 
Recombinant viruses with deletions in 3A of a.a 81-137 and 93-143 were also 
studied. Previously viruses with deletions in 3A have been described as 
‘porcinophillic’ as they cause severe disease in pigs, so it was thought that an 
81-137 3A deleted virus may show a preference for porcine cells. However, 
recovered viruses with this deletion were infectious for both IBRS2 and BTY 
cells. These observations appear not to fit with the replicon assay results as the 
81-137 deletion attenuated replication in a different bovine cell line, MDBK cells 
suggesting that effects on replication seen with replicons may differ to those 
seen with infectious viruses.  
During my studies, and as part of a BBSRC funded sLoLa investigating FMDV 
replication, a post doc in the lab (Dr Caroline Wright) carried out a mixed 
infection experiment in IBRS2 and BTY cells using equal amounts (infectious 
viruses) of the 3A 81-137 deleted and wildtype isolated viruses. Using PCR 
through the 3A region, this showed that for BTY cells the wildtype virus rapidly 
dominated the infection and by passage 5 the 3A deletion was lost. In contrast, 
in IBRS2 cells the opposite was seen and by passage 5 only the virus with the 
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3A deletion could be detected. These observations appear to agree with the 
results of the replicon experiments in MDBK cells and confirm that the deletion 
in 3A results in a virus that is more fit for replication in pig cells but weakens 
replication in bovine cells.  
Replicon experiments on a smaller deletion that spanned from the C terminal 
end of 3A, which removed the last 5 a.a of 3A and most of 3B1 except for the 
last 5 a.a, showed there was no effect of this deletion on replication in BHK-21 
cells compared to a wildtype replicon. Interestingly, the deletion resulted in a 
small improvement in replication in SK-RST cells and a small but statistically 
significant reduction in replication in MDBK cells. Infectious virus based on an 
existing infectious clone (FMDV O1K) containing this deletion grew to similar 
titres to the wildtype virus in BHK-21 cells suggesting this deletion was not 
detrimental to replication. However, a recombinant virus with a 3A sequence 
and deletion that matched the original isolate (SKR∆3B1) in which the deletion 
was first identified appeared to show reduced replication compared to its 
counterpart with full-length 3A and 3B1 suggesting that within the context of the 
SK isolate this deletion may affect replication. However due to time constraints 
this was only tested in BHK-21 cells using an end point titration and further work 
is required to fully characterise replication of this virus in porcine and bovine 
cells. 
Experiments investigating the effects of BFA on replication of replicons 
containing deletions in 3A (figure 3.4.1) showed that BFA inhibited replication of 
FMDV replicons with the 81-137 or 93-143 a.a deletions in the C terminal 
domain of 3A. However, unexpectedly BFA also had a similar inhibitory effect 
on the wildtype O1K Pt.GFP replicon. This was unexpected, as previous 
publications have reported that BFA has little or no effect on FMDV yield 
(O'Donnell et al., 2001, Martin-Acebes et al., 2008, Monaghan et al., 2004) 
suggesting that FMDV replication is insensitive to BFA. However, the study by 
Martín-Acebes et al., noted an increase in the number of infected cells following 
BFA treatment (Martin-Acebes et al., 2008). Similarly, another study by Midgley 
et al., also reported an increase (~40%) in the number of infected cells following 
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BFA treatment (Midgley et al., 2013). Closer inspection of the experimental 
conditions of the above experiments shows that the studies by Martín-Acebes et 
al., and Midgley et al., used a low MOI (0.5 and 0.3 respectively) whereas 
O’Donnell et al., and Monaghan et al., used higher MOI’s (10 and 1.0 
respectively). No effect of BFA on virus yield was reported by Monaghan et al., 
but the study by O’Donnell et al., showed a 2-fold reduction in FMDV yield on 
BFA treatment. Together these observations (plus the results shown in Figure 
3.41. and 3.4.2) suggest BFA could have multiple effects on FMDV replication 
and the outcome of the experiment could be influenced by the MOI. When 
carried out at a high MOI, inhibitory effects of BFA on FMDV vRNA replication 
may be masked by other beneficial effects on infection which could account for 
the small reduction in virus yield seen by O’Donnell et al., and no difference in 
virus yield reported by Monaghan et al. In contrast, when carried out at low MOI 
stimulation of infection may predominate as reported by Martín-Acebes et al., 
and Midgley et al., (Midgley et al., 2013, Martin-Acebes et al., 2008) who 
observed an increase in the number of infected cells after BFA treatment. The 
results shown in Fig 3.4.1 are consistent with this as BFA had an apparent 
inhibitory effect on replication. This would also suggest that the apparent 
enhancement in the number of infected cells seen by Martín-Acebes et al., and 
Midgely et al., results from an effect before intracellular replication, most likely 
cell-entry. The above observations suggest the possibility that BFA has a 
relatively small and previously uncharacterised inhibitory effect on post-entry 
FMDV replication while possibly stimulating FMDV cell-entry. Similar inhibitory 
effects of BFA were seen in the replicon assays for wildtype and 3A-deleted 
replicons with BHK-21 and SK-RST cells suggesting that the mechanisms of 
resistance to BFA is/are not provided by the extended C terminal of 3A. These 
observations also show that, in some cases results seen with replicons may be 
different to those with infectious virus, since studies with FMDV have concluded 
that replication does not appear to be effected by BFA treatment whereas in the 
replicon experiments a significant drop in replication was seen.  
Overall the results of this Chapter have shown that a naturally occurring, large 
deletion in the C terminal domain of 3A (found as part of a mixed viral 
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population) did not compromise replication and viruses with this deletion were 
able to replicate independently in BHK-21 and SK-RST but was attenuated in 
MDBK cells. It was also shown that viruses with this deletion were able to grow 
in both porcine and bovine cells, with only small differences in end-point viral 
titre when compared to the wildtype virus. However other studies suggest that 
the deletion results in a virus that has a strong preference for porcine cells (C 
Wright personal communication). My study also showed a smaller deletion 
across 3A and 3B1 may affect replication in cell lines derived from different 
FMDV hosts.  This suggests that 3A may play a role in viral host range but it is 
likely that multiple other factors are also involved. 
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Chapter 4: Identifying Potential Cellular Interaction partners of 
FMDV 3A 
4.1 Introduction 
It has been suggested that picornavirus 3A interacts with a number of cellular 
and viral proteins during the replication cycle (Chapter 1 section 1.7.3). 
However most of the proteins identified at present have been found to interact 
with the 3A of kobuviruses and enteroviruses, in particular PV 3A. Very few 
interaction partners for FMDV 3A have been identified. Since FMDV 3A is 
structurally different to the 3A proteins of other picornaviruses and appears to 
have varying roles during replication it is likely it will interact with different 
proteins when compared to that of other picornaviruses. 
Known interaction partners for both enteroviruses and kobuviruses include 
PI4KIIIβ, GBF1 and ACBD3 (Dorobantu et al., 2015b, Greninger et al., 2012, 
Klima et al., 2017, Sasaki et al., 2012, Wessels et al., 2006) (see Chapter 1 
section 1.7.3). However these have not been linked with interactions with FMDV 
viral proteins. One proposed interaction partner for FMDV 3A is DCTN3 
(Dynactin 3), a subunit of the dynactin complex that serves as a co-factor for the 
dynein motor protein and has been linked with intracellular transport between 
organelles (Gladue et al., 2014). PV 3A has also been reported to bind a 
component of the dynein complex, but it interacts with LIS1 rather than DCTN3 
(Kondratova et al., 2005). Furthermore it is thought that it is likely FMDV 3A 
may interact with proteins involved in the innate immune response pathway. Li 
et al suggested that FMDV 3A expression resulted in reduced expression of 
some proteins within this pathway including RIG-I and MDA5 (Li et al., 2016).  
In this chapter 3A-GFP fusion proteins have been used with the proteomics 
techniques of immunoprecipitation and mass spectrometry to identify additional 
interaction partners of FMDV 3A. 
Mass spectrometry (MS) is an analytical technique that can be used to identify 
different proteins in a sample according to their mass. The most widely used 
MS method of analysis of protein-protein interactions involves affinity pull-down 
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(immunoprecipitation (IP)) methods prior to analysis on a mass spectrometer to 
identify specific proteins that interact with the target protein. Protein complexes 
are isolated either using antibodies specific to the target protein or by 
expressing tagged variants of the target protein within cells and isolating the 
target protein (and interaction partners) using antibodies to the tag. Once 
isolated the eluted proteins are digested before undergoing LC/MS-MS where 
spectra are produced based on protein size and abundance (Georges and 
Frappier, 2015, ten Have et al., 2011, Trinkle-Mulcahy et al., 2008). A key factor 
that can influence results when using this technique is the potential for non-
specific interactions, particularly during the IP step where non-specific proteins 
may bind to the isolation beads, which could lead to sample contamination and 
a high number of non-specific hits.  In this work, GFP tagged 3A was expressed 
(i.e. 3A-GFP fusion proteins) to allow the isolation of 3A and bound cellular 
proteins by IP using a GFP antibody conjugated to magnetic beads. GFP was 
selected to use as a tag as it has been shown to bind to few contaminant 
proteins and or bead matrices (Trinkle-Mulcahy et al., 2008), making it ideal for 
use in mass spectrometry. Furthermore, protein expression of the tagged 3A 
proteins was easily monitored through expression of the GFP detected by 
fluorescence microscopy. 
Following analysis of data from the mass spectrometry two potential interaction 
partners were identified as good candidates to carry out further experiments 
with, and effects of reducing expression levels on FMDV infection was 
investigated. These proteins were the Rab GTPase Rab7L1 and the Tre-2 Bub2 
Cdc16 (TBC) protein TBC1D20. 
 
4.2 Development of 3A-GFP fusion proteins for use in IP and Mass 
Spectrometry experiments 
To identify possible interaction partners of 3A using IPs and mass spectrometry, 
expression plasmids were generated for 3A-GFP (i.e. GFP fused to the C 
terminus of 3A) and 3ABBB-GFP (i.e. GFP fused to the C terminus of 3B3) .The 
3A and 3ABBB regions were amplified by PCR from a replicon template using 
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primers that introduced restriction sites on either end. The restriction sites were 
then used to clone the PCR products into the multiple cloning site of the 
expression plasmid pEGFP-N1 to create plasmids in which the EGFP coding 
region was located downstream of that coding for 3A (referred to as 3A-GFP) or 
3ABBB (referred to as 3ABBB-GFP) creating C terminal fusion proteins 
(Chapter 2 section 2.1.4)). Plasmid maps of the fusion protein expression 
plasmids are shown in Figure 4.2.1.Sequencing of the plasmids (data not 
shown) revealed that in 3A-GFP full length 3A and GFP were present and 
joined in frame, while in 3ABBB-GFP part of the coding sequence for the 3BBB 
region was missing, full length 3B1 and 3B2 were encoded but only the first 7 
a.a of the 3B3 region were coded for. However, as full-length 3A and the 
remaining part of 3BBB were still encoded in frame with GFP it was decided to 
continue working with this construct. 
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Figure 4.2.1 3A-GFP and 3ABBB-GFP fusion protein expression plasmids: 
Fusion protein plasmids which would allow expression off GFP tagged 3A or 
3ABBB in cells were developed by PCR amplifying the corresponding regions of 
the FMDV genome and cloning the PCR products into the pEGFP-N1 
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expression plasmid to produce plasmids where GFP was fused to the C 
terminal of 3A or 3ABBB as shown in the plasmid maps above. 
 
To test if the GFP fusion proteins were being expressed correctly, plasmid DNA 
from 3A-GFP, 3ABBB-GFP and pEGFP-N1 (the vector control) was transfected 
into HEK-293 cells. Transfected cells were fixed and labelled for 3A expression 
(for analysis by confocal microscopy), or samples were lysed and analysed by 
western blot for both 3A and GFP expression. Confocal microscopy images, 
see Figure 4.2.2, show that GFP expression from pEGFP-N1 occurred 
throughout the cell, including in the nucleus (top panels), whereas GFP 
expression from the fusion proteins (middle and bottom panels for 3A-GFP and 
3ABBB-GFP respectively) was localised to the perinuclear region and 
cytoplasm but not seen in the nucleus. This suggests that most of the fusion 
protein was still intact as GFP alone appears to accumulate in the nucleus. 
Furthermore 3A expression (shown in red) was localised with the GFP 
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Figure 4.2.2: FMDV 3A-GFP fusion proteins show different cellular 
localisation to GFP expressed on its own (in form of pEGFP-N1). GFP fusion 
proteins were transfected into HEK 293 cells, at 12 hours post transfection cells 
were fixed and labelled for FMDV 3A (using Mab 2C2) and nuclei stained with 
DAPI (blue) and imaged using confocal microscopy. Images show GFP 
expression (green) FMDV 3A expression (red) and a merge image for each 
expression plasmid including the pEGFP-N1 control. 
 
Further analysis by western blot (Figure 4.2.3) showed that 3A remained fused 
to GFP in the 3A-GFP construct at both 12 and 16 hours post transfection. A 
band at the expected size (44 KDa) of the fusion protein was seen, in blots for 
both 3A (with antibody 2C2, panels A and C) and GFP (with antibody ab290, 
panels B and D). The 3ABBB-GFP construct also gave bands of the correct size 
(52KDa) showing that the fusion protein was intact at 12 hours (panels A and 
B). However when the GFP fusion proteins were expressed in cells for 16 hours 
it was found that 2 bands were detected for 3ABBB-GFP when blotting using an 
antibody for 3A (panel C) and the band detected when blotting using an 
antibody for GFP was a similar size to that seen with the vector plasmid control 
pEGFP-N1 of 27 KDa (panel D). These results suggest that while the 3A-GFP 
fusion protein is stably expressed and remains intact over 16 hours the 3ABB-
GFP fusion protein appears to be “cleaved” after prolonged expression. 
Therefore it was decided to only express the 3ABBB-GFP fusion protein in cells 
for 12 hours prior to the IP reactions, whereas the 3A-GFP fusion protein was 



















































































































































Figure 4.2.3: Western blots showing expression of fusion proteins 3A-GFP 
and 3ABBB-GFP. HEK 293 cells were transfected for 12 (panel A and B) or 16 
hours (panels C and D) with plasmid DNA of 3A-GFP, 3ABBB-GFP and GFP 
only control (pEGFP-N1). Transfected cells were lysed, and the lysates run on 
SDS PAGE gels and western blotted for expression of both FMDV 3A and GFP. 
Size markers are shown on the left hand side of the blots 
 
4.3 Using Immunoprecipitation and mass spectrometry to identify 
potential interaction partners of FMDV 3A 
4.3.1 Isolating 3A interaction complexes using IP reactions  
To identify potential cellular proteins that interact with FMDV 3A, IPs followed by 
mass spectrometry were carried out. BHK-21 and MDBK cells were transfected 
with DNA from 3A-GFP or 3ABBB-GFP expression plasmids (see section 4.2.1) 
and incubated for 12 or 24 hours, then checked for GFP expression using a 
fluorescent microscope.  
After observation of GFP expression cells were either fixed with 4% PFA (see 
Chapter 2 section 2.2.7.1) or left unfixed, t,hen harvested into IP buffer (see 
Chapter 2, section 2.2.6.4). Samples were then sonicated and incubated with a 
GFP specific antibody bound to magnetic beads. Following incubation beads 
were washed three times and protein complexes eluted. Samples of the original 
cell lysate (TCL), the washes (FT) and the final elution (IP) were western blotted 
using a GFP antibody to check IPs had worked. Figure 4.3.1 shows 
representative blots of samples from IPs conducted on cell lysates from cells 
transfected with 3A-GFP at 24 hour post transfection and those from cells 





Figure 4.3.1: Western blots of IP samples using antibody to GFP. 20µl 
samples of total cell lysate, flow through (from the wash steps) and IPs, (final 
elutions) from experiments done in BHK-21 (panel A) or MDBK cells (panel B), 
were run on a 4-20% gradient SDS-PAGE gel and western blotted using an 
antibody to GFP. Bands shown in red are the correct size for 3A-GFP and 
3ABBB-GFP and show that they had been successfully pulled down in BHK-21 
cells (panel A) as they are present in the final IP sample. Sample preparations 
and blots were carried out with the help of Dr Armel Nicolas (University of 
Dundee). 
 
As shown in Figure 4.3.1 panel B the IPs with samples from MDBK cells had 
not worked well as no bands at correct size (corresponding to the 3A-GFP 
fusion proteins) were seen in the eluted samples. However in BHK-21 cells, 
bands of the correct size (44 and 52 KDa) were seen and were more intense in 
the IP than in the flow through (wash) samples. (Figure 4.3.1 panel A) 
suggesting that for BHK the IP step was successful for both fusion proteins. 
Data from samples that were fixed prior to harvesting from cells is not shown in 
figure 4.3.1, to help with clarity but again the IPs from this set of samples in 
MDBK were unsuccessful whilst those in BHK-21 did show bands that were 
more intense in eluted IPs samples and at the correct sizes, suggesting that the 
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4.3.2 Mass spectrometry of IP samples  
The BHK-21 IP samples were further prepared for mass spectrometry using in 
gel digestion and fractionation (see Chapter 2 section 2.2.6.5). They were then 
run on the mass spectrometer. IPs, preparation and running of samples on 
Mass Spectrometry was carried out with the help of Dr Armel Nicolas 
(University of Dundee). Initial analysis of mass spectrometry data (kindly 
conducted by Dr Armel Nicolas) produced a large number of potential hits 
therefore further analysis was required. 
4.3.2.1 Results from Initial Mass Spectrometry Analysis 
This PhD was closely aligned with a BBSRC sLoLa grant to investigate FMDV 
replication. This included a yeast-2-hybrid (Y-2-H) investigation (carried out at 
Edinburgh University) of cellular interacting partners of FMDV 3A and 3A 
precursors (3AB, 3ABB and 3ABBB) in addition to other non-structural proteins 
of FMDV. The results of the mass spectrometry-based experiment from this 
study are considered in conjunction with the Y-2-H study.  
None of the major cellular proteins (GBF1, ACBD3, PI4KIIIa) that bind 
picornavirus 3A proteins or have previously been implicated in RO formation 
(PI4KIIIβ) by other picornaviruses were identified in the extensive list produced 
by initial analysis of the MS data (from the experiment using 3A or 3ABBB as 
the target proteins). In addition, LIS1, or RIGI and MDA5 were also not 
identified. DCTN3 (dynactin 3) has been proposed as a cellular interacting 
protein for FMDV 3A. In the mass spec analysis, a number of dynactin proteins 
were identified including DCTN1, DCTN2, DCTN3, DCTN4 and DCTN6. As the 
role of DCTN3 in FMDV infection has already been explored (Gladue et al., 
2014) and given that a number of other DCTN subunits were identified as 
potential FMDV 3A interacting partners, suggesting they may not bind 3A 
directly, it was decided not to pursue this interaction further. Other proteins of 
interest identified included VAP-B (see chapter 5), Rab7L1 and TBC1D20 (see 
below). Similarly, GBF1, ACBD3, PI4KIIIα and PI4KIIIβ) were not identified in 
the Y-2-H screen (using 3A, 3AB1, 3AB1B2 and 3AB1B2B3 as the target 
proteins). In addition, DCTN3 and LIS1, and RIGI and MDA5 were also not 
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identified. In addition, VAP- B and TBC1D20 were not identified while Rab7L1 
was identified but only with 3ABB as the target protein  
Based on results of initial analysis two proteins were selected to investigate 
further as discussed in sections 4.4 and 4.5. However to gain more useful 
insights from the data set additional and more extensive analysis is required, to 
establish potential impacts on cellular pathways and gene expression. 
 
4.4 Investigating effects of knocking down Rab7L1 expression on FMDV 
infection 
Rab7L1 was identified as a possible interacting partner for FMDV 3A in the 
initial mass spectrometry analysis and was also identified in a Y2H screen using 
3ABB as the target protein (the Y2H screen was carried out by collaborators at 
Edinburgh University). Therefore, as Rab7L1 was identified in two independent 
screens, using different methods, it was thought to be a good candidate to 
investigate further.  
Rab7L1 (also known as Rab29) is a member of the Rab GTPase family, a 
group of small proteins that have been shown to play multiple roles in 
intracellular vesicular transport. There are at least 70 Rab family members and 
many have been investigated in detail. However, the cellular functions of others 
including Rab7L1 are not well known.  
Rab7L1 was originally considered a close homologue of Rab7; however, 
sequence alignments have demonstrated that Rab7L1 is more closely related to 
Rab32 (46% a.a identity) and Rab38 (49% a.a identity), which regulate post-
Golgi trafficking events (Wasmeier et al., 2006). Recently Rab7L1 has been 
shown to be involved in maintenance of the integrity of the Golgi, and the 
retrograde trafficking of M6P receptors from endosomes to the Trans Golgi 
network (TGN) (Wang et al., 2014). In addition, Rab7L1 has been found to 
mediate Salmonella infection (Spanò et al., 2011) and modify intraneuronal 
protein sorting through interacting with LRRK2 and has been shown to be linked 
with Parkinson’s disease risk (MacLeod et al., 2013, Tang, 2017). In the 
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experiments below, siRNA was designed against target sequences of the 
porcine Rab7L1 gene and used to investigate effects of knocking down 
expression of Rab7L1 on FMDV infection in IBRS2 cells. 
Three separate siRNA’s were designed (using Dharmacon custom siRNA 
design tool) and equal amounts pooled together prior to transfection. The target 
sequences of each siRNA are shown in the table of Figure 4.4.1, along with 
their locations (highlighted in red) within one of the full transcript sequence of 
porcine Rab7L1 (Figure 4.4.1). All three of the Rab7L1 target sequences are an 
exact match for all currently identified transcript variants of the porcine Rab7L1 






Sus scrofa RAB29, member RAS oncogene family (RAB29), transcript variant 














siRNA to porcine Rab7L1 Target Sequence 
siRNA 1 GAGCAATTCCAAAGAAGAA 
siRNA 2 GGACAGAAACATCAGTCAA 
siRNA 3 CAACAGCCAGAGATGGAAA 
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Figure 4.4.1: Design of siRNA sequences targeting expression of porcine 
Rab7L1. Three different siRNAs were designed using the Dharmacon custom 
design tool. Three target sequences (as shown in the table) were selected 
based on highest scoring targets that required no modifications and whose 
locations didn’t overlap. The target sequences are present in all transcript 
variants available to date and location within one of the transcript variants are 
shown in red. 
 
IBRS2 cells were transfected with various amounts of the three pooled siRNAs 
(5pg, 10pg or 20pg) or a non-targeting control siRNA (5 pg, 10 pg or 20 pg) 
using Dharmafect 4 or left untreated (Chapter 2 section 2.2.1.3). At 48 hours 
post transfection cells were infected with O1K FMDV for 4 hours. Cells were 
then fixed, labelled for FMDV 3A (using 2C2 monoclonal antibody), and the 
nuclei stained with Topro 3 dye (allowing for quantification of the total number of 
cells per well). Infection was then quantified using 3A (here detected by GFP 
expression) as a marker of infection using a fluorescent imaging plate reader 
(Chapter 2 section 2.2.7.5). Results from 2 independent experimental repeats 







































































%  In fe c ted  ce lls













































































%  In fe c ted  ce lls


































 5 p g  s iR N A


































5 p g  s iR N A



































1 0 p g  s iR N A



































1 0 p g  s iR N A




































2 0 p g  s iR N A




































2 0 p g  s iR N A



















Figure 4.4.2 Effects of knocking down Rab7L1 expression on FMDV 
replication. IBRS2 cells were transfected with varying amounts of siRNA to 
target Rab7L1 or with a non-targeting control. At 48 hours post transfection cells 
were infected with FMDV O1K for 4 hours then fixed and labelled for infection  
using a primary antibody against FMDV 3A (mAb 2C2) and secondary antibody 
Alexa fluor 488. Cell nuclei were stained with Topro 3 dye and the total number 
of cells per well and number of infected cells per well counted using the 
Spectramax i3 plate reader. Panels AI and AII show the percentage of infected 
cells in cells treated with siRNA to Rab7L1 (red symbols) or the non-targeting 
control (green symbols). Error bars show mean +/-SD. Untreated cells were 
also infected for use as a positive control of infection (data not shown). Panels 
in rows B, C and D show the percentage of infected cells with each amount of 
siRNA used normalised to the non-targeting control. Two independent 
experiments (I and II) were carried out each with triplicate samples per condition 
 
The percentage of infected cells was determined  and is shown in Figure 4.4.2 
(panels AI and AII), and showed little or no difference for infection of the 
Rab7L1 siRNA treated cells in comparison to the cells treated with non-
targeting SiRNA control (green) for both experiments, and for each amount of 
siRNA (5, 10 or 20 pg). Figure 4.4.2 panels B, C and D show the percentage of 
infected cells in siRNA treated cells (red) when normalised to the percentage of 
infected cells treated with the non-targeting siRNA control (green), following 
treatment with 5, 10 or 20 pg of siRNA (panels B, C and D respectively). With 
the exception of experiment 1 where cells were treated with 5 pg of siRNA, 
(panel BI), the differences in infection levels between siRNA treated and non-
target treated cells was less than 20% in both experiments for all siRNA 
amounts. This suggests that any effect solely due to the siRNA directly 
knocking down Rab7L1 was likely to be very small and that there may have 
been non-targeting effects from the Rab7L1 siRNA or transfection effecting 
infection levels. Therefore it is possible the decrease in infection may not solely 






4.5 Investigating effects of knocking out TBC1D20 on FMDV Infection and 
replication 
Initial analysis of the mass spectrometry data (Section 4.3.2.1) showed that a 
number of TBC-domain proteins were detected  as potential interacting partners 
for 3A, including TBC1 Domain Family Member 20 (TBC1D20). TBC-domain 
proteins belong to a family of GTPase activator proteins (GAPs) of Rab-like 
small GTPases and contain Tre-2 Bub2 and Cdc16 (TBC) domains (Bernards 
and Settleman, 2004, Frasa et al., 2012). Rab proteins regulate many aspects 
of membrane trafficking and are essential for the coordination of budding, 
transport and fusion of vesicles (Stenmark, 2009). The Rab proteins cycle 
between inactive and active states, which regulates their binding to specific 
effector proteins. Rab proteins are activated by guanine nucleotide exchange 
factors (GEFs) that promote the formation of active, GTP-bound states, while 
GAPs promote Rab inactivation by stimulating GTP-hydrolysis activity.  
TBC1D20 has been identified as a GAP for the Rab 1 protein (Sklan et al., 
2007a) which plays a key role in Golgi biogenesis and ER-to-Golgi trafficking 
(Plutner et al., 1991, Tisdale et al., 1992). Therefore TBC1D20 has an indirect 
role in regulation of the early secretory pathway through regulating Rab-1-
mediated vesicular traffic between the ER and Golgi. Over-expression of 
TBC1D20 has been shown to have a dominant negative (DN) effect and causes 
loss of structure of the Golgi complex and inhibits vesicle transport from the ER 
(Haas et al., 2007, Sklan et al., 2007a). 
A study by Midgley et al (Midgley et al., 2013) showed that expression of DN 
Rab1 appeared to make FMDV infection more favourable. Midgley also 
investigated the effect of over expression of TBC1D20 on FMDV infection of 
IBRS2 cells (Midgley, 2011). Agreeing with previous studies (Haas et al., 2007, 
Sklan et al., 2007a) the over expression of TBC1D20 was shown to disrupt the 
ER, ERGIC and the Golgi suggesting that membrane flow through the early 
secretory pathway was inhibited (Midgley, 2011). In addition, this study showed 
that over expression of a catalytically inactive mutant of TBC1D20 (TBC1D20 
R105A) also appeared have a similar effect, as in cells expressing this mutant 
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the ER, ERGIC and Golgi were similarly affected. As TBC1D20 is a GAP for 
Rab1 and over expression of TBC1D20 acts as a DN protein, it would be 
thought that expression of TBC1D20 may reduce the amount of Rab1 activation 
and therefore have a similar inhibitory effect as DN Rab1 on FMDV infection. 
However over expression of TBC1D20 had an inhibitory effect on infection. 
Furthermore, over expression of the catalytic inactive mutant TBC1D20 R105A 
also inhibited infection showing that this effect was independent of Rab1 GAP 
activity. As a result it is possible that TBC1D20 is required for FMDV infection 
and that over expression of the wildtype or inactive TBC1D20 mutant could aid 
movement of FMDV non-structural proteins (including 3A) to a different cellular 
environment that is not favourable for replication.  
4.5 1 Investigating effects of knocking out TBC1D20 on FMDV Infection 
Parental and TBC1D20 knockout HeLa cell lines (in which different guide RNAs 
targeted different Exons to completely knockout the expression of TBC1D20 
using CRISPR methods) referred to as Exon 5 or Exon 7 (based on the exon 
targeted), were kindly provided by Dr Mark Handley (The Roslin Institute, 
Edinburgh University). Infection assays were carried out by seeding cover slips 
with each cell line, infecting with FMDV O1K WT for 4 hours, then fixing, and 
labelling the cells for infection using an antibody (2C2) to FMDV 3A. Ten fields 
of view per cover slip were imaged, each using three varying red laser settings 
(high, medium and low) to allow for easier discrimination between background 
fluorescence and infected cells (see figure 4.5.1 1 for example images). Levels 
of infection looked to be higher in the parent cells compared to the knockout 
cells although the labelling for FMDV 3A appeared to be strongest in intensity in 
the Exon 5 knockout cell line in comparison to the parent and Exon 7 cell lines. 
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Figure 4.5.1.1: FMDV infection of parent and TBC1D20 knockout HeLa cell 
lines. Parent and knockout cell lines (Exon 5 and Exon 7) were seeded onto 
cover slips and infected with FMDV O1K virus for 4 hours. Cells were fixed, and 
labelled with a monoclonal antibody against FMDV 3A (red), nuclei were stained 
using DAPI. To allow infected cells to be easily distinguished from background 
cells were imaged using three different laser intensities; high, medium and low 
and the images merged. Infected cells were then much brighter and easier to 
identify. The number of nuclei (blue) and number of infected cells from ten fields 
of view per cover slip were counted to quantify infection levels. Images above 
show a single field of view example. 
 
The total number of cells (based on the number of DAPI (blue) stained nuclei) 
and the number of infected cells (based on detection with an antibody to FMDV 
3A (red) as a marker of infection) were counted for each field of view. Ten fields 
of view per cover slip were counted with 3 cover slips being used for the parent 
and Exon 5 cell lines (30 fields of view in total) and 2 for the exon 7 cell line (20 
fields of view in total).  
Figure 4.5.1.2 (panel A) shows the total number of cells (blue) and the number 
of infected cells (red) from all fields of view counted per cell line. The total 
number of cells counted overall was similar between cell lines but the number of 
infected cells was slightly less in the knockout cells. The percentage of infected 
cells was calculated for each cell line (shown in Figure 4.5.1.2 panel B) and 
normalised data (normalised to the parental cell line) is shown in Figure 4.5.1.2 
panel C. The percentage of infected cells was lower in each of the knockout cell 
lines compared to the level of infection seen in the parental cell line (24.2% 
reduction in Exon 5 and 30.1% reduction in Exon 7, panel C). However, a one 
way ANOVA carried on data found these differences between the percentage 
infected cells in each cell line was non-significant. Nevertheless, there was a 
small decrease in the level of infection for the knockout cells suggesting that 













Figure 4.5.1.2: Effects of knocking out TBC1D20 on FMDV infection: 
Parental and TBC1D20 knockout cell lines (Exon 5 and Exon 7) on cover slips 
were infected with O1K FMDV for 4 hours, fixed and labelled with antibody to 
FMDV 3A as an indicator of infection. Ten fields of view per cover slip with 2 or 
3 cover slips per cell line were imaged. Total number of cells was counted 
based on DAPI staining of nuclei (blue bars, panel A), and infected cells were 
counted based on detection of FMDV 3A (red bars, panel A).  Cell counts were 
used to calculate the percentage of infected cells, shown in panel B. These 
percentages were normalised and are shown in panel C. Error bars show mean 
+/-SD of the counts or percentage from ten fields of view from 2 cover slips 
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4.5.2 Comparing intracellular structures of the parent and TBC1D20 
knockout cell lines  
To determine if changes in the ER and Golgi resulted from TBC1D20 depletion, 
uninfected parental and knockout cells (Exon 5 and 7), were labelled for 
confocal microscopy, using antibodies to the Golgi marker, GM130, and the ER 
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Figure 4.5.2.1:  Comparison of Golgi structure in parent and TBC1D20 
knockout cell lines. Parent and TBC1D20 knockout Hela cells were seeded 
onto cover slips, fixed Golgi apparatus labelled (using antibody to GM130 
(green)), cell nuclei were stained using DAPI (blue).  Labelled cells were 
imaged by confocal to allow comparison between the cell lines and see if 




Figure 4.5.2.2: Comparison of ER structure in parent and TBC1D20 
knockout cell lines. Parent and TBC1D20 knockout Hela cells were seeded on 
cover slips, fixed and the ER labelled (using antibody to PDI, shown in green). 
Nuclei were stained using DAPI (blue) and cells imaged by confocal   
microscopy to look for structural differences in the ER between the parental and 
knockout cell lines (Exon 5 and Exon 7). 
 
Labelling for GM130 (green), Figure 4.5.2.1, showed that the Golgi was 
extensively disrupted in the knockout cell lines when compared to the knockout 
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cells with the most disruption being observed in the Exon 5 cell line. The middle 
panels show that the labelling for GM130 was far more dispersed in each of the 
knockout cell lines (middle panels, middle and bottom rows) compared to in the 
parent cell line which did express TBC1D20 (middle panel, top row).In the 
parent cell line labelling was more consistent and showed clear structures. 
Labelling of the ER protein PDI (green) (Figure 4.5.2.2) on the other hand 
showed little difference in ER structure between the parent and knockout cell 
lines, although fluorescence was fainter in one of the knockout cell lines (Exon 
7). 
 
4.5.3 Effects of knocking out TBC1D20 expression on FMDV replication 
To determine the ability of the TBC1D20 knockout cell lines to support 
replication each cell line (parent, Exon 5 and Exon 7) was transfected with the 
wildtype FMDV O1K Pt.GFP and O1K Pt.GFP GNN replicons (see Chapter 2 
section 2.2.1.3) and GFP intensity measured (as an indirect measure of 










Figure 4.5.3: Effects of knocking out TBC1D20 on FMDV replication. Parent 
and knockout HeLa cell lines (Exon 5 and Exon 7) were seeded into 96 well 
plates and transfected with O1K Pt.GFP or O1K Pt.GFP GNN replicon RNA. 
Plates were read at hourly intervals on the minimax Spectramax i3 plate reader 
and the number of GFP expressing cells (A) and total GFP intensity of wells (B) 
was measured as indirect measures of FMDV replication. One experiment was 
carried out with 4 replicate wells per condition, data points and error bars show 
mean +/- SD. 
 
This experiment showed a similar reduction in the level of infected cells for the 
knock out cells compared to the parental cells as was found using infectious 
virus (section as the number of GFP expressing cells (Panel A) was reduced.  
In addition, the overall GFP intensity per well (Panel B) in the knockout cell lines 
was also decreased when compared to the parent cell line. This suggests that 
FMDV replication is reduced in both the knockout cell lines implying that 
TBC1D20 may be required for optimum vRNA replication. 
 
4.6 Discussion 
Experiments carried out in this chapter used proteomic techniques to identify 
novel cellular interaction partners of FMDV 3A and investigate effects of 
changing expression levels of possible partners on infection. FMDV 3A likely 
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interacts with a wide range of proteins, a great number of which have yet to be 
identified and which could likely help increase understanding of the roles it plays 
in replication. 
The 3A protein of picornaviruses plays a major role in formation of a viral RC 
and RO (as described in Chapter 1). However, none of the major cellular 
proteins (GBF1, ACBD3, PI4KIIIα) that bind picornavirus 3A proteins were 
identified in the initial FMDV 3A mass spectrometry analysis (carried out at 
University of Dundee) or in the  Y2H screen (carried out by collaborators at 
Edinburgh University). This is consistent with studies by Berryman et al 
(Berryman et al., 2016) who showed that FMDV replication was independent of 
PI4K and, therefore, unlikely to depend on GBF1 or ACBD3. However DCTN3 
(dynactin 3), which has been proposed as a cellular interacting protein for 
FMDV 3A (Gladue et al., 2014), and TBC1D20 (which had been identified by a 
previous PhD student at Pirbright as a potential cellular factor required for 
FMDV infection (Midgley, 2011) were identified in the mass spectrometry data 
analysis. Furthermore Rab7L1 was identified as a potential interacting partner, 
for FMDV 3A, in both the mass spectrometry and Y2H screens.   
A previous study carried out on FMDV, identified DCTN3 (Dynactin 3) as a 
cellular interacting partner of 3A using a Y2H screen (Gladue et al., 2014). 
DCTN3 is also a subunit of a dynactin complex, which serves as a cofactor for 
the dynein motor. In addition, it was reported that over expression of DCTN3 or 
proteins that have been shown to disrupt the dynactin complex decreased 
FMDV infection. The region of 3A proposed to bind DCTN3 lies with the C 
terminal region of 3A (Gladue et al., 2014) that is proposed to influence host 
range specificity of FMDV (see Chapter 3) which suggests that DCNT3 may be 
a requirement for FMDV infection of bovine but not porcine cells. However, 
deletions in this region do not affect FMDV infection of BHK cells suggesting 
that if FMDV 3A binds DCTN3 then this interaction is may influence 
pathogenesis in certain hosts but is not necessarily a requirement for 
replication. The 3A protein of PV has been reported to bind LIS1 which belongs 
to the same complex as DCTN3. However, the relevance of this interaction was 
not studied in infected cells (Kondratova et al., 2005). Furthermore a study by 
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Teterina et al did not identify LIS1 as an interaction partner in pull-down 
experiments using epitope tagged PV 3A. Neither did they detect PI4K as an 
interaction partner of 3A but did confirm binding of GBF1 supporting the theory 
that PV 3A may not bind LIS1 directly (Teterina et al., 2011). However it was 
decided not to pursue further the potential role of DCTN proteins in FMDV 
infection, instead other proteins were selected to carry out additional studies on. 
As mentioned above Rab7L1 was identified as a possible interacting partner for 
FMDV 3A in both the mass spectrometry analysis and the Y2H screen, 
suggesting that Rab7L1 may be required for FMDV infection. The cellular 
functions of Rab7L1 are largely unknown, although there is some evidence that 
HCV NS5 may partially localise with Rab7L1 during infection (Sklan et al., 
2007a, Sklan et al., 2007b), and Rab7L1 has previously been linked with 
maintenance of the structure of the trans-Golgi network (Wang et al., 2014). 
However, in siRNA experiments conducted in IBRS2 cells no effect on FMDV 
infection was seen, suggesting that Rab7L1 is not required by FMDV. This 
observation should be considered a preliminary one, as due to a lack of Rab7L1 
specific antibodies it was not possible to confirm the effect of the siRNA on the 
protein expression levels. If time had been permitting, it would have been useful 
to develop an RTqPCR to determine the effectiveness of the siRNA at the RNA 
level.  
TBC1D20 was also identified as a potential interacting partner for FMDV 3A. 
The TBC1D20 protein is a known GAP for Rab1, a Rab GTPase that is involved 
in protein trafficking between the ER and Golgi and is required for Golgi 
structure maintenance (Haas et al., 2007). Direct interactions between 
TBC1D20 and viral proteins have been identified. The NS5A protein of Hepatitis 
C virus (HCV) binds TBC1D20 and TBC1D20 was shown to be essential for 
HCV infection and its depletion leads to inhibition of viral replication and 
infection (Sklan et al., 2007a, Sklan et al., 2007b). The TBC1D20 protein has 
also been identified as a host factor required for HIV as over expression of 
TBC1D20 arrests trafficking of the HIV-1 envelope protein through the secretory 
pathway and hampered envelope processing (Nachmias et al., 2012). 
Deficiencies in the Rab GAPs, such as TBC1D20  are associated with a number 
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of disorders, and mutations in TBC1D20 have been associated with Warburg 
micro syndrome an autosomal recessive disorder characterized by severe eye 
and brain abnormalities (Handley et al., 2015).  
A previous PhD student in our laboratory has also studied the role of TBC1D20 
in FMDV infection. For FMDV, it was observed that over expression of 
TBC1D20 reduces the number of infected cells by ~40% whereas TBC1D20-
R105A appeared to have a greater inhibitory effect and reduced infection by 
~60%. The reduction in infection caused by TBC1D20-R105A (a catalytically 
inactive variant of TBC1D20) was attributed to a possible a dominant-negative 
effect on the cells endogenous TBC1D20, blocking an essential interaction with 
down-stream effectors (Midgley, 2011). However, these observations could be 
interpreted to show that TBC1D20 has a role in FMDV infection that does not 
depend on its GAP activity.  
Experiments using TBC1D20 knockout cell lines in this work showed there was 
a slight drop in FMDV infection levels in the knockout cell lines compared to in 
the parent cell line. However this drop was not enough to be significant 
suggesting TBC1D20 is not essential for FMDV infection but may have an 
enhancing effect. Furthermore it was found that the knockout cell lines 
appeared to have some disruption to the Golgi even when not infected, however 
as full disruption to the Golgi was observed in the parent cell line this difference 
in structure of the Golgi is likely not the only factor responsible for the drop in  
infection levels observed.  
Together, the observations by Midgley and the results of this Chapter confirm 
that an intact Golgi is not required for FMDV replication, and, suggest a role for 
TBC1D20 in FMDV infection. This conclusion is based on the observations that 
depletion of TBC1D20 appears to inhibit genome replication and infection 
(section 4.5), whereas a previous study found expression of DN mutants of 
TBC1D20 inhibited FMDV infection (Midgley, 2011). These observations appear 
to somewhat contradict the observation that DN Rab1 inhibits FMDV infection 
(Midgley et al., 2013), as TBC1D20 has been identified as the GAP for Rab1. 
However, Midgley et al also showed that DN Arf1 also appeared to enhance 
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infection (Midgley et al., 2013). Therefore it is possible that the effect of blocking 
membrane flow through the secretory pathway by expression of DN Arf1 or DN 
Rab1 is independent, and not linked to, the role of TBC1D20 in infection. 
Although not proven, this conclusion is supported by the apparent inhibition 
seen with the catalytically inactive mutant of TBC1D20 (TBC1D20-R105A) 
(Midgley, 2011), which shows that inhibitory effect on FMDV infection is 
independent of GAP activity. Nevertheless, it seems that TBC1D20 is not an 
absolute requirement for FMDV infection and may instead serve as a co-factor 
that improves the efficiency of replication. Further studies will be required to 
determine the TBC1D20 proteins precise role in infection.  
In summary this chapter has investigated effects of altering expression levels of 
two selected proteins, predicted to be possible interaction partners from mass 
spectrometry experiments, on FMDV infection and replication. However results 
from the mass spectrometry data produced an extensive range of possible hits 
that have yet to be identified and further analysis is required confirm how many 
of these are true interaction partners, and work on this data is ongoing. 
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Chapter 5: Investigating a potential FFAT-like motif in FMDV 3A 
5.1 Introduction 
FMDV replication occurs on intracellular membranes and requires interactions 
between viral proteins and intracellular organelles, and the proteins expressed 
on their surfaces (See chapter 1 sections 1.62 and 1.6.3). The ER and ERGIC 
resident proteins: Vesicle associated membrane proteins (VAMP) Associated 
Proteins (VAP) are known to interact with several proteins via a specific motif 
known as an FFAT motif (Wyles and Ridgway, 2004, Loewen and Levine, 2005, 
Loewen et al., 2003). 
Vertebrates have two VAP proteins: VAP-A and VAP-B while in yeast the main 
VAP-like protein is Scs2P (Loewen et al., 2003, Murphy and Levine, 2016). A 
splice variant of VAP-B known as VAP-C has also been identified but is not well 
characterised, although it has been shown to interact with HCV NS5B and over 
expression of VAP-C had a negative effect on viral replication (Kukihara et al., 
2009). The VAP proteins are type II integral membrane proteins that act as 
receptors for cytoplasmic proteins at membrane contact sites (Skehel et al., 
2000) and have been linked with roles in maintenance of the Golgi structure 
(Peretti et al., 2008) and intracellular protein trafficking (Peretti et al., 2008, 
Prosser et al., 2008, Wyles and Ridgway, 2004). 
Dysfunction of VAP proteins has been shown to have negative effects; 
dysfunction of VAP-B has been linked with motor neurone diseases, and a 
single mutation within VAP-B has been linked with late onset amyotrophic 
lateral sclerosis as it leads to large aggregates forming in the ER (Nishimura et 
al., 2004). Over expression of oxysterol binding protein (OSBP: which has a 
FFAT motif; see below) was able to reduce these aggregates (Prosser et al., 
2008). 
A number of VAP interacting proteins have been identified, some of which 
contain a FFAT motif (i.e. two phenylalanine (FF) in an acidic tract (FFAT)). The 
FFAT sequence acts as an ER targeting motif that directly interacts with VAP 
proteins located on the ER or ERGIC (Prosser et al., 2008). They are described 
121 
 
as having the canonical sequence of 7 residues: E1-F2-F3-D4-A5-x-E7 (using the 
single letter a.a code, where x is any a.a) and a flanking region with multiple 
acidic residues and few basic residues (Loewen and Levine, 2005). These 
FFAT motif containing proteins target a number of membrane contact sites 
across many organelles and have been found in a large number of proteins, 
although not all VAP interacting proteins have a FFAT motif. 
The majority of FFAT-motifs identified have been found in proteins involved in 
lipid transfer including the lipid transfer proteins OSBP and OSBP-related 
proteins (ORPs), and the ceramide transport protein (CERT) (Loewen et al., 
2003, Kawano et al., 2006). Other FFAT motif containing proteins include the 
Rab18 GEF, Rab3GAP1, which regulates the morphology of the ER 
(Gerondopoulos et al., 2014), the AKAP220 and AKAP110 proteins (Mikitova 
and Levine, 2012) and the retinal degeneration B proteins Nir1, 2 and 3 
(Amarilio et al., 2005). FFAT motifs have also been identified in yeast, e.g. the 
transcription factor Opi1p, which interacts with Scs2 (the yeast VAP homologue) 
via an FFAT motif (Loewen et al., 2003, Loewen and Levine, 2005) and some 
plant lipid transfer proteins (Mikitova and Levine, 2012). 
Each of the elements of FFAT motifs (the core motif residues and the acidic 
flanking sequence) have sequence flexibility and a number of proteins have 
been identified with one or more differences to the canonical sequence; these 
are known as FFAT-like motifs (Saita et al., 2009, Mikitova and Levine, 2012). 
Such motifs have been found in proteins such as Protrudin, which has the 
FFAT-like motif EFKDAIE (Saita et al., 2009). However it has also been shown 
that an acidic residue cannot replace a small neutral residue at position 5 
(Mikitova and Levine, 2012) and that substituting the aspartic acid (D) residue 
with alanine at position 4 of the FATT-like motif of Protrudin inhibited 
interactions with VAP (Saita et al., 2009). Furthermore many VAP proteins with 
a FFAT motif tend to contain an additional FFAT or FFAT-like motif and 
sometimes up to three such motifs have been identified in a single protein 
(Murphy and Levine, 2016). FFAT-like motifs may have differing strengths of 
interaction with the ER, which has been used as an estimate of VAP binding.  
Murphy and Levine developed a scoring system based on the 6 N terminal 
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residues of the acidic tract, and the 7 core motif residues whereby each 
variation to the canonical sequence was classed as a suboptimal element. In 
this system a canonical FFAT motif scores 0, and it is used to predict potential 
interactions between FFAT-motif containing proteins and VAP-A or VAP-B 
(Murphy and Levine, 2016). 
It has been shown that viral proteins of hepatitis C virus (HCV), in particular 
NS5A and NS5B, also interact with VAP proteins. NS5B interacts with VAP-B, 
although not through a FFAT motif, but through binding to the VAP-B MSP 
domain and it has been found knocking down expression of VAP-B can be 
detrimental to HCV replication (Gupta and Song, 2016, Hamamoto et al., 2005). 
It has also been shown NS5A of HCV interacts with VAP-A as long as GPS2 is 
present (Gupta et al., 2012, Xu et al., 2013). NS5A and NS5B are key 
components of the HCV replication complex, and the interactions with VAP-A 
and VAP-B appears to anchor the RNA replication complex to the ER, which is 
required for HCV genome replication (Gao et al., 2004). This shows that viral 
proteins are able to interact with VAP-A and VAP-B and that this is required to 
replicate efficiently. Other viral proteins have been shown to interact with VAP 
proteins including the p48 protein of Norwalk virus (Ettayebi and Hardy, 2003), 
which interacts with VAP-A, and p33 of tombusvirus, which interacts with the 
OpiI and Scs2 proteins in yeast (Barajas et al., 2014). 
Analysis of FMDV 3A sequences revealed a conserved region within the N 
terminal domain (residues 24-30) containing a possible FFAT-like motif with the 
core motif sequence E1-F2-F3-E4-G5-M6-V7, and flanking region with acidic 
residues and few basic residues (Figure 5.1.1). This predicted FFAT-like motif 
sequence was found to be conserved in strains from each of the seven FMDV 
serotypes and is located close to a predicted dimerization domain of 3A 
(spanning residues 25-44) (Gonzalez-Magaldi et al., 2012). Furthermore VAP-B 
was identified as a potential interaction partner of 3A, in the mass spectrometry 
experiments using a 3A-GFP fusion protein (Chapter 4 section 4.3.2). A 
secondary possible FFAT-like sequence in FMDV 3A was also identified but 
likely has too many basic residues in the 5’ flanking region to be considered a 
true FFAT-like motif. The lower panel of Figure 5.1.1 shows the sequences of 
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the FFAT and FFAT-like motifs of OSBP and Protrudin as well as that of the 
predicted first motif in FMDV 3A and the potential FFAT (although this is most 
likely not an FFAT domain, see above). The top panel shows the a.a sequence 
of O1K FMDV with the prediction of the likely FMDV-like domain in red and the 

















Figure 5.1.1: Location of a predicted FFAT-like motif in FMDV 3A: Analysis of FMDV 3A sequences found a region potentially 
fitting the characteristics of an FFAT-like motif located in the N terminal domain of 3A. The top panel shows the location of the 
predicted FFAT-like motif within the 3A. The FFAT-like motif is shown in red, with the secondary predicted FFAT motif in green, 
yellow highlights the predicted transmembrane domain of 3A. Lower panel shows sequence comparison between known FFAT and 
FFAT-like motifs of OSBP and Protrudin and the predicted motifs within FMDV 3A (FMDV 3A sequence was investigated in this 
work where as FMDV 3A (2) was determined to likely have too many basic residues upstream to be a true FFAT domain), and the 
canonical sequence of a FFAT motif. 
                                               1234567        
Canonical  ------/EFFDAXE/-- 
OSBP       DEDDEN/EFFDAPE/II 
Protrudin  EAEPDE/EFKDAIE/ET 
FMDV 3A    QHEAAI/EFFEGMV/HD 
FMDV 3A (2)AFKRLK/ENFEIVA/LC  
                  
                   






This Chapter investigates the possible roles that the predicted FFAT-like motif 
in 3A may play in FMDV replication. The experiments used the FMDV GFP 
replicon system to measure effects on replication of introduction of various 
mutations within the core FFAT-like motif. Infectious recombinant viruses 
containing some of the mutations (which were used to test stability of viruses 
with mutations in this region of FMDV 3A) were also generated. Work carried 
out includes the substitution of multiple residues within the core motif, and 
replacing the core motif residues with those of other known FFAT motifs from 
different cellular proteins. 
 
5.2 Effects on replication of changing multiple residues within the 
predicted FFAT-like motif of FMDV 3A  
The N terminal domain of FMDV 3A is much more conserved than the C 
terminal domain. Therefore, as the predicted FFAT-like motif is located close to 
the N terminus and conserved across all seven serotypes of FMDV it could play 
an important role in replication through interactions with VAP proteins, similar to 
that proposed for HCV (Gupta et al., 2012, Gupta and Song, 2016, Hamamoto 
et al., 2005). Previous studies have shown that substituting various residues 
within the FFAT motif of several cellular proteins prevents binding to VAP 
proteins and ER localisation (Loewen et al., 2003, Mikitova and Levine, 2012).   
To investigate if the predicted FFAT-like motif is required for FMDV replication a 
range of a.a substitutions were made in the 3A coding region within the O1K 
Pt.GFP replicon using quikchange mutagenesis (Chapter 2 section 2.2.3.7).  
These mutations altered two (EFFE to AAFE or EFAA) or four (EFFE to ALLA) 
a.a residues within the core motif creating replicons (i) O1K Pt.GFP AAFE, (ii) 
O1K Pt.GFP EFAA and (iii) O1K Pt.GFP ALLA respectively. Table 5.2 shows 
the mutations made in each replicon at both the a.a (top lines) and nucleotide 














Table 5.2: Mutations made in the predicted FFAT-like motif of FMDV 3A. 
Different mutations were made in the predicted FFAT-like motif in the 3A coding 
region of the O1K Pt.GFP replicon. These included changing the first 2 residues 
to alanine (O1K Pt.GFP AAFE), the third and fourth residues to alanine (O1K 
Pt.GFP EFAA) or residues 1 to 4 to alanine or leucine (O1K Pt.GFP ALLA).  
The changes to the a.a sequence for each replicon are shown with the 
nucleotide base changes shown below. The O1K Pt.GFP GNN replicon has a 
wildtype FFAT-like motif.  
 
In vitro transcribed RNA from each replicon with mutations (O1K Pt.GFP AAFE, 
O1K Pt.GFP EFAA and O1K Pt.GFP ALLA), the parental wildtype replicon O1K 
Pt.GFP and O1K Pt.GFP GNN (a translation control) was transfected into BHK-
21 cells (as described in Chapter 2 section 2.2.1.3) and GFP intensity levels 
measured over time on the IncuCyte zoom to determine the effects of the 
mutations on replication (Figure 5.2.1) 
. 
Replicon FFAT-like motif Sequence 
O1K Pt.GFP 
E   F   F   E   G   M   V 
GAA TTC TTT GAG GGC ATG GTC 
  
O1K Pt.GFP GNN 
E   F   F   E   G   M   V 
GAA TTC TTT GCG  GGC ATG GTC 
O1K Pt.GFP AAFE 
A   A   F   E   G   M   V 
GCA GCC TTT GAG GGC ATG GTC 
O1K Pt.GFP EFAA 
E   F   A   A   G   M   V 
GAA TTC GCT GCG GGC ATG GTC 
O1K Pt.GFP ALLA 
A   L   L   A   G   M   V 
































Figure 5.2.1:  Effects of mutating two or more residues within a predicted 
FFAT-like domain of FMDV 3A.  BHK-21 cells were transfected with replicon 
RNA from each of the replicons containing mutations within the predicted FFAT-
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like motif of FMDV 3A along with RNA for the O1K Pt.GFP wildtype and O1K 
Pt.GFP GNN replicons to act as positive and negative controls of replication. 
GFP intensity levels were measured at hourly intervals as an indirect measure 
of replication. Results are shown for 3 independent experiments each with 3 
replicate samples per replicon. Data points and error bars show mean +/- SD.  
 
Results from 3 independent experiments showed (Figure 5.2.1) that each of the 
replicons with mutations in the predicted FMDV 3A FFAT-like motif gave similar 
GFP intensities as the replication defective O1K Pt.GFP GNN replicon. This 
suggests that the mutations had no effect on translation of the input RNA (for 
which O1K Pt.GFP GNN is a control) but prevented replicon RNA replication. 
Experiments carried out in parallel using cell lines derived from natural hosts of 
FMDV (MDBK (bovine) and SK-RST (porcine) cells) showed a similar effect on 
replication levels as none of the replicons containing mutations in the FFAT-like 
motif had GFP intensity levels above that of the translation only control (O1K 
Pt.GFP GNN) (data not shown). This suggests that the N terminal domain with 
FMDV 3A is potentially conserved due to having an essential function in 
replication and does not tolerate multiple a.a substitutions.  
 
5.3 Effects of mutation of the glycine residue at position 5 of the predicted 
FFA-like motif in FMDV 3A on replication 
Substitutions at position 5 of the canonical FFAT motif sequence have 
previously been found to have varying effects on VAP binding and can either 
enhance or prevent ER targeting, dependent on the a.a changes (Mikitova and 
Levine, 2012).  Therefore, a second set of mutations were made that changed 
the glycine residue at position 5 within the predicted FFAT-like motif of FMDV 
3A. This residue was changed to alanine (O1K Pt.GFP EFFEA), glutamic acid 
(O1K Pt.GFP EFFEE) or serine (O1K Pt.GFP EFFES) in O1K Pt.GFP. The 









Table 5.3: Mutations made at position 5 of the predicted FFAT-like motif in 
FMDV 3A. The glycine residue at position 5 of the FFAT-like motif of FMDV 3A 
was changed to alanine (O1K Pt.GFP EFFEA), glutamic acid (O1K Pt.GFP 
EFFEE) or serine (O1K Pt.GFP EFFES) in the O1K Pt.GFP replicon. Amino 
acid sequence (top) and nucleic acid sequences (bottom) are shown for each of 
the replicons developed. 
 
Replicon RNA from each of the replicons with a mutation at residue 5 of the 
FFAT-like motif, along with RNA from O1K Pt.GFP and O1K Pt.GFP GNN 
controls was transfected into BHK-21 cells and GFP intensity measured at 
hourly intervals using the IncuCyte zoom, as described for the previous set of 
mutations (Section 5.2). Figure 5.3.1 shows that mutating the glycine residue at 
position 5 had varying effects on replication. 
. 
Replicon FFAT-like motif Sequence 
O1K Pt.GFP 
 E   F   F   E   G   M   V 
GAA TTC TTT GAG GGC ATG GTC 
O1K Pt.GFP GNN 
 E   F   F   E   G   M   V 
GAA TTC TTT GAG GGC ATG GTC 
O1K Pt.GFP EFFEA 
 E   F   F   E   A   M   V 
GAA TTC TTT GAG GCT ATG GTC 
O1K Pt.GFP EFFEE 
 E   F   F   E   E   M   V 
GAA TTC TTT GAG GAG ATG GTC 
O1K Pt.GFP EFFES 
 E   F   F   E   S   M   V 































Figure 5.3.1: Effects of mutating the glycine residue at position 5 of the 
predicted FFAT-like domain in 3A. RNA transcribed in vitro from replicons 
containing mutations at the glycine residue at position 5 of the predicted FFAT-
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like motif in FMDV 3A (O1K Pt.GFP EFFEE, O1K Pt.GFP EFFFEA and O1K 
Pt.GFP EFFES) was transfected into BHK-21 cells in addition to RNA from the 
positive (O1K Pt.GFP) and negative (O1K Pt.GFP GNN) controls. GFP intensity 
was measured at hourly intervals as an indirect measure of replication. Three 
independent experiments with triplicate samples were carried out, data points 
and error bars represent mean +/- SD 
 
The replicons where the glycine was mutated to alanine (O1K Pt.GFP EFFEA, 
shown in green) or glutamic acid (O1K Pt.GFP EFFEE, shown in red) gave 
similar GFP intensity levels to that of O1K Pt.GFP (shown in blue) suggesting 
they were able to replicate as efficiently as the wildtype replicon and that these 
mutations did not affect replication. However when the glycine residue was 
mutated to a serine (shown in pink) the GFP intensity levels were lower than 
those seen for O1K Pt.GFP, although levels were still higher than those 
observed with the translation only control (O1K Pt.GFP GNN), showing that the 
replicon was replication competent but partially attenuated compared to the 
wildtype and other mutated replicons. This was the case in each of the 
experimental repeats (Figure 5.3.1). Parallel experiments were carried out in 
MDBK and SK-RST cells (data not shown) for all three glycine substituted 
replicons and the results showed that the O1K Pt.GFP EFFEE and O1K Pt.GFP 
EFFEA replicons gave similar replication to the wildtype replicon as in BHK-21 
cells. However, the O1K Pt.GFP EFFES appeared more severely attenuated in 
MDBK and SK-RST cells in comparison to in BHK-21 cells, with GFP intensity 
levels similar to O1K Pt.GFP GNN. 
 
5.4 Changing the FMDV 3A predicted FFAT-like motif sequence to that of 
known FFAT motifs of cellular proteins 
To further test the sequence flexibility of the potential FFAT-like motif in FMDV 
3A, the sequence within O1K Pt.GFP was replaced with the sequence of the 
FFAT motif of OSBP, which has a canonical FFAT sequence of EFFDAPE 
(Loewen et al., 2003, Loewen et al., 2004), or to the FFAT-like motif of 
Protrudin, which varies from most other FFAT-like motifs as it only contains one 
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phenylalanine residue (EFKAIDE) (Saita et al., 2009).  Table 5.4 shows the 
mutations made at both a.a and nucleotide levels. Replicon RNA was 
transfected in BHK-21 cells and GFP intensity levels measured as in sections 
5.2 and 5.3 to generate a measure of vRNA replication.  
 
Replicon FFAT-like motif Sequence 
O1K Pt.GFP 
E   F   F   E   G   M   V 
GAA TTC TTT GAG GGC ATG GTC 
O1K Pt.GFP GNN 
E   F   F   E   G   M   V 
GAA TTC GCT GCG  GGC ATG GTC 
O1K Pt.GFP OSBP 
E   F   F   D   A   P   E 
GAA TTC TTT GAC GCC CCG GAG 
O1K Pt.GFP Protrudin 
E   F   K   D   A   I   E 
GAA TTC AAG GAC GCC ATC GAG 
 
Table 5.4: Changing the predicted FFAT-like motif of FMDV 3A to that of 
cellular proteins with known FFAT motifs. The sequence of the predicted 
FFAT-like motif in FMDV 3A was swapped with the sequences of the known 
FFAT motif of OSBP, which has the canonical sequence of EFFDAPE, or to that 
of the previously published FFAT-like motif of Protrudin, which has the 
sequence EFKDAIE.  The changes shown in the table were introduced into the 
3A coding region of the O1K Pt.GFP replicon. 
 
Figure 5.4.1 shows that both replicons in which the predicted FFAT motif was 
changed for the sequence of that of a previously identified FFAT motif of OSBP 
or the FFAT-like motif of Protrudin showed reduced levels of replication as the 
GFP intensity signals were similar to the O1K Pt.GFP GNN replicon. This was 
the case in all three independent experimental repeats, and suggests that 
although FFAT-like domains themselves can tolerate a certain amount of 
variation this is not the case for the FFAT-like motif in 3A. However, it is 
possible that changing multiple residues in the N terminal domain of FMDV 3A 































Figure 5.4.1: Changing the predicted FFAT-like motif sequence in FMDV 
3A to that of known FFAT motifs and its effects on replication. RNA from 
O1K Pt.GFP OSBP and O1K Pt.GFP Protrudin replicons, in which the predicted 
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FFAT-like motif in FMDV 3A had been changed to match that of OSBP or 
protrudin respectively, was transfected into BHK-21 cells alongside RNA from 
O1K Pt.GFP and O1K Pt.GFP GNN. The GFP intensity was measured at hourly 
intervals as an indirect measure of replication. Three independent experiments 
each with triplicate samples were carried out. Data points and error bars show 
mean +/-SD. 
 
5.5 Recovery of infectious FMDV containing mutations within the 
predicted FFAT-like motif in 3A 
Three of the replicons generated in sections 5.2 and 5.3 were selected to 
generate infectious cDNA clones (i.e. recombinant viruses).  The replicons 
selected were O1K Pt.GFP AAFE, O1K Pt.GFP ALLA (both appeared unable to 
replicate as replicons) and O1K Pt.GFP EFFES (reduced replication as a 
replicon).  Scores of the strengths of these FFAT-like motifs were also 
calculated using the system developed by Murphy and Levine that predicts the 
strength of possible FFAT motifs by assigning each element with a score and 
combining them (see section 5.1) (Murphy and Levine, 2016). The calculations 
and scores for O1K WT, O1K AAFE, O1K ALLA and O1K EFFES are shown in 
Figure 5.5.1 (panels A, B, C and D respectively). The score of the predicted 
wildtype sequence the (i.e. FFAT-like motif) of FMDV 3A was calculated to be 
6.5 (panel A), whereas the mutation of multiple residues to create the AAFE and 
ALLA mutations increased the scores (thereby weakening the motif) to 11.5 and 
12.5 respectively (panels B and C).  In the virus where a single a.a substitution 
of glycine to serine (O1K EFFES) had been made however, it actually improved 
the score reducing it to 3.5 (thereby making it closer to the optimum score of 0) 




Figure 5.5.1: Scoring of strength of predicted FFAT-like motif in FMDV 3A. The strength of the potential FFAT-like motif in 
3A was calculated using a scoring system developed by Murphy et al in which suboptimal elements of the core residues of the 
motif and the upstream 6 N terminal flanking residues were each assigned a score with that of an optimal FFAT domain 
scoring 0. The scores calculated for the wildtype FMDV (panel A), and 3 of the different mutations created (panels B, C and D) 
are shown with the residues that were used to calculate the binding score highlighted in blue. 
Score
Position A C D E F G H I K L M N P Q R S T V W Y
1 1 1 0 0 1 1 1 1 2 1 1 1 1 1 2 1 1 1 1 1 0
2 4 4 4 4 0 4 4 4 4 4 4 4 4 4 4 4 4 4 2 1 0
3 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
4 2 2 0 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2
5 0 0 4 2 2 2 2 2 2 2 2 2 2 2 3 1 1 2 2 2 2
7 1 1 0 1 1 1 2 1 2 1 1 1 1 1 2 1 1 1 1 1 1
Flankx6 1 1 -1 -1 1 1 1.5
Overall 6.5
Amino acid (Single letter code)
Add all flank scores ≥4=0, ≥3=0.5, ≥2=1, <2=1.5
Score
Position A C D E F G H I K L M N P Q R S T V W Y
1 1 1 0 0 1 1 1 1 2 1 1 1 1 1 2 1 1 1 1 1 1
2 4 4 4 4 0 4 4 4 4 4 4 4 4 4 4 4 4 4 2 1 4
3 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1
4 2 2 0 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2
5 0 0 4 2 2 2 2 2 2 2 2 2 2 2 3 1 1 2 2 2 2
7 1 1 0 1 1 1 2 1 2 1 1 1 1 1 2 1 1 1 1 1 1
Flankx6 1 1 -1 -1 1 1 1.5
Overall 12.5
Amino acid (Single letter code)
Add all flank scores ≥4=0, ≥3=0.5, ≥2=1, <2=1.5
Score
Position A C D E F G H I K L M N P Q R S T V W Y
1 1 1 0 0 1 1 1 1 2 1 1 1 1 1 2 1 1 1 1 1 1
2 4 4 4 4 0 4 4 4 4 4 4 4 4 4 4 4 4 4 2 1 4
3 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
4 2 2 0 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2
5 0 0 4 2 2 2 2 2 2 2 2 2 2 2 3 1 1 2 2 2 2
7 1 1 0 1 1 1 2 1 2 1 1 1 1 1 2 1 1 1 1 1 1
Flankx6 1 1 -1 -1 1 1 1.5
Overall 11.5
Amino acid (Single letter code)
Add all flank scores ≥4=0, ≥3=0.5, ≥2=1, <2=1.5
Score
Position A C D E F G H I K L M N P Q R S T V W Y
1 1 1 0 0 1 1 1 1 2 1 1 1 1 1 2 1 1 1 1 1 0
2 4 4 4 4 0 4 4 4 4 4 4 4 4 4 4 4 4 4 2 1 0
3 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0
4 2 2 0 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2
5 0 0 4 2 2 2 2 2 2 2 2 2 2 2 3 1 1 2 2 2 0.5
7 1 1 0 1 1 1 2 1 2 1 1 1 1 1 2 1 1 1 1 1 1
Flankx6 1 1 -1 -1 1 1 1.5
Overall 3.5
Amino acid (Single letter code)





Infectious clones were generated as described previously in Chapter 3 section 
3.5 by replacing the Pt.GFP coding region with the O1K WT capsid-encoding 
region from the pT7S3 infectious clone. Infectious copy RNA was transfected 
into BHK-21 cells and cells monitored for appearance of CPE. At total CPE, or 
48 hours post transfection, cells were freeze-thawed and lysate clarified and 
passaged onto new BHK-21 cells, and this process was repeated until viruses 
reached passage 2 or 3 (BHKp2 and BHKp3).  
Infectious virus was recovered from all three of the infectious copies (O1K 
AAFE, O1K ALLA and O1K EFFES) with CPE being observed from 20 hours 
post infection at passage 1 (BHKp1), with little difference in CPE levels 
observed in comparison to the wildtype O1K positive control (derived from 
Pt.GFP O1K) apart from O1K AAFE, which showed less CPE. By passage 2 
however viruses with mutations were achieving full CPE at times similar to the 
wildtype virus. Images showing CPE at passage 1 for each of the FFAT-like 
motif mutant viruses (from set 1) are shown in Figure 5.5.2. Similar 
observations were made in 3 independent experiments (referred to as 


















































Figure 5.5.2 Recovery of FFAT-like motif mutant viruses.  In vitro 
transcribed RNA from the 3 infectious clones with FFAT motif mutations in 3A 
(O1K AAFE, O1K ALLA and O1K EFFES) was transfected into BHK-21 cells, 
after 48 hours cells were freeze thawed and supernatant passaged onto new 
BHK-21 cells. Cell monolayers were checked regularly for appearance of CPE. 
The images show the time point post infection for passage 1. At the time shown, 
2 of the 3 mutated viruses gave almost complete CPE. Positive and negative 
controls (O1K WT and cell only) were also included. 
 
As the experiments using replicons with the mutations at the FFAT-like motif 
showed reductions in replication (O1K Pt.GFP EFFES), or complete attenuation 
to the level of the translation only control (O1K Pt.GFP AAFE and O1K Pt.GFP 
ALLA), it was thought that viruses with the AAFE and ALLA mutations may not 
be recoverable or would show reduced growth rate in comparison with the 
wildtype O1K virus. However, the rapid recovery of the mutant viruses and the 
observations that they appeared to cause CPE with similar kinetics at passage 
2 to the wildtype FMDV control (which was seen in three independent 
experiments, each carried out using newly transcribed RNA) suggested that the 
recovered viruses could show reversion of the a.a sequence to restore the 
wildtype FFAT-like motif. Therefore, RNA from each of the recovered viruses 
was extracted and sequenced by Sanger sequencing to see if the mutations 
were stably maintained or if reversion of the mutations had led to the viruses 
being recoverable (see Section 5.6). 
 
5.6 Sequencing recovered viruses for evidence of reversion of mutations 
made within the predicted FFAT-like motif of FMDV 3A 
Viral RNA from lysates of a selection of the recovered viruses for experiments 1 
and 2, at passage 1, 2 and 3 (BHKp1, BHKp2 and BHKp3) was extracted as 
described in Chapter 2 section 2.2.5.3. Single-stranded cDNA was made using 
reverse transcription (Chapter 2 section 2.2.5.4) and the 3A region amplified by 
PCR using primers that bind within 2C and 3B2. PCR products were purified by 
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gel extraction and sequenced using Sanger sequencing (as described in 
Chapter 2 section 2.2.8.1).  
The O1K EFFES virus, which as a replicon had remained replication competent 
but was partially attenuated in comparison to the wildtype (section 5.2), 
maintained the mutations within the predicted FFAT-like motif at passage 2 and 
3 in experiment 2. However, for experiment 1, by passage 1 the recovered virus 
appeared to have reverted back to wildtype sequence. These observations 
suggest that this mutation may be stably maintained and allow recovery of 
infectious virus containing the G to S a.a substitution at position 5 of the FFAT-
like motif within 3A. Further support for this outcome was seen following a third 
experiment (discussed below) that yielded similar results. 
The results of the sequence analysis also showed there appeared to be a 
reversion of the O1K ALLA virus (which contained the most nucleotide changes 
across the motif; 4 in total) back to the wildtype FFAT-like motif sequence for 
experiments 1 and 2. This occurred rapidly and could account for why little 
difference in the time taken for complete CPE to develop was seen in 
comparison to the O1K WT virus at passage 1 as the mutations had already 
been reverted. The other mutant virus (O1K AAFE) also reverted to wildtype but 
more slowly as in experiment 1, the consensus sequence at the first passage 
(BHKp1) appeared to be AFFDG before reverting fully to the wildtype sequence 
by passage 2 (BHKp2). However this slower change was not seen in the other 
experiment (experiment 2), where BHKp1 appeared to have the sequence 
EFFEA, which then changed to the wildtype sequence at passage 2 (BHKp2).  
The recovered viruses from experiment 2 were passaged once more (BHKp3) 
and sequenced, which showed that the EFFES sequence was faithfully 
maintained while the sequence of the other 2 viruses (with AAFE and ALLA 
mutations) gave the consensus wildtype sequences as expected, since they 
had already given wildtype consensus sequences at a prior passage (See Table 







Virus Transfected cells Passage 1 Passage 2 Passage 3 
O1K AAFE - EFFEA EFFEG - 
O1K ALLA EFFEG - - - 
O1K EFFES - - - EFFES 
 
Experiment 3: 
Virus Transfected cells Passage 1 Passage 2 
O1K AAFE EFFEG - - 
O1K ALLA EFFEG - - 
O1K EFFES - - EFFES 
 
Table 5.6: Sanger sequencing results from viral passages of viruses with 
FFAT-like motif mutations: Viruses with various mutations in the predicted 
FFAT-like motif in 3A were recovered and passaged in BHK-21 cells. RNA was 
extracted, used to make single stranded cDNA and the 2C to 3B2 region PCR 
amplified and sequenced by Sanger sequencing to look for reversions. For 
simplicity tables show consensus sequence results at each passage where a 
change from expected sequence was observed only. Results from 3 
independent experiments using different input RNA preparations are shown. 
 
The rapid appearance of the wildtype sequence for the AAFE and ALLA viruses 
suggested the possibility for contamination with the O1K WT, parental virus, 
particularly as the same apparent speed of reversion was observed in a 
subsequent “test” experiment where the positive control virus (O1K WT) was 
not included (data not shown). To address this issue further, each of the 
infectious copy plasmids (O1K AAFE, O1K ALLA and O1K EFFES) were re-
transformed in bacteria (DH5 α E.coli), and grown at a lower temperature of 
(30°C) and new plasmid stocks prepared from a single, isolated colony. The 
Virus Transfected cells Passage 1 Passage 2 
O1K AAFE - AFFDG EFFEG 
O1K ALLA EFFEG - - 
O1K EFFES - EFFEG - 
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new plasmid DNA was then linearised and used to produce new in vitro 
transcribed RNA that was subsequently transfected into BHK-21 cells to recover 
virus and repeat the viral passage and Sanger sequencing (referred to as 
experiment 3).  
In addition, the transcribed RNA was used as a template to obtain the sequence 
of the 3A FFAT motif for each of the infectious copy plasmids which showed the 
presence of the mutations that had been introduced to the FFAT-like motif.  
In experiment 3 sequencing RNA extracted from transfected cells showed that 
the O1K AAFE virus appeared to have the complete wildtype consensus 
sequence at the nucleotide level. In comparison the O1K EFFES virus 
appeared to have maintained the mutations at BHKp2, which supports the 
results from experiment 2 that this virus is recoverable with the mutation. In 
contrast to the EFFES virus, but similar to the AAFE virus, the O1K ALLA virus 
again had the consensus wildtype sequence. This was seen following 
sequencing of RNA extracted from the transfected cells despite sequencing of 
the transcribed RNA suggesting the mutations were present. The sequencing 
results from experiment 3 are shown in table 5.6. 
To further address the possibility of contamination by the wildtype virus, the 
O1K ALLA infectious copy plasmid (selected as it had the most mutations 
present but still appeared to change rapidly to wildtype) was deep sequenced to 
see if there was evidence of mixed populations at the plasmid level, and if the 
DNA was potentially contaminated. DNA was prepared and deep sequenced 
using an Illumina Miseq (Chapter 2 section2.2.8.2). Deep sequencing revealed 
that not a single run had a complete wildtype FFAT-like motif and the majority 
(and hence consensus) had the complete ALLA FFAT motif sequence. With an 
error rate of 0.5% for the process, this showed that >99.5% of infectious copy 
plasmid had the ALLA sequence and that the level of contamination, if any, was 
below the detection threshold of the software. In vitro transcribed viral RNA 
derived from this plasmid was also sequenced over the 3A region (as described 
above for previous viral passage experiment), which also showed that the 
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consensus sequence of the FFAT-like motif was ALLA. This RNA was then 
used in a subsequent transfection.  
A transfection time course using the vRNA from above was carried out using 
BHK-21 cells. RNA samples were collected from the transfected cells at 2, 4, 6, 
8 and 10 hours post transfection. RNA was extracted from the samples and 
reverse transcribed to make single stranded cDNA, which was then used as a 
template to amplify the 3A region by PCR as described previously. Aliquots 
(5µl) of the PCR products were analysed by gel electrophoresis and the 
remainder column purified and sequenced by Sanger sequencing.  
The region containing the predicted FFAT-like motif was sequenced using 3 
different primers, and each sequence obtained showed potential mixed 
populations, with major and minor peaks occurring at the nucleotides that had 
been mutated to create the ALLA sequence, suggesting potential contamination 
with a wild type virus. Importantly, two peaks were not observed in the input 
RNA at the mutated nucleotides and the traces either side of the mutations (i.e. 
outside of the region encoding the FFAT motif) showed only one clear peak at 
every position. Figure 5.6.1 shows the detailed chromatogram obtained for one 
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Figure 5.6.1: Chromatogram traces showing sequencing of RNA extracted 
from cells transfected with O1K ALLA RNA over time. Sanger sequencing of 
PCR products derived from single stranded cDNA of RNA extracted from 
transfected cells or from in vitro transcribed RNA prior to transfection. This 
showed that from 2 hours post transfection mixed peaks were seen at positions 
where the mutations had been made. One representative trace is shown from a 
single primer (in total 3 primers were used to obtain sequencing data). 
Consensus sequence data and sequences based on both the larger (major 
peak) and smaller (minor peaks) is summarised in table 5.6.2. 
 
Analysis of the sequences showed that the chromatogram for the input RNA 
had single peaks across the entire region sequenced and that each of the 4 
nucleotide changes made was present (Figure 5.6.2 panel A). However, by 2 
hours (panel B) the chromatogram showed duplicate peaks at each of the 4 
mutation sites; the larger peaks (major) showed that the nucleotide sequence 
for the EFFE wildtype motif had become the dominant sequence present, 
whereas smaller peaks (minor) showed the nucleotide sequence for the ALLA 
mutation virus. A similar pattern was observed in the chromatogram for the 
samples from 4 hours post transfection (panel C) although at this time point the 
minor peaks appeared smaller. This pattern of minor peaks for the ALLA 
sequence decreasing in size continued across the remaining time points (6 and 
8 hours post transfection, data not shown) until by 10 hours post transfection 
where the smaller peaks were barely visible and the predominating peaks were 
the nucleotide sequence for the wildtype FFAT-like motif (data not shown). 
Sequence data for the first 4 hours is summarised in table 5.6.2 showing the 
sequence observed from the larger (major peaks), the smaller (minor peaks) 
and the overall consensus sequence provided by the software. A further 
observation made was that no double peaks were present throughout the 
sequences flanking the FFAT-like motif residues, which could indicate 
compensatory mutations from reversion. Although reversion to the wildtype 
sequence cannot be completely ruled out, the almost immediate replacement of 
the ALLA mutations by the wildtype sequence, and the observation that the 
change at each mutation site appeared simultaneously suggests the O1K ALLA 
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virus was likely outcompeted by a wildtype virus suggesting the presence of a 







Input RNA - - 
GCA TTA CTTGCG 




GAA TTC TTT GAG 
E   F   F   E 
GCA TTA CTT GCG 
A   L   L   A 
GMA TTC TTT GAG 




GAA TTC TTT GGC 
E   F   F   E 
GCA TTA CTT GCG 
A   L   L   A 
GAA TTC TTT GAG 
E   F   F   E 
 
Table 5.6.2 Results of sequencing samples from transfection time course 
of O1K ALLA: In vitro transcribed RNA from O1K ALLA was transfected into 
BHK-21 cells and samples frozen at 2 hourly intervals.  RNA was extracted from 
samples, single stranded cDNA made and the 3A region amplified by PCR. 
PCR products were sequenced by Sanger sequencing using 3 primers (one 
forward and 2 reverse). Table shows the nucleotide and a.a sequences for both 
the larger peaks (major sequence) and smaller peaks (minor peaks), as well as 
the consensus sequence output from the software following alignment of 
sequences from each of the primers used (3 in total). 
 
5.7 Discussion 
Proteins with FFAT motifs have been shown to interact with VAP proteins 
(Furuita et al., 2010, Kaiser et al., 2005). However, the ability of proteins with 
FFAT and FAAT-like motifs to bind VAP has been determined mostly by 
determining the ability of cytosolic proteins to interact with the ER.  Although 
these studies have defined an optimal sequence of EFFDAxE for interaction 
with VAP proteins, they have also shown that some of the positions within the 
core motif tolerate variations and that FFAT binding can be retained when more 
that one of the core residues are mutated (Kaiser et al., 2005, Mikitova and 
Levine, 2012). This means that FFAT binding motifs are noted for their flexibility 
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and a large number of FFAT and FFAT-like binding motifs have been described 
(Murphy and Levine, 2016). 
FMDV replication complexes (RC) form on cellular membranes and 3A is a 
membrane-associated protein that is likely to contribute to RC formation (Se 
Chapter 1 sections 1.6.2 and 1.6.3). Therefore it is possible that 3A requires a 
host factor or protein to tether to membranes, to initiate RC formation. Analysis 
of FMDV 3A identified a region near the N terminus of the protein, at residues 
24 to 30, which fits the profile of a potential FFAT-like motif having the 
sequence EFFEGMV, as well as multiple acidic residues located in the N 
terminal flanking region. As FAAT motifs bind to VAP this suggested the 
intriguing possibility that FMDV 3A could use VAP proteins as a membrane 
tether. With this in mind, VAP A has been implicated as a host factor required 
for replication of HRV (Roulin et al., 2014). Testing the effects of a range of 
different mutations made within the 3A FFAT-like motif on viral replication using 
the FMDV replicon showed that substitution of 2 or more residues within the 
FFAT motif (EFFE to AAFE, EFAA or ALLA) led to a decrease in replication with 
GFP intensity levels similar to that of the translation only control, which would 
be consistent with these mutations abrogating VAP binding (Mikitova and 
Levine, 2012, Loewen and Levine, 2005). 
Similar observations were made when the entire 3A FFAT-like motif was 
changed to that of previously identified FFAT motifs of OSBP and Protrudin. 
This shows that if the FMDV 3A sequence is a functional FFAT-like motif then 
changing it to other FFAT motifs was not tolerated. In addition, major changes 
to the FMDV sequence could impact on other processes mediated by 3A that 
are required FMDV replication. For example, the EFFEGMV sequence is 
located in the N terminal domain of FMDV 3A, an area which is more highly 
conserved than the C terminal domain of 3A, suggesting it may play an 
important role in viral replication that may or may not be due to an interaction 
with the VAP proteins. The fact it is conserved could also suggest there could 
be potential RNA structures in that region that may be disrupted in the mutant 
replicons/viruses although this explanation requires further exploration 
potentially using replicons and viruses with silent mutations as opposed to those 
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which change the a.a sequence. In addition, it is possible that changes at the 
FFAT-like motif could adversely affect 3A dimerization, which has been 
proposed to be required for FMDV infection as the predicted FFAT-like 
sequence within 3A is located adjacent to the predicted dimerization domain 
region (Gonzalez-Magaldi et al., 2012).  
Changing the a.a at position 5 within the core motif in FMDV 3A was also 
studied and was found to have varying effects on replication; no effect on 
replication was seen upon changing the wildtype glycine residue to alanine or 
glutamic acid but replication dropped to around half the levels of the wildtype 
O1K Pt.GFP replicon when the glycine was replaced by a serine residue. This 
was seen in BHK-21, MDBK and IBRS2 cells although attenuation of O1K 
Pt.GFP EFFES was more severe in MDBK and IBRS2 cells. The observation 
that the introduction of alanine (A) at position 5 does not appear to affect FMDV 
replication is consistent with the effect of this change for other VAP binding 
proteins as previously observed by Mikitova et al (Mikitova and Levine, 2012). 
The introduction of serine (S) at position 5 appears to partially inhibit replication 
of the FMDV replicon. This is also consistent with the study by Mikitova et al 
who showed that the FFAT-like motif found in the AKAP 220 protein, has an S 
residue at position 5 (EFFDSxD) and shows only moderate ER binding 
(Mikitova and Levine, 2012). Therefore it is possible this change may have 
negatively impacted on the ability of the predicted FMDV 3A motif to interact 
with VAP causing the observation of reduced FMDV replication.  
The results from studies on the glycine to alanine, and glycine to serine 
mutations are consistent with the expected outcome of previous studies 
introducing these mutations into other proteins known to bind VAP.  However, 
this study also showed that the introduction of an acidic residue (e.g. glutamic 
acid (E)) at position 5 leads to a major reduction in VAP binding (Mikitova and 
Levine, 2012). Here my results show that changing the residue at position 5 
from a glycine residue (G) to an acidic residue, glutamic acid (E) in the 
predicted FMDV 3A FFAT-like motif did not affect replication of the replicon 
(O1K Pt.GFP EFFEE), which could be interpreted to indicate that it does not 
function as a VAP binding site. However, as stated above there is considerable 
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flexibility in FFAT binding motifs and the inclusion of an E residue at position 5 
may be tolerated within the context of different surrounding core sequences and 
the apparent viability of the EFFEE replicon does not completely rule out VAP 
binding.  
Attempts to recover infectious viruses with FFAT mutations (AAFE and ALLA) 
appeared to suggest that viruses with mutations that inhibited replication 
completely (based on results from replicon assays) were unrecoverable as they 
consistently were found to have wildtype FFAT domains at early passage. 
Despite showing that the ALLA infectious copy plasmid (sequenced by both 
Sanger and deep sequencing) and in vitro transcribed RNA (sequenced by 
Sanger sequencing) derived from this plasmid had the ALLA sequence, it 
appears that the most likely explanation for recovery of viruses with the wildtype 
3A sequence was a very low level of contamination with the wildtype virus (O1K 
WT) that was able to outcompete the non-replicative O1K ALLA virus. The one 
virus that was recoverable and retained the FFAT motif mutations was that with 
the glycine to serine substitution at position 5 (O1K EFFES).  Experiments using 
GFP-based replicons showed this mutation led to a decrease in replication of 
the replicon, however this virus could be recovered, and the mutation was 
maintained. This was the one mutation that was selected to make into a virus in 
which the mutation led to the FFAT-like sequence being more similar to that of 
the predicted canonical sequence and hence was predicted to be a stronger 
FFAT-like domain than the wildtype based on the system derived by Murphy 
and Levine 2016 (Murphy and Levine, 2016). A retained ability to bind VAP may 
explain why the EFFES replicon appeared to be replication competent (although 
reduced compared to the wildtype) but also why the mutation was retained 
within the recovered viruses.  In contrast, the other mutations (AAFE and ALLA) 
greatly reduce the FFAT-motif score and are predicted to abrogate VAP 
binding. Consistent with the above, if a low level of a contaminating wildtype 
virus was present in the EFFES virus then, as the mutant virus was replication 
competent and able to grow, it could outcompete the wildtype virus. One way to 
avoid this problem in future work would be to include marker mutations into the 
infectious clone, located somewhere upstream of the changes made that could 
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be used to differentiate between reverted virus and a contaminating wildtype 
virus. Nevertheless, the problems caused by this apparent contamination were 
time consuming and prevented further attempts to recover and characterise 
mutant viruses.  
The predicted FFAT-like motif overlaps a region within the N terminal domain of 
FMDV 3A that is predicted to form one of two alpha helices and to serve as a 
3A dimerization domain and mutations within this region had a negative effect 
on viral infectivity (Gonzalez-Magaldi et al., 2012). In addition, peptides 
corresponding in sequence to this region were reported to interfere with 
dimerization of 3A and decrease in FMDV infection (Gonzalez-Magaldi et al., 
2015). Therefore it is possible that creating mutations within the FFAT-like motif 
could also be affecting protein structure and having an impact on regions 
downstream that are responsible for other functions required for viral replication, 
such as dimerization. Therefore, further work is required to identify if there is a 
direct interaction between FMDV 3A and VAP-A and VAP-B before it can be 
confirmed that this region within 3A does act as an FFAT-like domain.  
Overall the results of this Chapter have shown that FMDV 3A has a potential 
FFAT-like motif located at the N terminal region of the protein that is conserved 
across the seven FMDV serotypes. Using a GFP-based replicon showed that 
mutations within this motif have varying effects on replication. In addition, a 
virus with mutations in this motif that did not completely inhibit replication of the 
replicon appears to be recoverable and the mutations stably maintained. These 
studies also suggest that results of experiments with recombinant viruses with 
mutations need to be treated with caution when reversions to wildtype 
sequences are seen, and suggest that the introduction of additional silent 
mutations distant to the sequence under investigation, that effectively act as 
markers of the recovered viruses as having truly reverted (and not having been 





Chapter 6: Investigating the potential role of 3A as the 
chaperone for delivery of VPg to the viral replication complex 
6.1 Introduction 
The proteins encoded by the P3 region of the genome of picornaviruses and the 
intermediate products generated during P3 processing have been shown to play 
a variety of roles in viral replication. One potentially important role of the P3 
precursors is acting as the source of VPg (3B) for uridylation. VPg is uridylated 
on its third a.a residue (a tyrosine) to form VPg-pUpU, which serves as the 
primer for initiation of viral RNA replication (See Chapter 1 introduction section 
1.4.9). 
The initial models of picornavirus RNA replication (see Chapter 1 section 1.5.6) 
predicted that the intermediate precursor 3AB was the template for VPg 
uridylation (Liu et al., 2007, Murray and Barton, 2003). However, more recently 
a study by Pathak et al using PV suggested that a P3 intermediate processing 
product with 3B at its amino terminus (3BC or 3BCD) is the more likely 
precursors that act as the VPg donor as they showed that 3BC and 3BCD can 
bind more efficiently to the cre than VPg alone and be uridylated (Pathak et al., 
2008). In addition to full length P3 (3AB1B2B3CD), FMDV has the potential to 
produce several 3A-containing (e.g. 3AB1B2B3, 3AB1B2, 3AB1) or 3C-containing 
precursors (e.g. 3B1B2B33C, 3B2B33C, 3B33C, or each of these with 3CD) of 
VPg. However, it is not yet known which of these (or 3B alone) is uridylated in 
infected cells and used for viral genome replication. However, the recombinant 
FMDV 3C precursor proteins 3B1B2B33C and 3B33C have each been shown to 
be uridylated in vitro although neither was as efficient as “free” 3B3 (Nayak et 
al., 2006).  
This Chapter investigates the donor of VPg for FMDV replication, using sub-
genomic replicons and recombinant viruses. The P3 coding region was modified 
by inserting the ‘2A-like’ sequence from the insect virus, Thosea Asigna virus 
(TaV) so that VPg (3B) could only be covalently linked to either 3A (referred to 
as 3A Donor) or 3C (referred to as 3C Donor). A third construct was created 
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with 2 copies of the TaV 2A in which 3B would only be produced as the ‘free’ 3B 
peptide(s) and not covalently linked to 3A or 3C (known as the No Donor).  
The 2A peptide of many viruses, including FMDV, has been shown to allow co-
translational “cleavage” of polyproteins, as they prevent formation of a covalent 
bond at their C terminal residue (Donnelly et al., 2001b, Ryan and Drew, 1994). 
Therefore, inclusion of a TaV “2A-like” peptide sequence provided a method of 
preventing a covalent linkage forming between 3A and 3B1, or between 3B3 
and 3C that would still allow ongoing translation of downstream proteins. The 
TaV 2A sequence was chosen as it has previously been shown to be as active 
as the FMDV 2A peptide sequence in its ability to “cleave” itself at the C 
terminus (Donnelly et al., 2001a). In the Donor constructs (3A Donor, 3C Donor 
and the No Donor), to ensure that the processed P3 proteins had authentic N 
and C termini following cleavage at the TaV 2A sites, additional a.a (6 in total) 
were included (these are shown in Figure 6.1.1) to generate artificial cleavage 
sites. In the 3A Donor, the first 6 a.a of FMDV 3C were inserted between 3B3 
and TaV2A to generate an artificial 3C site that would (when processed) give an 
authentic C terminus to 3B3. Similarly, the last 6 a.a of FMDV 3B3 were included 
before 3C to create an artificial 3C site, to generate an authentic N terminus for 
3C.  
For the 3C Donor, the first 6 a.a of 3B1 were inserted between 3A and TaV 2A 
to generate an artificial 3C site that would (when processed) give an authentic C 
terminus to 3A. Similarly, the last 6 a.a of 3A were included before 3B1 to create 
an artificial 3C site to generate an authentic N terminus for 3B1. In addition, the 
first 6 a.a of 3B1 included a Y3F mutation to prevent this sequence for 
functioning as a primer for vRNA replication.  
In the No Donor cassette, 4 artificial 3C cleavage sites were included as follows: 
1. The first 6 a.a of 3B1 were inserted between 3A and the first copy of TaV 2A 
to generate an artificial 3C site that would (when processed) give an 
authentic C terminus to 3A. In addition, a Y3F mutation was included to 
prevent this sequence for functioning as a primer for vRNA replication.  
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2. The last 6 a.a of 3A were included before 3B1 to create an artificial 3C site to 
generate an authentic N terminus for 3B1.  
3. The first 6 a.a of 3C were inserted between 3B3 and the second copy of TaV 
2A to generate an artificial 3C site that would (when processed) give an 
authentic C terminus to 3B3.  
4. The last 6 a.a of 3B3 were included before 3C to create an artificial 3C site to 
generate an authentic N terminus for 3C. 
 
The nucleotide sequence for these additional short a.a sequences (each 6 
residues) were changed by introducing silent mutations in an attempt to limit 
recombination and distinguish revertant viruses from potential contaminating 
wildtype viruses. In addition, where the artificial cleavage site included the first 6 
a.a of 3B1 the tyrosine at position 3 was substituted for a phenylalanine to 
prevent this sequence acting as primer for replication. Furthermore, a proline 
was added after each of the TaV sequences in order to facilitate cleavage. 
Silent mutations (8 in total) were also introduced into the second TaV 2A 
sequence of the No Donor construct in order to limit recombination. 
The design of the P3 Donor cassettes is shown in figure 6.1.1. In the 3A Donor, 
only 3A is linked to 3B1-3 and 3B (VPg) can only be supplied to the replication 
complex by 3A. In the 3C Donor, 3B1-3 is only covalently linked to 3C therefore 
only 3C can supply VPg to a replication complex. In the No Donor, neither 3A 
nor 3C were linked to 3B1-3 so 3B would only ever be generated as “free” 3B 
peptide. However free 3B could also be generated by both of the other 
constructs (i.e. the 3A and 3C Donors) in addition to 3B intermediates. Natural 
3C cleavage sites are indicated by the black arrows whereas the additional 
artificial cleavage sites are shown by blue arrows. The full sequence of the 
donor cassettes are shown in appendix 2 (A2).  
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Dashed lines indicate TaV 2A cleavage site, blue arrows indicate artificial  3C cleavage site, black arrows show natural 3C 
cleavage sites 
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Figure 6.1.1 Design of P3 region of Donor Cassettes: 3B donor constructs 
were designed where 3B could only ever be covalently linked to 3A (3A Donor), 
3C (3C Donor) or free 3B produced (No Donor) through addition of a TaV 2A 
sequence between 3A and 3B1, or 3B3 and 3C or both. Proline residues (P) 
were added after the TaV 2A sequences to aid the 2A mediated cleavage. 
Additional a.a were included (3B1 a.a 1-6, 3C a.a 1-6, 3B3 a.a 19-24 or 3A 148-
153) between the copies of TaV 2A and P3 proteins to act as artificial 3C 
cleavage sites and ensure authentic N and C termini were produced during 
processing. The predicted primary processing products produced following TaV 
2A mediated cleavage (occurring at the site indicated by dashed lines) are also 
shown. 
 
Each Donor cassette was cloned into the O1K Pt.GFP replicon generating 3B 
Donor replicons (referred to as O1K Pt.GFP 3A Donor, O1K Pt.GFP 3C Donor 
and O1K Pt.GFP No Donor) that were used to assess replication in BHK-21 and 
natural host-derived cell lines (porcine and bovine). Infectious clones based on 
each of the replicons were also constructed and viruses recovered, passaged 
and sequenced. Finally processing experiments (western blots and TnT 
reactions) were carried out to ensure that each construct was processing as 
expected and that any unwanted changes in processing were not responsible 
for differences seen in replication and growth between the different replicons 
and viruses. 
6.2 Determining the effects on FMDV replication of the addition of TaV 2A 
sequences using replicons in different cell lines  
DNA gene blocks for FMDV P3 which encoded the additional copies of TaV 2A 
and the other a.a changes described above (Table 6.1.1) were cloned in to the 
O1K Pt.GFP replicon plasmid replacing the existing P3 region. This led to the 
development of 3 new replicons, O1K Pt.GFP 3A Donor, O1K Pt.GFP 3C Donor 
and O1K Pt.GFP No Donor. RNA was transcribed in vitro from each of these 
replicons and transfected into BHK-21 cells. Replicons, O1K Pt.GFP and O1K 
Pt.GFP GNN were included as controls for normal replication and the 
background signal from translation of input RNA. GFP intensity was measured 
at regular intervals using the IncuCyte zoom as described previously.  
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Results (as shown in Figure 6.2.1) showed that both the O1K Pt.GFP 3A Donor 
and O1K Pt.GFP No Donor replicons appeared unable to replicate and gave 
GFP intensity signals that were similar to the  O1K Pt.GFP GNN control. The 
O1K Pt.GFP 3C Donor, in comparison, appeared to be replication competent, 
giving a higher intensity signal than O1K Pt.GFP GNN. However, the O1K 
Pt.GFP 3C Donor was attenuated as the GFP signal was approximately 57% 





Figure 6.2.1 Replication of the 3A, 3C and No donor replicons in BHK-21, 
MDBK and SK-RST cells: RNA for the Donor replicons (O1K Pt.GFP 3A 
Donor, O1K Pt.GFP 3C Donor and the O1K Pt.GFP No Donor) were transfected 
into the indicated cell line (BHK-21, MDBK or SK-RST). In parallel cells were 
also transfected with RNA from the wildtype O1K Pt.GFP and the translation 
control O1K Pt.GFP GNN replicons. GFP intensity was measured at hourly 
intervals as an indirect measure of replication. Three independent experiments 
were carried out for each cell line each with triplicate samples. Panels A, B and 
C show all 3 experiments for BHK-21 cells. Panels D and E show one 
representative experiment for MDBK and SK-RST cells. Data points and error 
bars show mean +/- SD. 
 
These results suggest that 3B needs to be covalently linked to 3C for efficient 
replication of FMDV in BHK-21 cells. The donor replicon experiments were also 
carried out (in parallel, using the same replicon RNA preparations) in cell lines 
derived from the natural hosts of FMDV, i.e. MDBK (bovine) and SK-RST 
(porcine) cells. Figure 6.2.1 panels B and C show results from one 
representative experiment (in MDBK and SK-RST cells respectively) of three 
independent repeats, each with triplicate samples. In both MDBK and SK-RST 
cells each of the ‘donor’ replicons (O1K Pt.GFP 3A Donor, O1K Pt.GFP 3C 
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Donor and O1K Pt.GFP No Donor) gave similar GFP intensities to the O1K 
Pt.GFP GNN replicon suggesting that the changes made to the P3 region had 
not impacted on translation but had affected replication in these cell lines. 
6.3 Recovery of infectious VPg donor viruses  
Each of the Donor replicons was made into infectious clones by swapping the 
Pt.GFP coding region with the capsid coding region of O1K FMDV. In vitro 
transcribed RNA from each of the infectious clones (O1K 3A Donor, O1K 3C 
Donor and O1K No Donor) was transfected into BHK-21 and cells monitored for 
CPE as evidence for the production of infectious viruses. 
Each of the viruses appeared to be recoverable with all producing CPE at 
passages 1 (BHKp1) and 2 (BHKp2) (See Figure 6.3.1). At passage 1 (Panel 
A), both the O1K 3A Donor and No Donor viruses produced extensive CPE at 
48 hours post infection, whereas CPE was observed earlier in cell monolayers 
infected with O1K 3C Donor (28 hours). Of note, all of the Donor viruses 
produced CPE slower than the positive control O1K WT virus which produced 
total CPE by ~20 hours post infection. At passage 2 (panel B), CPE was 
observed at 18 hours post infection for each of the Donor viruses. Passage 2 
viruses were titrated on BHK-21 cells by plaque assay (as described in Chapter 
2 section 2.2.5.2); the results showed similar titres were obtained for each of the 
donor viruses (data not shown), although further work is required to clarify if the 
changes made to P3 impacted at all on viral growth kinetics. 
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Figure 6.3.1: Recovery of the Donor viruses in BHK-21 cells. RNA was 
transcribed in vitro from each infectious clone (O1K 3A Donor, O1K 3C Donor 
and O1K No Donor) and transfected into BHK-21 cells. Infected cell lysates 
were passaged through BHK-21 cells. Cells were monitored for appearance of 
CPE. Shown is CPE for each virus at the indicated times post infection for 
passage 1 (A) and passage 2 (B). Data for O1K WT and uninfected cell 
monolayers are also shown. 
 
At passages 1 and 2 in BHK-21 cells (BHKp1 and BHKp2), RNA was extracted 
from clarified cell-supernatants (as described in Chapter 2 section 2.2.5.3), 
reverse transcribed to make single stranded cDNA and the 3A to 3C coding 
region amplified by PCR. Sanger sequencing of the gel purified PCR products 
showed that at passage 1 and 2 (BHKp2), the O1K FMDV 3A Donor (which had 
TaV 2A between 3B3 and 3C) appeared to have reverted to the wildtype a.a 
sequence as no part of the TaV 2A sequence remained and the coding region 
of 3B3 was followed directly by that of 3C. However, careful inspection of the 
sequence traces revealed that at the nucleotide level the 3A donor virus 
showed twin peaks (Major and Minor) at 2 positions within the coding region for 
the C terminus of 3B3, and at 2 positions within the coding region for the N 


































Figure 6.3.2: Chromatogram traces showing sequencing of RNA extracted from BHKp1 and BHKp2 recovered viruses 
for O1K 3A Donor. PCR products derived from RNA extracted from infected BHK-21 cells were Sanger sequenced using 3 
different primers covering the P3 region. Chromatograms from one representative reaction are shown. Analysis revealed that 
the TaV 2A sequence was deleted at both passages suggesting possible reversion to wildtype virus. Two peaks were seen at 
some of the locations where silent mutations were made to limit recombination at the artificial 3C cleavage sites and additional 
proline residues that were present in the 3A donor cassette (Red boxes). The table (B) shows both the expected wildtype and 
mutated nucleotide sequences along with those observed from sequencing data of passages 1 and 2. 
Amino acid and nucleotide sequence at the 3B3 and 3C boundary in the recovered O1K 3A Donor virus 
 3B3 3C 
aa N L I V T E S G A P P T 
Wt AAC CTG ATT GTC ACT GAG AGT GGT GCC CCA CCG ACC 
Mut AAC CTC ATT GTT ACC GAG AGC GGA GCC CCG CCC ACC 
P1 AAC CTG ATT GTC/T ACT/C GAG AGT/C GGT/A GCC CCA CCG ACC 
P2 AAC CTG ATT GTC/t ACT/c GAG AGt/C GGt/A GCC CCa/G CCG ACC 
a.a = wt a.a sequence: Wt = wild-type sequence: Mut = mutations introduced into the short regions for 3B3 and 3C flanking TaV 2A in 
the original construct: P1 = sequence at the 3B3/3C boundary in the recovered virus at BHKp1: P2 = sequence at the 3B3/3C 




These peaks correspond to a mixture of the wildtype nucleotides and the third 
base mutations introduced into the coding region of the additional, short a.a 
sequences that were inserted to create artificial 3C cleavage sites either side of 
TaV 2A (i.e. residue 1-6 of 3C inserted between 3B3 and TaV 2A, and the last 6 
residues of 3B3 inserted after TaV 2A and immediately before 3C; see Figure 
6.3.2). Specifically, the twin peaks were at (i) the last 2 nucleotide positions (of 
4) corresponding to where mutations were introduced into the short region 
encoding residue 1-6 of 3C and, (ii) at the first 2 nucleotide positions (of 3) 
corresponding to where mutations were introduced into the short region 
encoding the last 6 residues of 3B3. At the other sites where mutations were 
made only one peak was seen and this corresponded to the wildtype sequence. 
At BHKp1 (Figure 6.3.2, panel A upper trace), the major and minor peaks at 
these positions in 3B3 (C/T and C/T) and 3C (T/C and A/T) were of similar 
intensity while at BHKp2 (Figure 6.3.2, panel A lower trace), there were larger 
differences in peak intensity between the major and minor peaks. At the first 
position in 3B3 the C predominated over the T while at the second position a T 
predominated over the C; thus at these positions the wildtype nucleotide were 
predominant. In contrast, in 3C, at the first position the C predominated over the 
T while at the second position an A predominated over a T; consequently at 
these positions the mutations were the predominant nucleotides. The table in 
panel B of figure 6.3.2 shows the predicted nucleotide sequences of both the 
wildtype a.a codon and that of the mutation in addition to the codon sequences 
found in passages 1 and 2. The presence of twin peaks at these sites, and at 
the observed pattern, suggests that the recovered virus was a mixed population 
resulting from different deletions spanning the TaV 2A region and therefore a 
true reversion rather than contamination by a wildtype virus. Nevertheless, the 
results could also be explained by the presence of 2 main virus populations; 
one with a full wildtype sequence and the other with mutations in both 3B3 and 
3C. However, given the design of the original construct it is difficult to explain 
how the latter virus could be generated by deletion or recombination which 
supports the conclusion that the sequencing results are best explained by 2 
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separate deletion events spanning the TaV 2A occurring on different RNA 
molecules. 
In contrast to the 3A Donor virus, the sequence of the recovered O1K 3C Donor 
virus remained unchanged at passage 2 (Figure 6.3.3). The copy of TaV 2A and 
all other nucleotide changes present in the input RNA were faithfully retained. 
This virus was passaged on further to passage 4 (BHKp4) on BHK-21 cells and 
the sequenced of the PCR product (produced as above) showed that same 
result as no changes in the region of P3 sequenced were observed from the 
input RNA. A second experiment was carried out with new in vitro transcribed 
RNA derived from plasmid DNA that had been retransformed through bacteria 
and yielded similar results as the O1K 3A Donor virus appearing to revert to the 
wildtype a.a sequence at passage 1 (BHKp1)) but again 2 peaks were observed 
at positions where mutations had initially been introduced suggesting a possible 
mix of virus populations. The O1K FMDV 3C Donor recovered virus maintained 










Figure 6.3.3 Recovery of O1K 3C Donor Virus: RNA extracted from passage 2 of the O1K 3C Donor virus (BHKp2) was 
reverse transcribed to produce single stranded cDNA which the P3 region was then used as a template in a PCR for the P3 
region. The PCR products were sequenced by Sanger sequencing. The chromatogram produced from a single reaction is 
shown and indicates the changes made to the P3 region are still present at passage 2 in BHK -21 cells 
TaV 2A 3A 
Last 6 a.a 
3A 




The results of sequencing the O1K No Donor recovered viruses were less clear. 
Sequencing passage 2 (BHKp2) gave the wildtype FMDV nucleotide sequence 
with no TaV 2A sequence or mutations present. Therefore, the O1K FMDV No 
Donor plasmid was sequenced on the Miseq to obtain deep sequence data to 
look for possible contamination with wildtype FMDV at the plasmid level. An 
analysis of the data from the Miseq showed no evidence for a mixed population 
with a 99.5% confidence that the No Donor plasmid was correct. In addition, the 
earlier passage (BHKp1) was also sequenced along with the input RNA used 
for transfection and RNA extracted from the transfected cells. Analysis of the 
sequencing data from PCR products from both passage 1 and the transfection 
stage showed that the virus sequence exactly matched the wild-type O1K virus. 
In contrast, the PCR product derived from the input RNA showed that the 
sequence of the transcribed RNA appeared to be correct, matching that of the 
predicted O1K FMDV No Donor virus. This suggests, if the virus is reverting to 
wildtype it is doing so quickly and within the transfected cells. To see if this was 
possible a transfection time course (as described for O1K ALLA, Chapter 5 
section 5.6) was carried out. Interestingly, when the PCR products were run on 
a gel, prior to sequencing, a clear size difference was observed between PCR 
products derived from the input RNA and the PCR products for all other time 
points investigated. This difference was approximately 150 base pairs which 
matched the expected size difference between the O1K No Donor and O1K 
wildtype virus (Figure 6.3.4). Sequencing of the PCR products showed that 
while the input RNA was correct and matched the expected O1K No Donor 
sequence, by 2 hours post transfection, and at all subsequent time points, the 












Time point Consensus Sequence  
Input RNA O1K No Donor 
2 hours post 
transfection 
O1K WT 
4 hours post 
transfection 
O1K WT  
 
Figure 6.3.4: Sequencing of O1K No Donor RNA in transfected cells: BHK-
21 cells were transfected with the O1K FMDV No Donor RNA. Total RNA was 
extracted from the transfected cells at 2 hourly intervals post transfection. RT 
and PCR reactions spanning the P3 region of the genome were carried out 
using the extracted RNA as the starting template. PCR products were analysed 
by gel electrophoresis (upper panel) and sequenced by Sanger sequencing 
(lower Table). Input RNA used for the transfection was also used to generate a 
PCR product and sequenced.  M indicates size markers. The PCR products for 
2-10 hours post-transfection were ~150 base pairs smaller that the PCR for the 
input RNA.  By 2 hours post transfection the PCR product had a sequence 
corresponding to a wildtype virus (O1K WT).  
Lane M: 1Kb DNA marker 
Lane 1: Input RNA  
Lane 2: 2 hours post transfection 
Lane 3: 4 hours post transfection 
Lane 4: 6 hours post transfection 
Lane 5: 8 hours post transfection 




These results could be explained by the presence of a contaminating wildtype 
virus, which would be expected to out compete the O1K No Donor virus. 
However, if this were the case and wildtype and O1K No donor RNA were co-
transfected then it might be expected that at 2h post-transfection two PCR 
products would be generated; one derived from the input O1K No donor RNA 
and the other from the contaminating wildtype RNA assuming there was enough 
of each type of RNA to be detected by running products on an agarose gel. 
Furthermore, the PCR product for the input O1K No donor RNA would likely 
persist in the transfected for longer and show a gradual replacement by the 
replication competent wildtype RNA. Although still to be confirmed this suggest 
that the apparent reversion to the wildtype sequence is more likely the result of 
an internal deletion within the input RNA that restores the wildtype sequence.  
 
6.4 Investigating processing of the Donor Replicons and viruses 
6.4.1 Investigating processing of Donor replicons and viruses by Western 
Blots 
To ensure the addition of TaV 2A and the extra a.a included to generate 
artificial 3C cleavage sites had not affected P3 processing and therefore the 
ability of the Donor replicons to replicate, processing experiments were carried 
out using samples from both replicon transfected and infected cells. BHK-21 
cells were transfected with in vitro transcribed replicon RNA or infected with the 
recovered donor viruses (MOI of 1). At 8 hours post transfection or 4 hours post 
infection, cells were lysed and supernatants boiled (see Chapter 2 section 
2.2.6.1.). Samples were run on 12% SDS PAGE gels and western blots for both 











































































































































































Figure 6.4.1:  Western Blots for FMDV 3A and 3D in transfected and 
infected BHK-21 cells. Lysates were prepared from replicon (3A, 3C and No 
donor replicons) transfected cells at 8 hours post transfection or from cells 
infected with the Donor viruses (O1K FMDV 3A Donor, O1K FMDV 3C Donor 
and O1K FMDV No Donor) at 4 hours post infection and run on SDS-PAGE 
gels. Proteins were transferred to nitrocellulose membranes and probed with 
antibodies to the 3A (panels A and C) and 3D proteins (panels B and D). Panels 
A and B show blots using replicon transfected cell lysates while panels C and D 
show blots using lysates from infected cells. 
 
Figure 6.4.1 (Panels A and B) shows results from western blots using samples 
from replicon transfected BHK-21 cells. Panel A shows that a band of 
approximately 20 KDa was detected with the antibody to 3A for the wildtype 
O1K Pt.GFP however for the O1K Pt.GFP 3C Donor replicons 2 bands of 
approximately 20 and 25 KDa were seen. For the O1K Pt.GFP replicon the 
band is likely to be 3A although it could be a 3A3B intermediate (3AB, 3ABB, or 
3ABBB). In the O1K Pt.GFP 3C Donor, the lower band is similar in size to that 
observed in O1K Pt.GFP suggesting this could be mature 3A, which is possible 
as in O1K Pt.GFP 3C Donor, 3A is not covalently linked to 3B (assuming that 
the TaV 2A is working correctly). However, this band is slightly larger than the 
band for 3A seen for the wildtype replicon indicating the possibility that this 
band could be the 3A-TaV2A fusion protein (i.e. 3A3B1aa1-6+Y3F:TaV2A). 
This implies that the 3C Donor is unable to make mature 3A due to failure of 3C 
to process the artificial 3C cleavage site inserted between 3A and the TaV2A. 
This could possibly be due to the tyrosine to phenylalanine (Y3F) mutation 
created to prevent 3B1aa1-6+Y3F:TaV2A acting as a primer for replication. A 
second 3A positive band was also seen for the 3C Donor, which could be a 
higher-order precursor that contains 3A. For cells transfected with the No Donor 
or 3A Donor replicons, bands for 3A were not detected most likely as insufficient 
quantities of viral proteins are produced from replication-defective replicons. 
Figure 6.4.1, Panel B shows western blots (using the same samples as used in 
panel A) with an antibody to 3D. Again bands were observed only for O1K 
Pt.GFP and O1K Pt.GFP 3C Donor. Of the two bands seen, the larger 
(approximately 50 KDa) is likely to be 3D (which has a molecular weight of 52 
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KDa), whereas the lower band is potentially a non-specific protein or a 3D 
degradation product picked up by the antibody. The above results are not 
surprising as the wildtype and 3C Donor replicons were the only replicons that 
showed evidence of replication and for the non-replicating replicons (O1K 
Pt.GFP 3A Donor, O1K Pt.GFP No Donor and O1K Pt.GFP GNN), it is possible 
that not enough of the 3A or 3D proteins are being produced to be detected by 
western blot.  
Panels C and D of Figure 6.4.1 show western blots for detection of 3A (panel C) 
and 3D (panel D) proteins in supernatants from virally infected cells (BHKp2).  
In the blot for 3A (panel C) a similar banding pattern was observed for O1K WT, 
O1K 3A Donor and O1K No Donor viruses and multiple bands were seen 
corresponding in size to be 3A and 3AB intermediates. The similar banding 
patterns observed for the 3A and No Donor viruses to the wildtype O1K virus 
can be explained by the observation that by passage 2, the 3A and No donor 
viruses had restored the wildtype sequence (see section 6.3). In contrast, the 
O1K 3C Donor virus gave a different banding pattern to the other viruses, which 
could be the result of different processing of P3, as 3AB intermediates were not 
expected to be produced from this construct. However, there was also no 
evidence of a band of the correct size for 3A, which might have been expected. 
This supports the conclusion that the artificial 3C cleavage site inserted after 3A 
(3B1aa1-6+Y3F) may not be processed correctly therefore leading to generation 
of 3A3B1aa1-6+Y3F:TaV2A as opposed to mature 3A. Nevertheless, the 
banding pattern of O1K 3C Donor virus appears to fit with the observation that it 
retained the original modifications made (see Figure 6.3.3). 
Figure 6.4.1 Panel D shows a western blot for 3D and that similar patterns were 
produced by the wildtype and each of the Donor viruses. An intense band was 
seen at the correct size for 3D.  In addition, a similar sized band of lesser 
intensity was seen in a cell only control lysate. However, the actin loading 
control shows that this difference in intensity is not due to loading less sample 
and suggests there may be a non-specific cellular protein of similar size to 3D 
that is detected. Despite this, it appears that all of the recovered Donor viruses 
generate processed 3D. In support of this conclusion, a band corresponding in 
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size to 3CD (~75kD) is only seen in the virus samples and not in the cells only 
control. These results can be explained by the observations that the O1K 3C 
Donor was replication competent as a replicon while the 3A and No Donor 
viruses had changed to the wildtype sequence by the passage used to infect 
cells (BHKp2). 
 
6.4.2 Using TnT reactions to further investigate processing of the Donor 
replicons and viruses 
P3 processing of the Donor constructs was investigated further using a TnT 
reaction (see Chapter 2 section 2.2.6.6). These experiments were carried out, 
with the help of Dr Joseph Newman. For this analysis, P3 templates were 
generated that included full-length 3A or the Donor changes (No, 3A or 3C) but 
3C was truncated just before the coding region for the active site. This was 
done to clearly determine the functionality of the inserted TaV2A sequences 
and to help identify processing products.  In addition, an aliquot of samples from 
each of the TnT reactions were treated with purified 3C to determine if the 
primary products from the TnT reaction could be further processed in trans by 
3C. 
 
PCR products, derived from each of the infectious clones, were generated using 
primers that incorporated a T7 promoter, an ATG start codon and a Kozak 
sequence upstream of the N terminus of 3A, and a second primer 
complementary to the mid region of 3C that included a translation stop codon 
(translation of this PCR would produce a truncated inactive 3C) (Full primer 
sequences are detailed in appendix 1). PCR products were confirmed to be 
correct size by gel electrophoresis before being used as templates in TnT 
reactions. Following incubation, samples were split into 2 and half of each 
sample treated with exogenous purified FMDV 3C protease (supplied by Dr 
Newman). An extensive list of the major predicted processing products that 
could be produced by these constructs with and without the addition of 
exogenous 3C is detailed in Table 6.4.2.  
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WT template: T7[met3A3B1B2B3Δ3C]stop 
Products - added 3C KDa 
On 
gel 
Products + added 3C KDa 
On 
gel 
met3AB1B2B3Δ3C 95.4 * 
met3AB1B2B3 25.2 * 
met3AB1B2 22.6 * 
met3AB1 20 * 
met3A 17.4 * 
Δ3C 10.2 * 
3A Donor: T7[met3A3B1B2B3]-[3Caa1-6:TaV2A] // P-[3B3aa19-24]-[Δ3C]stop 
Products - added 3C KDa 
On 
gel 
Products + added 3C KDa 
On 
gel 
met3AB1B2B3-[3Caa1-6:TaV2A] 87.5 * 
met3AB1B2B3 25.2 * 
met3AB1B2 22.6 * 
met3AB1 20 * 
met3A 17.4 * 
3Caa1-6:TaV2A 2.3 ≠ 
P-[3B3aa19-24]-Δ3C 10.9 * 
P-[3B3aa19-24] 0.7 ≠ 
Δ3C 10.2 * 
3C Donor:  
T7[met3A]-[3B1aa1-6+Y3F:TaV2A] // P-[3Aaa148-153]-[3B1B2B33Δ3C]stop 
Products - added 3C KDa 
On 
gel 
Products + added 3C KDa 
On 
gel 
met3A-[3B1aa1-6+Y3F:TaV2A] 19.6 * 
met3A 17.4 * 
3B1aa1-6+Y3F:TaV2A 2.2 ≠ 
P-[3Aaa148-153]-3B1B2B3Δ3C] 65 * 
P-[3Aaa148-153] 0.8 ≠ 
3B1B2B3Δ3C 18.0 * 
B2B3Δ3C 15.4 * 
B3Δ3C 12.8 * 




Δ3C 10.2 * 
No Donor: T7[met3A]-[3B1aa1-6+Y3F:TaV2A] //  
P-[3Aaa148-153]-[3B1B2B3]-[3Caa1-6:TaV2A] // P-[3B3aa19-24]-[Δ3C]stop 
Products - added 3C KDa 
On 
gel 
Products + added 3C KDa 
On 
gel 
met3A-[3B1aa1-6+Y3F:TaV2A] 19.6 * 
met3A 17.4 * 
3B1aa1-6+Y3F:TaV2A 2.2 ≠ 
P-[3Aaa148-153]-[3B1B2B3]-
[3Caa1-6: TaV2A]  
 
10.8 * 
P-3Aaa148-153 0.7 ≠ 
3B1B2B3  
(+ “free” 3B peptides) 
7.8 ≠ 
3Caa1-6:TaV2A 2.3 ≠ 
P-[3B3aa19-24]-[Δ3C] 10.9 * 
P-3B3aa19-24 0.7 ≠ 
Δ3C 10.2 * 





Table 6.4.2 Potential processing products of the VPg Donor Cassettes: 
The design of the wildtype and Donor templates used in the TnT is shown in 
blue. Predicted processing products produced without addition of exogenous 3C 
(-added 3C) are shown in left hand columns and those following further 
predicted processing with added 3c (added 3C) are shown on right hand 
columns. Predicted sizes (in KDa) and the corresponding symbol on the TnT gel 
of Figure 6.5.1are also indicated. 
 
Protein product Symbol 
-3C = 3B3(19-24)∆3C  



















* This product was not expected to still 
be present following treatment with 
exogenous 3C 















Figure 6.4.2: Investigating processing of VPg Donor constructs using 
Transcription and Translation coupled reactions: PCR products were made 
by amplifying the 3A to mid 3C region using infectious copy DNA for each of the 
donor constructs and he wildtype infectious clone plasmid. These products were 
then used in transcription and translation coupled reactions. Subsequently half 
of each reaction was treated with exogenous 3C protease. Samples were run 
on gradient SDS gels, which were soaked in salicylic acid and dried prior to 
exposing to X-ray film. 
 
Figure 6.4.2. shows a representative result from one of two experimental 
repeats and the predicted products are marked with asterisks. In the samples 
that did not have active 3C added (panel A), the wildtype template produced a 
single major band at the expected size for unprocessed 3ABBB∆3C (red 
asterisk). Both the 3A and No Donor templates showed a product of 
approximately 10 KDa which is likely to be the truncated ∆3C (black asterisk) 
(i.e. the last 6 residues of 3B3 + ∆3C; see primary processing products Figure 
6.1.1) and suggests that the TaV 2A between 3B3 and 3C is self-cleaving  
correctly at its C terminus. Consistent with this conclusion, for the 3A donor 
template the most abundant band was seen at approximately 37 KDa, which is 
the correct size for the 3ABBBTaV2A fusion protein (3ABBB[3Caa1-6]TaV2A : 
orange asterisk). The No Donor template also gave a single major band at the 
expected size for the 3ATaV2A fusion protein (3A-(3B1aa1-6)TaV2A : green 
asterisk). The No Donor should also produce a third primary processing product 
(i.e. P-[3Aaa148-153]-[3B1B2B3]-[3Caa1-6:TaV2A] which is similar in size but 
has less methionine residues and would therefore appear less intense. 
Alternatively the upper band in the No Donor lane could be a combination of 
each of the products (See Table 6.4.2).  
As expected, in the absence of added 3C the 3C Donor template also gave a 
band for 3ATaV2A fusion protein (i.e. met3A-[3B1aa1-6+Y3F:TaV2A] green 
asterisk) and a product of approximately 20KDa in size that matched the 
predicted size of the 3BBB∆3C fusion protein (i.e. 3A148-153)-3BBB∆3C 
(purple asterisk). These results show that in the absence of active 3C the 




efficient self-cleavage at the inserted TaV 2A sequences (as shown in Table 
6.4.2).  
Upon addition of purified 3C (panel B) further processing events were seen for 
some of the constructs (predicted sizes are shown in the +3C column of Table 
6.4.2). For each template (wildtype and all 3 Donor constructs), a products of 
~10KDa (likely again to be ∆3C) was seen consistent with the presence of TaV 
2A cleavage and further processing carried out by exogenous 3C. As expected 
the WT and 3A donor templates gave similar banding patterns with 3 additional 
products, most likely to be a combination of 3A and 3AB precursors (pale blue 
asterisks). The lower major-band in the untreated samples for the 3C donor 
template (purple asterisk) was not seen after the addition of purified 3C as this 
band corresponds to 3BBB∆3C and would be extensively processed to yield 
∆3C and the individual 3B peptides (which  would be too small to be seen on 
this gel). However there was no bands visible to indicate mature 3A had been 
produced instead the larger band at the size expected for the 3A-TaV2A fusion 
protein (i.e. 3A-[3B1aa1-6+Y3F:TaV2A]) was still visible. Taken together with 
the results seen for the western blot for 3A, carried out on a cell lysate from the 
3C donor replicon (O1K Pt.GFP 3C Donor, Figure 6.4.1 panel A), this suggests 
that the 3C artificial cleavage site between 3A and TaV2A of the 3C donor 
construct is not able to be processed correctly. This is supported by the results 
of the No Donor construct which upon addition of 3C produced the same 
banding pattern to that of the 3C Donor and contains the same artificial 3C 
cleavage site between 3A and 3B as seen in the 3C Donor and would again if 










6.4.3 Conclusions of VPg Donor experiments  
The No Donor did not replicate as a replicon and could not be recovered as a 
virus. For the No Donor, the inability to replicate could be explained by four 
potential defects (see below), or by a combination of these.  
 
1. The inability to form a covalent bond between 3A and 3B1. 
2. The inability to form a covalent bond between 3B3 and 3C. 
3. The artificial 3C cleavage site inserted between 3A and TaV2A (i.e. 
insertion of the first 6 a.a of 3B1 immediately after 3A) may not be 
cleaved resulting in a lack of mature 3A.  
4. The artificial 3C cleavage site inserted between the second copy of 
TaV2A and 3C (i.e. insertion of the last 6 aa of 3B3 immediately before 
3C) may not be cleaved resulting in a lack of mature 3C (i.e. an 
extension of 6 aa at the N terminus of 3C may inhibit 3C enzyme activity) 
 
The first two explanations (1 and 2) suggest that the inability of the No Donor to 
construct to replicate (or be recovered as a virus) is a direct event resulting in 
reduced replication caused by the lack of 3B precursors (3ABBB or 3ABBBC). 
On the other hand the remaining two explanations (3 and 4) suggest the 
inability of the No Donor to replicate could be due to impacts from artificial 
insertions and mutations made to the genome which may interfere with the 
processing of the viral polyprotein and inhibit production of mature viral proteins. 
 
The 3A Donor also did not replicate as a replicon and could not be recovered as 
a viable virus. In the 3A Donor cassette, as 3ABBB was the wt sequence two of 
the potential defects of the No Donor were restored. Therefore for the 3A 
Donor, the inability to replicate could be explained by the 2 remaining potential 
defects, or by a combination of these.  
 
1. The inability to form a covalent bond between 3B3 and 3C  
2. The artificial 3C cleavage site inserted between the second copy of 




3C) may not be cleaved resulting in a lack of mature 3C (i.e. an 
extension of 6 aa at the N terminus of 3C may inhibit 3C enzyme 
activity). 
 
As described above for the No Donor, the inability to replicate could be a direct 
effect on replication (defect 1) or due to indirect effects on processing of the 
polyprotein (defect 2), rather than the inability to replicate being solely due to 3B 
not being linked to 3A. 
The 3C Donor was partially attenuated as a replicon and the virus based on this 
replicon was recovered with the 3C Donor cassette intact. In the 3C Donor, the 
other two potential defects of the No Donor were repaired, as 3BBBCD was 
restored to the wt sequence. Hence for the 3C Donor, the attenuation of 
replication could be explained by the 2 remaining potential defects, or by a 
combination of these.  
 
1. The artificial 3C cleavage site inserted between 3A and TaV2A (i.e. 
insertion of the first 6 a.a of 3B1 immediately after 3A) may not be 
cleaved resulting in a lack of mature 3A. This may be the result of the 
Y3F mutation in the added 3B1 sequence and the TnT using the P3∆3C 
template shows this site is not cleaved in trans by added 3C so it is 
unlikely to be cleaved in cis when 3C is part of a larger precursor (An 
artificial effect due to introduction of additional sequences) 
2. The inability to form a covalent bond between 3A and 3B1.  
 
As with the other Donor constructs, the negative impact on replication could be 
a result of the inclusion of artificial cleavage sites and other features influencing 
protein processing (as described in point 1), as opposed to a true effect seen 
due to preventing a covalent bond between 3A and 3B1. 
Taken together, these observations support the conclusion that formation of 








The original models of picornavirus replication suggested that 3A was likely to 
be the donor of VPg (3B) to the replication complex (Liu et al., 2007, Murray 
and Barton, 2003); however, more recently it has been suggested that a 3C 
containing precursor is more likely to play this role (Pathak et al., 2008). A study 
by Pathak et al was carried out using PV, which encodes a single 3B; in 
comparison FMDV is unique among picornaviruses in that encodes three copies 
of 3B and therefore may use a different mechanism to deliver VPg to the RC 
(see Chapter 1 section 1.6.2 and 1.6.3). Each of the copies of 3B have been 
found linked to the genome although they are uridylated with different efficiency 
with 3B3 being the most efficient in vitro (Nayak et al., 2005), therefore 
changing the 3B donor source could have an effect on replication efficiency. 
In this work FMDV replicons and recombinant viruses were used to investigate 
the impact of inserting copies of a ‘2A like’ sequence (from the insect virus TaV) 
into the P3 encoding region of the FMDV genome to prevent 3B from being 
covalently linked either to 3A or 3C. Therefore, in these constructs 3B could 
only be donated to the replication complex as either a 3AB or 3BC precursor but 
never a combination of both. A third arrangement was also investigated where 
3B was neither covalently linked to 3A or 3C (O1K No Donor). 
Experimental data from replicon assays carried out as part of this work supports 
the conclusion that 3C is the preferred donor of 3B to a RC, as the 3C Donor 
replicon (O1K Pt.GFP 3C Donor) was the only Donor replicon that was 
replication competent, as both the 3A and No Donor replicons were completely 
attenuated. However in comparison to the wildtype O1K Pt.GFP replicon, 
replication of O1K Pt.GFP 3C Donor was partially attenuated, so it is possible a 
combination of both 3A and 3C and potentially free 3B is required for fully 




The above observations were made using BHK-21 cells but all 3 donor 
replicons appeared to be completely attenuated in MDBK and SK-RST cells, 
which derive from the natural bovine and porcine hosts of FMDV. It is not clear 
why the 3C donor replicon appeared attenuated in these cells (and not for BHK-
21 cells) and suggests that there are subtle differences in the details of 
replication in BHK-21 in comparison to bovine and porcine cells. Nevertheless it 
appears BHK cells can be used to reveal the basic requirements for FMDV 
genome replication.   
Furthermore, sequencing data derived from the recovered donor viruses also 
supports the conclusion that a 3BC containing precursor plays an important role 
in FMDV replication. Sequencing of the  recovered O1K 3A Donor virus (in 
which 3B could only be covalently linked to 3A due to addition of a TaV 2A 
sequence between 3B3 and 3C), showed that the virus quickly reverted to a 
mixture of variants with deletions that removed the inserted TaV 2A but 
maintained the open reading frame of the genome. It is likely that this resulted 
from deletion events as third base changes that were included in additional a.a 
added at each terminus of the 2A protein remained. These results support the 
idea that a 3BC containing precursor is required as the source of 3B for 
replication as a virus where only 3AB, and not 3BBBC, is made (as in the case 
of the 3A Donor virus) was not able to be maintained when passaged in BHK-21 
cells. 
In contrast to the 3A donor, sequencing of a recovered virus in which 3B could 
only be covalently linked to 3C (O1K 3C Donor) maintained its additional copy 
of TaV 2A (and the mutations in the additional a.a residues included to create 
additional cleavage sites), without any apparent impact on the viruses ability to 
replicate in BHK-21 cells based on viral end point titre (data not shown). 
Although further investigations into growth kinetics of this virus are required. 
Additional passages and corresponding sequencing data showed that both the 
mutations and copy of TaV 2A were maintained up to passage 4, suggesting 
the virus is able to maintain these changes and utilise a 3BC precursor as a 




The O1K No Donor virus also appeared to be recoverable despite not 
replicating as a replicon (i.e. O1K Pt.GFP No Donor). However sequencing of 
the recovered virus (O1K No Donor) consistently came back showing the virus 
appeared to be wildtype, even at early stages post transfection of infectious 
copy derived RNA despite deep sequencing of the infectious copy DNA 
plasmid, which showed that there was no contamination by a wildtype plasmid. 
These results are similar to those observed from attempts to recover another 
virus in this study (O1K ALLA, chapter 5 section 5.6) that was not able to 
replicate as a replicon and attempts to recover it as a virus showed either rapid 
reversion to wildtype or contamination by a wildtype virus. Since the O1K FMDV 
No Donor virus has many changes in the P3 region (including two additional 
copies of a TaV 2A sequence and multiple additional a.a residues and single 
base mutations), and reverted to the wildtype FMDV sequence at 2 hours post 
transfection the reason behind recovery of the wildtype virus was not clear. 
However, the rapid disappearance in transfected cells of a PCR product for the 
No donor cassette (See Figure 6.3.4) coupled to the rapid appearance of a PCR 
product the correct size for the wildtype sequence spanning the cassette region, 
suggest that the recovered virus was generated by an internal deletion in the No 
donor virus that resulted in restoring the wildtype sequence as opposed to 
contamination with a replication competent wildtype virus.  
Experiments investigating if the donor constructs were able to process P3 
correctly were also carried out by both western blot and TnT reactions. The 
western blots showed that while each of the recovered Donor viruses were able 
to make the polymerase protein 3D (Note: the 3A and No donor viruses were 
recovered with the wildtype a.a sequence), O1K 3C Donor appeared to be 
compromised in its ability to process the 3A protein correctly. This lack of full-
length 3A is one possible reason for the partial attenuated replication observed 
with O1K Pt.GFP 3C Donor particularly as 3A has been linked with other roles 
in replication. The similar banding patterns to the wildtype O1K virus seen for 
the 3A and No Donor recovered viruses in the blots to detect 3A can be 
explained as the lysates used were from the passage 2 viruses which had 




Western blots were also carried out using antibodies to detect the 3A and 3D 
proteins in samples from cells transfected with FMDV replicon RNA. These 
experiments showed that 3D was only expressed in detectable amounts, at 8 
hours post transfection, in samples from O1K Pt.GFP and O1K Pt.GFP 3C 
Donor, both of which were replication competent based on GFP replicon assay 
data. Western blots to detect 3A within the replicon-transfected samples again 
only detected 3A for the O1K Pt.GFP and O1K Pt.GFP 3C Donor replicons. 
However, in contrast to the recovered 3C donor virus, where no 3A or 3A 
intermediate proteins were detected the blot from replicon transfected cells 
gave bands that could have been 3A and 3AB intermediates or potentially a 
3ATaV2A fusion protein. 
Further processing studies were carried out to confirm that the TaV 2A proteins 
were self-processing as expected at the C terminal end and to confirm they 
were being cleaved correctly by 3C. Results of TnT reactions suggested that 
the TaV 2A sequences were correctly and efficiently cleaving themselves in 
each construct at the C terminal as predicted for TaV 2A which has been shown 
to be 99.5% effective at cleaving itself from downstream proteins (Donnelly et 
al., 2001a). However results of TnT reactions where exogenous active 3C was 
added implied potential processing defects within the donor constructs. This 
could be explained by impaired cleavage of the inserted artificial 3C cleavage 
site inserted between 3A and TaV 2A, causing a lack of generation of mature 
3A. This site also contained a mutation of tyrosine to phenylalanine which may 
have led to this deficiency. 
Overall this chapter has shown that as in the 3C Donor a covalent bond is not 
formed between 3A and 3B1, 3ABBB may not be essential for replication  and 
therefore that  3C could  be the preferred donor of VPg (as a 3BC intermediate) 
for replication. Viruses with modifications that altered the covalent links between 
3B, and 3A or 3C were recoverable. However, only the virus where 3B is linked 
to 3C (O1K FMDV 3C Donor) retained the modifications whereas the others 
(the 3A and No donor viruses) restored the link between 3B and 3C during 
recovery, thereby providing further evidence for the requirement for 3B to be 




the conclusion that the preferred donor of VPg is 3BC rather than 3AB. 
However, it is possible that 3B could be donated to a RC in multiple forms of 




Chapter 7: Final Discussion and Future Work  
 
The Picornaviridae have been extensively studied although the majority of work 
has been carried out using the enteroviruses in particular PV. However FMDV 
differs from PV in a number of key aspects including having a longer 3A protein 
and encoding more than one copy of the 3B protein. Some of the non-structural 
proteins of picornaviruses have well characterised roles e.g. the 3D protein 
being the RNA-dependent RNA polymerase that of other non-structural proteins 
and processing intermediates (e.g. 3CD) have been shown to be functionally 
different across genera. This includes the non-structural protein 3A, which has 
been implicated as a determinant of viral host range and is thought to play a 
central role in vRNA replication but the exact role of 3A is still poorly understood 
in comparison to other viral proteins. Therefore this thesis focused on identifying 
possible roles of the FMDV 3A protein during replication. 
As mentioned above, FMDV has a much longer 3A protein than other 
picornaviruses and has an extended C terminal domain. FMDV isolates from 
outbreaks in Asia have previously been identified that contain small deletions 
within the C terminal domain of 3A. These virus isolates replicated in porcine 
cells and were highly pathogenic for pigs but appeared to have attenuated 
growth in bovine cells in vitro and are significantly less virulent for cattle. This 
suggests that FMDV 3A may play a key role in determining viral host range 
(Pacheco et al., 2013, Pacheco et al., 2003, Beard and Mason, 2000). In this 
thesis, work carried out using GFP reporter, FMDV sub-genomic replicons (to 
allow quantification of replication) and recombinant viruses were used to 
investigate the effects of a much larger deletion (57 a.a in length) that was 
identified in viruses that existed as part of a mixed population within a vaccine 
strain of FMDV (Chapter 3). Results of replicon assays showed that the deletion 
had a negative impact on replication in a bovine kidney cell line (MDBK) 
whereas replication appeared to be enhanced in a porcine kidney cell line (SK-
RST). Furthermore experimental results from assays using recombinant viruses 




severely attenuate infection of MDBK cells and infection was slightly enhanced 
in porcine cells. However, the deletion had little effect on virus growth in primary 
bovine thyroid cells which appeared more susceptible to infection than MDBK 
cells. However, as described in the Discussion of Chapter 3, the virus with the 
3A deletion was rapidly out competed in mixed infection studies by the wildtype 
virus with full-length 3A in BTY cells (C.Wright Personal Communication), 
thereby confirming that the deletion was detrimental to replication in bovine 
cells. These observations confirmed that the virus with the 57 aa deletion is able 
to replicate independently without the presence of a helper virus with full length 
3A. These observations also suggest that the cell type (or cell line) could be a 
key factor in determining the effects of 3A deletions on replication and those 
deletions in the C terminal domain of 3A may enhance replication in porcine 
cells. Viruses with deletion in the C terminal domain of 3A are described as 
porcinophillic as they appear to replicate normally in porcine cells and cause 
classic FMD in pigs while they appear attenuated for bovine cells and are non-
pathogenic for cattle. This information could be exploited for more host specific 
vaccine manufacture. 
Part of the work for this thesis also examined the possibility that the extended C 
terminal domain of 3A in FMDV could be responsible for resistance to the fungal 
metabolite BFA. However when tested in replicon assays, the results showed 
that the same decrease in replication was observed in the wildtype, positive 
control replicon as that seen in the replicons with deletions in 3A. This inhibition 
in replication following pre-treated with BFA wasn’t expected as previously little 
or no effect on virus yield has been observed in BFA treated cells. Previously, 
some studies had shown an increase in FMDV infection (i.e. the number of 
infected cells) for BFA treated cells (Martin-Acebes et al., 2008, Midgley et al., 
2013, Monaghan et al., 2004, O'Donnell et al., 2001). Therefore the replicon 
assays in this study have shown that BFA may have multiple effects on FMDV 
including a negative impact on viral replication that could masked by other 
positive effects on infection. 
In contrast to the deletions described above, a deletion that removed the last 5 




replication in porcine or bovine cells when tested in replicon assays. This 
deletion effectively removed the first copy of 3B (i.e. 3B1) and was originally 
identified in a natural isolate during and outbreak of FMD in pigs in South 
Korea. The previous study that identified this isolate showed they were virulent 
for pigs but did not investigate infection in cattle, therefore it was undetermined 
if the removal of the last 5 a.a influenced replication in cattle (Park et al., 2016). 
Interestingly, results from the studies with recombinant virus (Chapter 3) 
showed that effects on replication differed slightly depending on if the remainder 
of the 3A sequence was based on O1K (where little difference was seen in viral 
titre between the wildtype and deleted virus) or on the original South Korean 
virus isolate, where there was a clear decrease in viral titre between the virus 
with full length 3A and that with the deletion (Chapter 3 section 3.7). This 
suggests that other regions, outside of the deletion could influence host range, 
partially agreeing with a previous study by Ma et al (Ma et al., 2014, Ma et al., 
2016).  It is also interesting to speculate that deletions in 3A may be occurring in 
pigs in Asia due to the introduction of intensive pig farming in that region and 
that variants containing such deletions (in 3A and 3B1) could be linked with 
evolution of the viruses within one host (Knowles et al., 2001). 
Future work to determine the effects of the deletion studied here on host range 
could involve investigation of virus replication in additional bovine and porcine 
cell lines (to those tested here) and in addition to characterising the innate 
immune status of the various cell lines used. This could determine if the 
deletions in 3A are restricting replication in specific cells or if the differences 
seen are due to altered immune status of the cell lines. Additional experiments 
the growth kinetics of the different viruses with deletions should also be carried 
out in multiple cell lines. In addition, further work investigating the effects of the 
MOI and BFA concentration on both replication and infection levels could 
determine if BFA does act on FMDV at different stages of the viral lifecycle. 
The 3A protein of picornaviruses interacts with a number of cellular proteins and 
appears to be involved in generating replication complexes and replication 
organelles. The other main aim of this thesis was to identify and investigate 




proteins were used in immunoprecipitation reactions to pull out cellular proteins 
that interacted with 3A. Mass spectrometry of the IP samples produced a large 
number of potential hits (possible interaction partners) which was then searched 
for previously identified partners of picornavirus 3A proteins (Lanke et al., 2009, 
Teterina et al., 2011, Wessels et al., 2006, Greninger et al., 2012, Klima et al., 
2017). Despite a number of these not being present (e.g. GBF1, ACBD3 and 
PI4K), a high number of Rab proteins were identified including Rab7L1 (Rab29), 
which had previously been identified in a Y2H screen (carried out by 
collaborators at Edinburgh) as potential interaction partner for the precursor 
protein 3ABB. Rab7L1 has previously been identified in maintaining the 
structural integrity of the TGN (Wang et al., 2014) and shown to interact with the 
NS5 protein of HCV (Sklan et al., 2007b). The role of Rab 7L1 was investigated 
using siRNA designed to target the porcine Rab7L1 gene and appeared to 
show that levels of infection were lower in siRNA treated cells when compared 
to the untreated cells. Unfortunately a non-target siRNA control appeared to 
have a similar effect to the Rab7L1 specific siRNA with both leading to a 
reduction in the number of infected cells when compared to levels in untreated 
infected cells. Therefore it was not possible to determine if the effect of the 
specific siRNA was directly due to knockdown of expression of Rab7L1. 
Furthermore, due to a lack of a reliable antibody to Rab7L1 it was not possible 
to confirm the efficiency of Rab7L1 knockdown and further investigations are 
required to establish if Rab7L1 is a true interaction partner of FMDV 3A and if 
depleting its expression directly impacts on FMDV infection. 
Experiments were also carried out on a second protein, TBC1D20, which was 
also identified as a potential interacting partner of 3A in the mass spectrometry, 
experiment. Using TBC1D20 knockout cell lines revealed that FMDV infection 
levels were reduced in the knockout cell lines when compared to the parental 
cell lines suggesting TBC1D20 availability may aid viral infection but that it is 
not essential as infection still occurred within the knockout cell lines. This was 
confirmed in replicon assays as replication (based on GFP expression) was 
detected in the knockout cells but at a decreased level in comparison to that 




improve efficiency of replication and infection. However, it should be noted that 
the knockout cell lines were Hela cells and therefore not derived from a natural 
host of FMDV, so the effect of TBC1D20 depletion may differ for cells derived 
from the natural hosts of FMDV. Future work could include the use of siRNA to 
knockdown TBC1D20 in cells derived from natural hosts of FMDV to gain a 
more realistic result of effects on infection levels. 
A major opportunity for future study is to maximise use of the information from 
the 3A mass spectroscopy experiments.  A number of proteomic pipelines for 
post-acquisition data analysis are available including various tools to analyses 
potential protein interactions. This could also include network analysis to identify 
the broader biological context and pathways that could be expected to 
negatively impact on FMDV replication; this could also include the potential 
relevance of the identified pathways to epithelial cells (the preferred cell type 
infected by FMDV).  Such analysis could be used to develop testable models 
how FMDV 3A binding to cellular proteins could enhance virus replication.  
 
Other potential roles played by FMDV 3A were also investigated as part of the 
work conducted for this thesis. A conserved sequence located in the N terminal 
domain of FMDV 3A was found to have the characteristics of a previously 
described VAP binding motif known as a FFAT-like domain (Loewen and 
Levine, 2005, Loewen et al., 2003). Introduction of mutations within this motif of 
FMDV 3A was found to have a variety of effects on replication, dependent on 
position of the mutation and the replacement a.a residue, suggesting VAP 
binding may have been impaired in some cases. In addition, these studies 
showed that certain positions can tolerate a.a substitutions that do not appear to 
affect replication which is in agreement with observations from other studies 
that characterised the FFAT motif (Mikitova and Levine, 2012, Murphy and 
Levine, 2016, Kaiser et al., 2005). In particular, position 5 of FFAT motifs has 
been shown to tolerate some variation (Mikitova and Levine, 2012), and in this 
study results from experiments with different substitutions at this position of the 
predicted FFAT-like motif in FMDV 3A also showed varying effects on 




alanine had no impact on replication, whereas changing to a serine led to partial 
attenuation of replication suggesting a potential partial inhibition of VAP binding, 
agreeing with a study by Mikitova et al (Mikitova and Levine, 2012). Moreover 
this was the only mutation (of three selected to make into recombinant viruses) 
that was maintained by the virus when passaged in culture, suggesting FMDV 
can tolerate substitutions that lead to partial attenuation but not those that are 
lethal to replication. Interestingly the substitution of glycine to glutamic acid had 
no effect on FMDV replication, and therefore potentially interaction of 3A with 
VAP, whereas Mikitova et al had found this mutation led to a major reduction of 
VAP binding by proteins (Mikitova and Levine, 2012). This difference could be 
due to the highly flexible nature of FFAT-like domains as described by Murphy 
et al (Murphy and Levine, 2016). 
Taken together these results suggest it is highly likely that 3A could interact with 
the ER via VAP proteins expressed on its surface through a FFAT-like motif to 
allow efficient replication. However further work is required to confirm a direct 
interaction between the VAP proteins and FMDV 3A, and confocal microscopy 
could be used to investigate co-localisation of 3A and the VAP proteins in 
FMDV infected cells. 
This thesis also investigated the possibility that 3ABBB could act as the donor 
of VPg to a RC (possibly as substrate for uridylation of 3B) during replication 
(Chapter 6). Previously it was suggested that 3AB was the primary source of 3B 
for this reaction (Liu et al., 2007) although more recently studies with PV 
observed that a 3C containing intermediate was the more likely substrate 
(Pathak et al., 2008). However key differences between FMDV and PV is that 
FMDV encodes 3 copies of 3B within its genome (all of which can be uridylated) 
(Nayak et al., 2005) thereby potentially increasing the number of 3B containing 
precursors that could donate VPg to a RC. 
Results from experiments with replicons and recombinant viruses, in which 3B 
could only be covalently linked to either 3A or 3C or produced as a free peptide, 
provided support for a 3BC precursor as being the template utilised for 
uridylation of 3B. This agrees with the studies on PV of Oh et al and Pathak et 




which 3B was only covalently linked to 3C was the only one seen to be 
replication competent and recoverable as a virus it was partially attenuated 
compared to the wildtype suggesting a combination of precursors may be 
required for efficient replication. However, evidence was found that suggested 
that impaired processing of 3A may have contributed to attenuation of 
replication of the 3C Donor virus. Therefore it is not possible to precisely define 
the exact product utilised for uridylation of 3B during replication, nevertheless, 
from the results presented in Chapter 6 it can be concluded that 3ABBB is not  
essential for FMDV replication. 
Future work could include investigation into the growth kinetics of the O1K 3C 
Donor (in comparison to the O1K wildtype virus) to establish the effects of 
restricting the number of 3B-containing precursors on replication. In addition, it 
would be interesting to extend the observations made by Nayak et al (Nayak et 
al., 2006), to look to see if 3ABBB is a substrate for uridylation in vitro.  
Recovery of the No Donor virus and viruses with mutations in the FFAT domain 
of 3A were affected by potential contamination by low levels of wildtype virus 
that appeared to out -compete the viruses that had mutations that appeared to 
cause attenuation of replication. This stresses the importance of including 
marker mutations, outside of the regions where changes are made to allow 
clear differentiation between contamination with a replication competent wild 
type virus and reversion events. Key evidence of the usefulness of this 
approach was seen in the case of sequencing the O1K 3A donor viruses where 
third base changes that were initially included to prevent recombination were 
still present following reversion of the virus to the wildtype sequence (Chapter 
6). 
In summary this thesis provides new insights into the roles of 3A in FMDV 
infection. Evidence supporting previous theories that deletions within 3A 
enhance infection in porcine cells was found, as were results suggesting that 
attenuation of replication in one bovine cell line could not be fully restored by 
supplying wildtype 3A in trans. However further work is required to investigate 




Potential interaction partners were also identified and investigated including 
VAP, TBC1D20 and Rab7L1. Interactions between the flavivirus HCV and VAP 
have previously been described (Gupta et al., 2012, Gupta and Song, 2016, 
Hamamoto et al., 2005) and results from this work suggest potential for 
interaction between FMDV 3A and VAP is also highly likely, particularly as 
mutations that were likely to have inhibited this interaction were not maintained 
in viruses and totally attenuated replication. Assays TBC1D20 knockout cells 
showed that it could be a cellular factor that aids FMDV infection. Investigations 
into the possible interaction of FMDV 3A with Rab7L1 however require further 
optimisation and investigation as these experiments were highly impacted by a 
lack of reliable antibodies to Rab7L1. 
Finally key results from Chapter 6 provided evidence that a 3BC containing 
precursor is the preferred donor of 3B for uridylation. Previously this was 
unknown for FMDV as previous studies were conducted using PV and the 
number of FMDV potential precursors being much larger due to FMDV 
encoding 3 copies of 3B in its genome. Although not possible to define which 
exact precursor is the most utilised for this reaction, the results show that 
3ABBB is not essential for FMDV replication.  
In conclusion FMDV remains an important pathogen globally and gaining 
greater understanding of key aspects involved in replication, including that of 
the 3A protein, is vital for development of new and safer therapeutics, 
vaccinations and control methods to prevent and reduce the impacts of FMD 
outbreaks worldwide. Although this thesis presents a number of findings related 
to roles of FMDV 3A there is still a number of gaps remaining with regards to 
understanding of FMDV replication. The roles in replication of number of the 
non-structural proteins are still poorly understood particularly those of the P2 
proteins. Furthermore it is still not understood why FMDV 3A is so much longer 
in comparison to other picornaviruses and the potential roles of 3A in subverting 
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A1 Primers used for construction of Fusion Proteins and PCR products 








Forward primer used to 
produce PCR product 
for use in TnT reaction 
Including T7 promoter 
(red), Kozak  sequence 
(yellow) and 







Reverse primer used to 
produce PCR product 
for TnTs where 3C was 




Forward primer to 
amplify 3A or 3ABBB 




Reverse primer to 
amplify 3A  region to 
create fusion proteins 
N1-3AB R ATGACCGGTCCCTCAGTGACAATC
AGGTTCTTAGC 
Reverse primer to 
amplify 3ABBB  region 
to create fusion 
proteins 
Table A1 Primers used in this study: PCR primers used to amplify the 3A to 
mid 3C region for use in TnT coupled reactions are shown. The forward primer 
incorporated a T7 promoter, Kozak sequence and start codon upstream of 3A 
sequence. Primers used to amplify 3A or 3ABBB regions from O1K FMDV to 





A2 Complete sequences of Donor Cassettes: 
 





T CTA GAG ACC AGC GGC GCC AGC ACC GTT GGC TTT AGA GAG AGA ACT CTC CCA GGT CAA  
   L   E   T   S   G   A   S   T   V   G   F   R   E   R   T   L   P   G   Q   
 
AAG GCA TGC GAT GAC GTG AAC TCC GAG CCT GCC CAA CCT GTT GAG GAG CAA CCA CAA  
 K   A   C   D   D   V   N   S   E   P   A   Q   P   V   E   E   Q   P   Q     
 
        3B1 
GCT GAA GGA CCC TAC GCC GGA CCA CTC GAG CGT CAG AAA CCT CTG AAA GTG AGA GCC  
 A   E   G   P   Y   A   G   P   L   E   R   Q   K   P   L   K   V   R   A   
 
                        3B2 
AAG CTC CCA CAG CAG GAG GGG CCT TAC GCT GGT CCG ATG GAG AGA CAA AAA CCG CTA  
 K   L   P   Q   Q   E   G   P   Y   A   G   P   M   E   R   Q   K   P   L   
 
                                            3B3 
AAA GTG AAA GCA AAA GCC CCG GTC GTG AAG GAA GGA CCT TAC GAG GGA CCG GTG AAG  
 K   V   K   A   K   A   P   V   V   K   E   G   P   Y   E   G   P   V   K   
 
                                                                aa 1-6 3C 
AAG CCT GTC GCT TTG AAA GTG AAA GCT AAG AAC CTG ATT GTC ACT GAG AGC GGA GCC  
 K   P   V   A   L   K   V   K   A   K   N   L   I   V   T   E   S   G   A   
 
             2A TaV 
CCG CCC ACC GAG GGC AGG GGA AGT CTT CTA ACA TGC GGG GAC GTG GAG GAA AAT CCC  
 P   P   T   E   G   R   G   S   L   L   T   C   G   D   V   E   E   N   P      
 
    PRO   last 6 aa 3B3         3C 
GGG CCC AAC CTC ATT GTT ACC GAG AGT GGT GCC CCA CCG ACC GAC TTG CAA AAG ATG 
G    P   N   L   I   V   T   E   S   G   A   P   P   T   D   L   Q   K   M    
                                SacI 
GTC ATG GGC AAC ACA AAG CCT GTT GAG CTC 






3C is the only possible donor 
 
 




T CTA GAG ACC AGC GGC GCC AGC ACC GTT GGC TTT AGA GAG AGA ACT CTC CCA GGT CAA  
   L   E   T   S   G   A   S   T   V   G   F   R   E   R   T   L   P   G   Q   
 
AAG GCA TGC GAT GAC GTG AAC TCC GAG CCT GCC CAA CCT GTT GAG GAG CAA CCA CAA  
 K   A   C   D   D   V   N   S   E   P   A   Q   P   V   E   E   Q   P   Q     
 
 
GCT GAA GGA CCA TTT GCC GGC CCA GAG GGC AGG GGA AGT CTT CTA ACA TGC GGG GAC 
 A   E   G   P   F   A   G   P   E   G   R   G   S   L   L   T   C   G   D    
 
 
GTG GAG GAA AAT CCC GGG CCC GAA CAA CCT CAA GCA GAA GGA CCC TAC GCC GGA CCA  
 V   E   E   N   P   G   P   E   Q   P   Q   A   E   G   P   Y   A   G   P      
 
 
CTC GAG CGT CAG AAA CCT CTG AAA GTG AGA GCC AAG CTC CCA CAG CAG GAG GGG CCT 
 L   E   R   Q   K   P   L   K   V   R   A   K   L   P   Q   Q   E   G   P 
 
 
TAC GCT GGT CCG ATG GAG AGA CAA AAA CCG CTA AAA GTG AAA GCA AAA GCC CCG GTC 
 Y   A   G   P   M   E   R   Q   K   P   L   K   V   K   A   K   A   P   V    
 
GTG AAG GAA GGA CCT TAC GAG GGA CCG GTG AAG AAG CCT GTC GCT TTG AAA GTG AAA 
V   K   E   G   P   Y   E   G   P   V   K    K   P   V   A   L   K   V   K    
 
 
GCT AAG AAC CTG ATT GTC ACT GAG AGT GGT GCC CCA CCG ACC GAC TTG CAA AAG ATG 
A   K   N   L   I   V   T   E   S   G   A    P   P   T   D   L   Q   K   M   
 
GTC ATG GGC AAC ACA AAG CCT GTT GAG CTC 






3B ONLY EVER “FREE” no donor  
 
 





T CTA GAG ACC AGC GGC GCC AGC ACC GTT GGC TTT AGA GAG AGA ACT CTC CCA GGT CAA  
   L   E   T   S   G   A   S   T   V   G   F   R   E   R   T   L   P   G   Q   
 
AAG GCA TGC GAT GAC GTG AAC TCC GAG CCT GCC CAA CCT GTT GAG GAG CAA CCA CAA  
 K   A   C   D   D   V   N   S   E   P   A   Q   P   V   E   E   Q   P   Q     
 
GCT GAA GGA CCA TTT GCC GGC CCA GAG GGC AGG GGA AGT CTT CTA ACA TGC GGG GAC 
 A   E   G   P   F   A   G   P   E   G   R   G   S   L   L   T   C   G   D    
  
 
GTG GAG GAA AAT CCC GGG CCC GAA CAA CCT CAA GCA GAA GGA CCC TAC GCC GGA CCA 
 V   E   E   N   P   G   P   E   Q   P   Q   A   E   G   P   Y   A   G   P    
 
 
CTC GAG CGT CAG AAA CCT CTG AAA GTG AGA GCC AAG CTC CCA CAG CAG GAG GGG CCT 
 L   E   R   Q   K   P   L   K   V   R   A   K   L   P   Q   Q   E   G   P    
 
 
TAC GCT GGT CCG ATG GAG AGA CAA AAA CCG CTA AAA GTG AAA GCA AAA GCC CCG GTC 
 Y   A   G   P   M   E   R   Q   K   P   L   K   V   K   A   K   A   P   V 
 
GTG AAG GAA GGA CCT TAC GAG GGA CCG GTG AAG AAG CCT GTC GCT TTG AAA GTG AAA 
 V   K   E   G   P   Y   E   G   P   V   K   K   P   V   A   L   K   V   K    
 
 
GCT AAG AAC CTG ATT GTC ACT GAG  AGC GGA GCC CCG CCA ACC GAG GGA AGG GGC AGT 
 A   K   N   L   I   V   T   E    S   G   A   P   P   T   E   G   R   G   S    
 
 
CTA CTT ACA TGC GGA GAC GTT GAG GAG AAT CCA GGG CCC AAC CTC ATT GTT ACC GAG   
 L   L   T   C   G   D   V   E   E   N   P   G   P   N   L   I   V   T   E 
 
AGT GGT GCC CCA CCG ACC GAC TTG CAA AAG ATG GTC ATG GGC AAC ACA AAG CCT GTT 
 S   G   A   P   P   T   D   L   Q   K   M   V   M   G   N   T   K   P   V   
 
GAG CTC 
 E   L   
 
 
 
